var title_f18_60_19392="Angiogram coronary a fistula";
var content_f18_60_19392=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80061&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80061&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Angiogram coronary a fistula",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 419px; height: 244px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Right anterior oblique view of left coronary angiogram showing fistulous connection of left anterior descending coronary artery to the right ventricle (left panel). This connection was occluded by transcatheter placement of occluding coils (right panel).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Okubo, M, Nyaken, D, Benson, LN. Outcomes of transcatheter embolization in the treatment of coronary artery fistulas. Cathet Cardiovasc Intervent 2001; 52:510. Copyright &copy; 2001 John Wiley &amp;Sons, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_60_19392=[""].join("\n");
var outline_f18_60_19392=null;
var title_f18_60_19393="Mitral stenosis apical long axis echocardiogram 1";
var content_f18_60_19393=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/62748/aplaxms1_conv.mp4?title=Mitral+stenosis+apical+long+axis+echocardiogram+1\" style=\"width:312px;height:224px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mitral stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 236px; height: 369px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Apical long axis view from a 2-D echocardiogram shows thickened mitral valve leaflets which have marked limitation of mobility and show doming, with failure to open normally during diastole.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_60_19393=[""].join("\n");
var outline_f18_60_19393=null;
var title_f18_60_19394="Patient information: Mitral regurgitation (The Basics)";
var content_f18_60_19394=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15754\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/42/36516\">",
"         Chambers and valves of the heart",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/43/16050\">",
"          Pitting edema",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?24/13/24787\">",
"         Patient information: Echocardiogram (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/4/21571\">",
"         Patient information: Mitral valve prolapse (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/23/11635\">",
"         Patient information: Prosthetic valves (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/2/32803\">",
"         Patient information: What can go wrong after a heart attack? (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?30/37/31314\">",
"         Patient information: Antibiotics before procedures (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?26/59/27575\">",
"         Patient information: Mitral regurgitation (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Mitral regurgitation (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/mitral-regurgitation-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1741881955\">",
"      <span class=\"h1\">",
"       What is mitral regurgitation?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Mitral regurgitation is a condition in which one of the valves in the heart, called the mitral valve, leaks (",
"      <a class=\"graphic graphic_figure graphicRef58389 \" href=\"UTD.htm?35/42/36516\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      When the heart valves are working normally, they keep blood flowing in only one direction. The valves work like swinging doors that open only one way &mdash; letting blood out, but not back in. Normally, little or no blood is able to leak backward. But if the valves are not working properly, more blood can go back in the direction it came from. This can cause problems.",
"     </p>",
"     <p>",
"      The mitral valve normally keeps blood flowing from the left atrium to the left ventricle (",
"      <a class=\"graphic graphic_figure graphicRef58389 \" href=\"UTD.htm?35/42/36516\">",
"       figure 1",
"      </a>",
"      ). When it leaks, it lets blood flow back into the left atrium. A small amount of mitral regurgitation occurs in most healthy people. Some people have larger amounts of mitral regurgitation, and this can get worse with time.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1741881962\">",
"      <span class=\"h1\">",
"       What are the symptoms of mitral regurgitation?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people with mitral regurgitation have no symptoms. But some people with severe mitral regurgitation have one or more of the following symptoms:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Trouble breathing",
"       </li>",
"       <li>",
"        Tiredness",
"       </li>",
"       <li>",
"        Weakness",
"       </li>",
"       <li>",
"        Swelling in the ankles (",
"        <a class=\"graphic graphic_picture graphicRef61706 \" href=\"UTD.htm?15/43/16050\">",
"         picture 1",
"        </a>",
"        ), legs, or belly",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1741881969\">",
"      <span class=\"h1\">",
"       Is there a test for mitral regurgitation?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If your doctor or nurse thinks you could have more than slight mitral regurgitation, he or she might order one or more of these tests:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         An electrocardiogram (ECG or EKG)",
"        </strong>",
"        <strong>",
"         &mdash;",
"        </strong>",
"        This test measures the electrical activity in your heart. It can show whether you have signs of abnormal heart muscle or had a heart attack in the past. These are some of the things that can cause mitral regurgitation.",
"       </li>",
"       <li>",
"        <strong>",
"         A chest X-ray &mdash;",
"        </strong>",
"        A chest X-ray shows if there is fluid in the lungs. It also shows the general shape and size of the heart. Many people with severe mitral regurgitation have an enlarged heart.",
"       </li>",
"       <li>",
"        <strong>",
"         An echocardiogram (or &ldquo;echo&rdquo; for short) &mdash;",
"        </strong>",
"        This test uses sound waves to create a picture of your heart as it beats. It shows the size of the heart chambers, how well the heart is pumping, and how well the heart valves are working.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1741881976\">",
"      <span class=\"h1\">",
"       How is mitral regurgitation treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have a mild amount of mitral regurgitation, you may not need any treatment or follow-up. But even if you have larger amounts of mitral regurgitation, you may not need treatment. It's possible that your doctor will simply want to keep an eye on you to see if a need for treatment develops.",
"     </p>",
"     <p>",
"      For those who do need treatment, options might include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Surgery to repair or replace the mitral valve",
"       </li>",
"       <li>",
"        Surgery to correct heart rhythm problems that often affect people with mitral valve disease",
"       </li>",
"       <li>",
"        Medicines that lower blood pressure and make it easier for the heart to do its job",
"       </li>",
"       <li>",
"        Medicines that help prevent blood clots, which sometimes form more easily in people who have mitral regurgitation",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1741881983\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Women with mitral regurgitation who have no symptoms or mild symptoms are often able to have normal pregnancies. But women who have significant symptoms or severe mitral regurgitation can have serious problems during pregnancy.",
"     </p>",
"     <p>",
"      If you have significant mitral regurgitation and would like to get pregnant, ask your doctor about it before you start trying. Some women need to have surgery to replace or repair their mitral valve before they try to have a baby.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1741881990\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=see_link\">",
"       Patient information: Echocardiogram (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/2/32803?source=see_link\">",
"       Patient information: What can go wrong after a heart attack? (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/4/21571?source=see_link\">",
"       Patient information: Mitral valve prolapse (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/23/11635?source=see_link\">",
"       Patient information: Prosthetic valves (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/59/27575?source=see_link\">",
"       Patient information: Mitral regurgitation (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/37/31314?source=see_link\">",
"       Patient information: Antibiotics before procedures (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?18/60/19394?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15754 Version 5.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-AF7A4312D5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_60_19394=[""].join("\n");
var outline_f18_60_19394=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1741881955\">",
"      What is mitral regurgitation?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1741881962\">",
"      What are the symptoms of mitral regurgitation?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1741881969\">",
"      Is there a test for mitral regurgitation?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1741881976\">",
"      How is mitral regurgitation treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1741881983\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1741881990\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15754\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/42/36516\">",
"      Chambers and valves of the heart",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/43/16050\">",
"       Pitting edema",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/37/31314?source=related_link\">",
"      Patient information: Antibiotics before procedures (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=related_link\">",
"      Patient information: Echocardiogram (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/59/27575?source=related_link\">",
"      Patient information: Mitral regurgitation (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/4/21571?source=related_link\">",
"      Patient information: Mitral valve prolapse (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/23/11635?source=related_link\">",
"      Patient information: Prosthetic valves (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/2/32803?source=related_link\">",
"      Patient information: What can go wrong after a heart attack? (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_60_19395="Florbetapir F18: Drug information";
var content_f18_60_19395=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Florbetapir F18: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?35/11/36018?source=see_link\">",
"    see \"Florbetapir F18: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F14385998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Amyvid&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F14085370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Radiopharmaceutical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F15962211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Measure dose by a suitable radioactivity calibration system immediately prior to administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Radioimaging:",
"     </b>",
"     I.V.: 10 mCi (370 MBq); maximum: 50 mcg mass dose",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F15962212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15881441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15881442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F14387478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Amyvid&trade;: Florbetapir 0.1-19 mcg and F 18 500-1900 MBq (13.5-51 mCi) per 1 mL (10 mL, 30 mL, 50 mL) [contains dehydrated ethanol 0.1 mL/mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F15962170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F15962213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer as a single intravenous bolus in a total volume of 10 mL or less; do not dilute. Following injection, flush with NS to ensure full delivery of dose. Administer through a short I.V. catheter (&le;1.5 inches) to minimize potential drug adsorption to the catheter (may adhere to longer tubing/catheters). Initiate 10-minute PET image 30-50 minutes after injection. Patient should remain supine with brain centered in the PET scanner field of view; stabilize head to reduce movement if necessary.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F14080682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Radioactive agent for positron emission tomography (PET) imaging estimation of beta-amyloid neuritic plaque density in the brain of patients being evaluated for cognitive decline (eg, Alzheimer's disease)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F15245841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F15962179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (2%), fatigue (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Musculoskeletal pain (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Anxiety, back pain, blood pressure increased, claustrophobia, feeling of cold, insomnia, neck pain",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F15962175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F15962176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel (eg, wear waterproof gloves and use effective shielding). Use only under supervision of individuals who have received training in the handling of radioactive materials and who are authorized by the applicable regulatory authority.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cancer: Patients are exposed to some radiation during treatment; large cumulative amounts of radiation exposure may increase the risk of cancer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Experienced staff: Images should only be interpreted by specially trained personnel.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Limitations: A positive scan does not establish a diagnosis of Alzheimer&rsquo;s disease or other cognitive disorders. Safety and effectiveness have not been established for predicting the development of a neurological condition (eg, dementia) or monitoring responses to therapy. Image interpretation provides an estimate of the brain &beta;-amyloid plaque density; it does not determine clinical diagnosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Risk for misinterpretation and errors: The use of clinical information in the interpretation of images has not been evaluated and may lead to errors. Scan results are indicative of the brain neuritic amyloid plaque content only at the time of imaging. A negative scan result does not preclude the development of brain amyloid in the future.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F15977004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F15977002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F15962171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F15962172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Animal reproduction studies have not been conducted. Radiopharmaceuticals have the potential to cause fetal harm. Women should be evaluated for pregnancy prior to administration.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F15962173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F15962174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for adverse reactions in the nursing infant, breast-feeding should be avoided. The manufacturer recommends interrupting breast-feeding for 24 hours to minimize radioactivity exposure and risk to the infant; breast milk should be pumped and discarded and alternate infant nutrition should be used for 24 hours after drug administration.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16570437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Amyvid Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500-1900 mbq/ml (1): $1920.00",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F15962189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Florbetapir F18 binds to &beta;-amyloid plaques; the F18 isotope produces a positron signal that is detected by a PET scanner.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F15962191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: &lt;5% of total dose present in blood 20 minutes post administration; &lt;2% of total dose present in blood 45 minutes post administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Florbetapir F18: ~110 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Predominately through biliary/gastrointestinal tract",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83331 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.96.59.103-18C17D12B8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_60_19395=[""].join("\n");
var outline_f18_60_19395=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14385998\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14085370\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962211\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962212\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15881441\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15881442\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14387478\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962170\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962213\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14080682\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15245841\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962179\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962175\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962176\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15977004\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15977002\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962171\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962172\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962173\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962174\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570437\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962189\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962191\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/83331\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/83331|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/11/36018?source=related_link\">",
"      Florbetapir F18: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_60_19396="Infiltrating gastric cancer UGI";
var content_f18_60_19396=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F62794&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F62794&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Infiltrating gastric carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 284px; height: 341px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Upper GI series showing infiltrating gastric carcinoma in the region of the incisura. There is irregular narrowing affecting both the lesser and greater curvatures (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul C Schroy III, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal upper GI series",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 286px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal air-contrast upper gastrointestinal study showing normal gastric folds and small intestinal anatomy, and no masses.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul C Schroy III, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_60_19396=[""].join("\n");
var outline_f18_60_19396=null;
var title_f18_60_19397="Histrelin: Drug information";
var content_f18_60_19397=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Histrelin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?11/28/11716?source=see_link\">",
"    see \"Histrelin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/57/917?source=see_link\">",
"    see \"Histrelin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F179193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Supprelin&reg; LA;",
"     </li>",
"     <li>",
"      Vantas&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2934287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Vantas&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F179209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Gonadotropin Releasing Hormone Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F179195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prostate cancer, advanced: SubQ (Vantas&reg;): 50 mg implant surgically inserted every 12 months",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F5025514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/57/917?source=see_link\">",
"      see \"Histrelin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     CPP: SubQ (Supprelin&reg; LA): Children &ge;2 years: 50 mg implant surgically inserted every 12 months. Discontinue at the appropriate time for the onset of puberty.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F179196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F179197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Vantas&reg;: Clcr: &ge;15mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Supprelin&reg; LA: No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15897520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vantas&reg;, Supprelin&reg; LA:  No dosage adjustment is provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F179173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Implant, subcutaneous:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Supprelin&reg; LA: 50 mg (1s) [releases ~65 mcg/day over 12 months]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vantas&reg;: 50 mg (1s) [Releases ~50 mcg/day over 12 months; packaged with implantation kit]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vantas&reg;: 50 mg (1s [DSC]) [releases 50-60 mcg/day over 12 months]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F179161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F179176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     SubQ: Surgical implantation (using a sterile field) into the inner portion of the upper arm requires the use of the implantation device provided. Use the patient's nondominant arm for placement; implant should be placed halfway between the shoulder and the elbow at the crease between the tricep and the bicep. Implant removal should occur after ~12 months; a replacement implant may be  inserted if therapy is to be continued. Palpate area of incision to locate implant for removal. If not readily palpated, ultrasound, CT or MRI may be used to locate implant; plain films are not recommended because the implant is not radiopaque.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F179175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Palliative treatment of advanced prostate cancer; treatment of children with central precocious puberty (CPP)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F179207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      CPP:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Local: Insertion site reaction (51%; includes bruising, discomfort, itching, pain, protrusion of implant area, soreness, swelling, tingling)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Metrorrhagia (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Keloid scar (6%), scar (6%), suture-related complication (6%), pain at the application site (4%), post procedural pain (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &le;2% (Limited to important or life-threatening): Amblyopia, breast tenderness, cold feeling, disease progression, dysmenorrhea, epistaxis, erythema, flu-like syndrome, gynecomastia, headache, infection at the implant site, menorrhagia, migraine, mood swings, pituitary adenoma, pituitary apoplexy, pruritus, seizures, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Prostate cancer:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hot flashes (66%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Implant site reaction (6% to 14%; includes bruising, erythema, pain, soreness, swelling, tenderness)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (10%), headache (3%), insomnia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Gynecomastia (4%), sexual dysfunction (4%), libido decreased (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation (4%), weight gain (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Expected pharmacological consequence of testosterone suppression: Testicular atrophy (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Renal impairment (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;2% (Limited to important or life-threatening): Abdominal discomfort, alopecia, anemia, appetite increased, arthralgia, AST increased, back pain, bone density decreased, bone pain, breast pain, breast tenderness, cold feeling, contusion, craving food, creatinine increased, depression, diaphoresis, dizziness, dyspnea (exertional), dysuria, fluid retention, flushing, genital pruritus, hematoma, hematuria, hepatic injury (severe), hypercalcemia, hypercholesterolemia, hyperglycemia, irritability, LDH increased, lethargy, limb pain, liver disorder, malaise, muscle twitching, myalgia, nausea, neck pain, night sweats, pain, palpitation, peripheral edema, prostatic acid phosphatase increased, pruritus, pituitary apoplexy, renal calculi, renal failure, stent occlusion, testosterone increased, tremor, urinary frequency, urinary retention, ventricular asystoles, weakness, weight loss",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F179179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to histrelin acetate, GnRH, GnRH-agonist analogs, or any component of the formulation; females who are or may become pregnant",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F179163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hyperglycemia: Hyperglycemia has been reported with androgen deprivation therapy (in prostate cancer)  and may manifest as diabetes or worsening of pre-existing diabetes. Monitor blood glucose and/or Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pituitary apoplexy: Rare cases of pituitary apoplexy (frequently secondary to pituitary adenoma) have been observed with GnRH agonist administration (onset from 1 hour to usually &lt;2 weeks); may present as sudden headache, vomiting, visual or mental status changes, and infrequently cardiovascular collapse; immediate medical attention required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Spinal cord compression: Has been reported, may contribute to paralysis when used for prostate cancer; closely observe patients with metastatic vertebral lesions for weakness and paresthesias in first few weeks of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Tumor flare: Transient increases in serum testosterone (in men with prostate cancer) occur during the first week of use and may result in a worsening of disease signs and symptoms (bone pain, neuropathy, hematuria, ureteral/bladder outlet obstruction, spinal cord compression) during the first week of treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Urinary tract obstruction: Ureteral obstruction may occur when used for prostate cancer; closely observe patients for urinary tract obstruction or poor urine output in first few weeks of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Worsening of symptoms: Transient increases in estradiol serum levels (female) or testosterone levels (female and male) may occur during the first week of use for CPP; however, manifestations of puberty should decrease within 4 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Androgen-deprivation therapy may increase the risk for cardiovascular disease (Levine, 2010). An increased risk of MI, sudden cardiac death, and stroke has been reported with GNRH agonist use in men; monitor for symptoms associated with cardiovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Safety and efficacy have not been established in prostate cancer patients with hepatic dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F179166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Luteinizing Hormone-Releasing Hormone Analogs may diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F179169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F179180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fetal harm and an increase in fetal mortalities have been noted in animal studies. Histrelin is contraindicated for use during pregnancy or in women who may become pregnant.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F179199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5025538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Products are not indicated for use in postpubertal women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Supprelin LA Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (1): $19012.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Vantas Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (1): $3840.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F179171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CPP: LH, FSH, estradiol, or testosterone (after 1 month then every 6 months); height, bone age (every 6-12 months); tanner staging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostate cancer: Serum testosterone levels, prostate specific antigen (PSA); bone mineral density; weakness, paresthesias, and urinary tract obstruction (especially during first few weeks of therapy); screen for diabetes; monitor for symptoms associated with cardiovascular disease",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F179174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Prostate cancer:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Testosterone level: Expected to rise during the first few days and decline to below initiation level by week 2 before reaching &le;50 ng/dL (castrate level)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     PSA: Expected to decrease to normal levels after 6 months of therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Lack of response (testosterone and PSA decreases) should prompt suspicion that the implant has been expelled.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4301435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Vantas (AR, BG, CH, CZ, DE, DK, EE, FI, FR, GB, IE, MY, NO, PL, SE, SG, TH);",
"     </li>",
"     <li>",
"      Vantasse (BE, NL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F179162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potent inhibitor of gonadotropin secretion; continuous administration results in, after an initiation phase, the suppression of luteinizing hormone (LH), follicle-stimulating hormone (FSH), and a subsequent decrease in testosterone and dihydrotestosterone (males) and estrone and estradiol (premenopausal females). Testosterone levels are reduced to castrate levels in males (treated for prostate cancer) within 2-4 weeks. Additionally, in patients with CPP, linear growth velocity is slowed (improves chance of attaining predicted adult height).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F179178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Prostate cancer: Chemical castration: Within 2-4 weeks; CPP: Progression of sexual development stops and growth is decreased within 1 month",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 1 year",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Adults: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~58 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Adults: 70% &plusmn; 9%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via C-terminal dealkylation and hydrolysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Adults: 92%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Adults: Terminal: ~4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Adults: 12 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Dineen MK, Tierney DS, Kuzma P, et al, &ldquo;An Evaluation of the Pharmacokinetics and Pharmacodynamics of the Histrelin Implant for the Palliative Treatment of Prostate Cancer,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2005, 45(11):1245-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/60/19397/abstract-text/16239357/pubmed\" id=\"16239357\" target=\"_blank\">",
"        16239357",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine GN, D&rsquo;Amico AV, Berger P, et al, &ldquo;Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk. A Science Advisory from the American Heart Association, American Cancer Society, and American Urological Association,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 121:831-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/60/19397/abstract-text/20124128/pubmed\" id=\"20124128\" target=\"_blank\">",
"        20124128",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rahhal S, Clarke WL, Kletter GB, et al, \"Results of a Second Year of Therapy With the 12-Month Histrelin Implant for the Treatment of Central Precocious Puberty,\"",
"      <i>",
"       Int J Pediatr Endocrinol",
"      </i>",
"      , 2009, 2009:812517.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/60/19397/abstract-text/19956699/pubmed\" id=\"19956699\" target=\"_blank\">",
"        19956699",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schlegel PN, Histrelin Study Group, &ldquo;Efficacy and Safety of Histrelin Subdermal Implant in Patients With Advanced Prostate Cancer,&rdquo;",
"      <i>",
"       J Urol",
"      </i>",
"      , 2006, 175(4):1353-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/60/19397/abstract-text/16515997/pubmed\" id=\"16515997\" target=\"_blank\">",
"        16515997",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8753 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.117.136.88-C2C11C53A9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_60_19397=[""].join("\n");
var outline_f18_60_19397=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179193\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2934287\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179209\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179195\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5025514\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179196\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179197\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897520\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179173\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179161\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179176\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179175\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179207\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179179\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179163\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299447\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179166\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179169\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179180\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179199\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5025538\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323184\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179171\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179174\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4301435\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179162\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179178\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8753\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8753|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/28/11716?source=related_link\">",
"      Histrelin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/57/917?source=related_link\">",
"      Histrelin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_60_19398="Renal effects of ACE inhibitors in hypertension";
var content_f18_60_19398=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Renal effects of ACE inhibitors in hypertension",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/60/19398/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/60/19398/contributors\">",
"     Johannes FE Mann, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/60/19398/contributors\">",
"     Karl F Hilgers, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/60/19398/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/60/19398/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/60/19398/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/60/19398/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/60/19398/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/60/19398/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of angiotensin-converting enzyme (ACE) inhibitors on renal function in the hypertensive patient is related both to the glomerular actions of angiotensin II and to the mechanism of autoregulation of the glomerular filtration rate (GFR) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19398/abstract/1\">",
"     1",
"    </a>",
"    ]. Angiotensin II constricts both the afferent and efferent arterioles, but preferentially increases efferent resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19398/abstract/2\">",
"     2",
"    </a>",
"    ]. At least three factors may contribute to this response:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The efferent arteriole has a smaller diameter in the basal state; as a result, further constriction at this site will produce a greater increase in resistance than at the afferent arteriole [",
"      <a class=\"abstract\" href=\"UTD.htm?18/60/19398/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Angiotensin II stimulates the release of the vasodilator nitric oxide from the afferent arteriole, thereby minimizing constriction at this site [",
"      <a class=\"abstract\" href=\"UTD.htm?18/60/19398/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Angiotensin II minimizes vasoconstriction at the afferent arteriole via the stimulation of angiotensin II type 2 receptors, which results in vasodilation through a cytochrome P-450 dependent pathway [",
"      <a class=\"abstract\" href=\"UTD.htm?18/60/19398/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The net effect of the more prominent increase in efferent tone is that the intraglomerular pressure is stable or increased, thereby tending to maintain or even raise the GFR. In addition to these arteriolar actions, angiotensin II constricts the mesangial cells, an effect that tends to lower the GFR by decreasing the surface area available for filtration.",
"   </p>",
"   <p>",
"    An overview of the renal effects of ACE inhibitors will be reviewed here. The use of ACE inhibitors and angiotensin receptor blockers in patients with kidney disease are presented in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=see_link\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANGIOTENSIN II AND AUTOREGULATION OF GFR",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the renal perfusion pressure is diminished (due for example to antihypertensive therapy), the kidney is initially able to maintain both blood flow and glomerular filtration via the phenomenon of autoregulation (",
"    <a class=\"graphic graphic_figure graphicRef57043 \" href=\"UTD.htm?32/29/33245\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19398/abstract/5\">",
"     5",
"    </a>",
"    ]. The first part of the autoregulatory response is decreased afferent (precapillary) arteriolar tone, thereby allowing more of the systemic pressure to be transmitted to the glomerulus. Afferent dilatation is mediated both by tubuloglomerular feedback and by a direct myogenic response. With more marked reductions in renal perfusion pressure, renin release is stimulated; the ensuing increase in angiotensin II production maintains both intraglomerular pressure and the GFR via a preferential increase in resistance at the efferent arteriole [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19398/abstract/5\">",
"     5",
"    </a>",
"    ]. The net effect is that the GFR and renal blood flow do not begin to fall until these autoregulatory changes in arteriolar resistance are maximized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PRIMARY HYPERTENSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with primary hypertension, renal perfusion pressure is elevated and therefore maintenance of the GFR is not as dependent upon angiotensin II. As a result, an ACE inhibitor generally induces little change in GFR in patients who have normal renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19398/abstract/6\">",
"     6",
"    </a>",
"    ]. In comparison, some patients with relatively recent onset hypertension have increased angiotensin II activity, renal vasoconstriction, and a GFR below 80",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    In this setting, an ACE inhibitor can raise the GFR by 10 to 30",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    presumably due to reversal of angiotensin II-induced mesangial contraction [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19398/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The outcome may be different in patients who develop renal disease due to benign nephrosclerosis. In this setting, an ACE inhibitor can lead to an acute decline in GFR due to intrarenal vascular disease via a mechanism similar to that in bilateral renal artery stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19398/abstract/8\">",
"     8",
"    </a>",
"    ]. However, in one study of over 1000 blacks with hypertensive renal disease, the ACE inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/37/24152?source=see_link\">",
"     ramipril",
"    </a>",
"    retarded the progression of renal disease better than the calcium channel blocker,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19398/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Long-term effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;It remains uncertain whether ACE inhibitors offer preferential long-term protection of renal function in patients with primary hypertension as they do in a variety of forms of chronic renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19398/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    .) One study of 257 patients with primary hypertension suggested that there may be a lower rate of loss of glomerular filtration rate in patients who are treated with an ACE inhibitor compared to a beta-blocker despite equivalent degrees of blood pressure control [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19398/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/42/6824?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical features, diagnosis, and treatment of hypertensive nephrosclerosis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RENOVASCULAR HYPERTENSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hemodynamic response to ACE inhibition in renal artery stenosis may be different from that with uncomplicated primary hypertension. In this setting, lowering the systemic blood pressure will, because of the stenotic lesion, tend to reduce the intraglomerular pressure below normal. Although the GFR can be maintained by autoregulation, blocking angiotensin II formation with an ACE inhibitor will blunt this response and tend to reduce the GFR (",
"    <a class=\"graphic graphic_figure graphicRef57043 \" href=\"UTD.htm?32/29/33245\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19398/abstract/5\">",
"     5",
"    </a>",
"    ]. This effect is more pronounced in the presence of diuretic-induced volume depletion, since the increase in baseline angiotensin II levels makes maintenance of the GFR more angiotensin II-dependent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19398/abstract/5,12\">",
"     5,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The net effect is that between one-third and one-half of patients with renal artery stenosis will have a usually mild decline in GFR after the administration of an ACE inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19398/abstract/13\">",
"     13",
"    </a>",
"    ]. For similar reasons, bilateral renovascular disease should be strongly suspected in hypertensive patients who are not hypovolemic and in whom the plasma creatinine concentration rises after starting an ACE inhibitor. Although many of these patients will have renal artery stenosis, a similar change can occur with hypovolemia (often induced by diuretics) and with",
"    <strong>",
"     intrarenal",
"    </strong>",
"    vascular disease due to hypertensive nephrosclerosis or systemic vasculitis (such as polyarteritis nodosa) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19398/abstract/8,14\">",
"     8,14",
"    </a>",
"    ]. It has been estimated, for example, that of all hypertensive patients in whom an ACE inhibitor raises the plasma creatinine concentration, more than one-half will have renal artery stenosis, while most of the remaining patients have nephrosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19398/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The decline in GFR induced by an ACE inhibitor typically occurs within the first few days after the onset of therapy, since angiotensin II levels are rapidly reduced. As a result, the plasma creatinine concentration should be remeasured three to five days after the institution of therapy in patients with known renal artery stenosis and in those at high risk for the disease (as with severe hypertension in the presence of atherosclerotic vascular disease). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/17/31001?source=see_link\">",
"     \"Establishing the diagnosis of renovascular hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When it occurs, the rise in the plasma creatinine concentration is usually mild and acceptable [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19398/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. In one study, for example, 75 patients with known renovascular hypertension were randomly assigned to therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    or hydrochlorothiazide plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/2/31776?source=see_link\">",
"     timolol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19398/abstract/16\">",
"     16",
"    </a>",
"    ]. A 0.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or larger increase in creatinine occurred in 20 percent of patients treated with enalapril (the mean reduction in glomerular filtration rate in this group was 23",
"    <span class=\"nowrap\">",
"     mL/min),",
"    </span>",
"    half of whom had pre-existing renal impairment and one third of whom had bilateral renal artery stenosis. Blood pressure control was slightly better in patients treated with enalapril. &nbsp;",
"   </p>",
"   <p>",
"    The decline in glomerular filtration rate that may occur with ACE inhibitors is indicative of a decrease in intraglomerular pressure, a probable mechanism for protection against progression of renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19398/abstract/17\">",
"     17",
"    </a>",
"    ]. Patients with renal artery stenosis who are able to tolerate ACE inhibitor therapy may derive a similar benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19398/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. In one study of 621 patients with renal artery stenosis followed at a single referral center, ACE inhibitors were prescribed in 378 patients, and nearly all such patients tolerated therapy (92 percent overall and 78 percent of those with bilateral renal artery stenosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19398/abstract/18\">",
"     18",
"    </a>",
"    ]. Compared with those prescribed other therapy, those taking ACE inhibitors had a significantly lower mortality after controlling for possible confounders (hazard ratio 0.61, 95% CI 0.40-0.81). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A large and persistent decline in renal function resulting in a 30 percent or greater rise in serum creatinine (or 30 percent or greater fall in estimated glomerular filtration rate) occurs in less than 5 to 10 percent of cases. These patients generally require either institution of other antihypertensive agents that do not interfere with autoregulation (such as a calcium channel blocker) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19398/abstract/21\">",
"     21",
"    </a>",
"    ] or correction of the stenosis by angioplasty or surgery. Patients with severe bilateral disease may not tolerate any form of antihypertensive therapy, since an adequate intraglomerular pressure can be maintained only at very high systemic pressures (",
"    <a class=\"graphic graphic_figure graphicRef75208 \" href=\"UTD.htm?25/35/26173\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19398/abstract/22\">",
"     22",
"    </a>",
"    ]. In this setting, the GFR falls because the intraglomerular pressure is reduced below the level at which it can be maintained by autoregulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8040?source=see_link\">",
"     \"Treatment of bilateral atherosclerotic renal artery stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ACE inhibitor-induced reduction in GFR in renovascular disease almost always resolves after cessation of therapy. In addition, the plasma creatinine concentration can often be returned toward the baseline level by discontinuation of diuretic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19398/abstract/12\">",
"     12",
"    </a>",
"    ]. It has been suggested, however, that irreversible renal failure can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19398/abstract/23\">",
"     23",
"    </a>",
"    ]. How this might happen is not clear. In most such patients, the decline in renal function was noted weeks to months after the ACE inhibitor was started, thereby making a cause-and-effect relationship uncertain. One possible mechanism is the development of renal artery thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19398/abstract/24\">",
"     24",
"    </a>",
"    ]. This complication has been reported primarily in patients with marked (&ge;95 percent) stenotic lesions who have an excessive reduction in blood pressure. It is therefore unclear if there was any specific predisposing effect of the ACE inhibitor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Unilateral renal artery stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect in unilateral renal artery stenosis is more subtle. An ACE inhibitor may decrease the GFR in the stenotic kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19398/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. However, a substantial fall in the total GFR with a rise in the plasma creatinine concentration is usually not seen because of an equivalent increment in GFR in the contralateral kidney (due to removal of angiotensin II-induced renal vasoconstriction).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Risk of ischemic atrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even when the total GFR is relatively well maintained, there is a concern that hypofiltration and the fall in perfusion pressure might eventually lead to ischemic atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19398/abstract/27\">",
"     27",
"    </a>",
"    ]. The risk of this complication and whether it is more likely to occur with an ACE inhibitor are currently unresolved. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29369?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of unilateral atherosclerotic renal artery stenosis\", section on 'Medical therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prolonged ACE inhibitor or angiotensin receptor blocker (ARB) use may result in significant worsening of kidney function in a few patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19398/abstract/28\">",
"     28",
"    </a>",
"    ], and one small study has suggested that discontinuing these agents in patients with advanced CKD may improve renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19398/abstract/29\">",
"     29",
"    </a>",
"    ]. The possible detrimental effects of ACE inhibitors and ARBs in people with Stage 4 nephropathy should be considered until long-term outcome studies are performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21519415\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The effect of angiotensin-converting enzyme (ACE) inhibitors on the glomerular filtration rate (GFR) in hypertensive patients is related both to the glomerular actions of angiotensin II and to the mechanism of autoregulation of the GFR. Angiotensin II constricts both the afferent (pre-glomerular) and efferent (post-glomerular) arterioles, but preferentially increases efferent resistance. The net effect of the more prominent increase in efferent tone is that the intraglomerular pressure is stable or increased, thereby tending to maintain or even raise the GFR. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As the renal perfusion pressure is diminished, the kidney is initially able to maintain both blood flow and the GFR via the phenomenon of autoregulation (",
"      <a class=\"graphic graphic_figure graphicRef57043 \" href=\"UTD.htm?32/29/33245\">",
"       figure 1",
"      </a>",
"      ). The initial autoregulatory response is decreased afferent arteriolar tone, thereby allowing more of the systemic pressure to be transmitted to the glomerulus. However, with more marked reductions in renal perfusion pressure, renin mediated increases in angiotensin II production maintain both intraglomerular pressure and the GFR via a preferential increase in resistance at the efferent arteriole. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Angiotensin II and autoregulation of GFR'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      These concepts are critical to understanding the effects of ACE inhibitors on GFR in various forms of hypertension:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In patients with primary hypertension, renal perfusion pressure is elevated and therefore maintenance of the GFR is not as dependent upon angiotensin II. As a result, an ACE inhibitor generally induces little change in GFR in patients who have normal renal function. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Primary hypertension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The outcome may be different in patients who develop renal disease due to benign nephrosclerosis. In this setting, an ACE inhibitor can lead to an acute decline in GFR due to intrarenal vascular disease via a mechanism similar to that in bilateral renal artery stenosis, discussed below. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Primary hypertension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with renovascular hypertension, lowering the systemic blood pressure with an ACE inhibitor will, because of the stenotic lesion, tend to reduce the intraglomerular pressure below normal. Although the GFR could be maintained by autoregulation, blocking angiotensin II formation with an ACE inhibitor will blunt this response and tend to reduce the GFR (",
"      <a class=\"graphic graphic_figure graphicRef57043 \" href=\"UTD.htm?32/29/33245\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Renovascular hypertension'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Between one-third and one-half of patients with renal artery stenosis will have a usually mild decline in GFR, occurring within a few days after the administration of an ACE inhibitor. A large decline in renal function occurs in less than 5 to 10 percent of cases. The ACE inhibitor-induced reduction in GFR in renovascular disease almost always resolves after cessation of therapy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Renovascular hypertension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bilateral renovascular disease should be strongly suspected in hypertensive patients in whom the plasma creatinine concentration rises by more than 30 percent within a week after starting an ACE inhibitor. Although many of these patients will have renal artery stenosis, a similar change can occur with intrarenal vascular disease due to hypertensive nephrosclerosis or systemic vasculitis (such as polyarteritis nodosa). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Renovascular hypertension'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19398/abstract/1\">",
"      Braam B, Koomans HA. Renal responses to antagonism of the renin-angiotensin system. Curr Opin Nephrol Hypertens 1996; 5:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19398/abstract/2\">",
"      Denton KM, Fennessy PA, Alcorn D, Anderson WP. Morphometric analysis of the actions of angiotensin II on renal arterioles and glomeruli. Am J Physiol 1992; 262:F367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19398/abstract/3\">",
"      Ito S, Arima S, Ren YL, et al. Endothelium-derived relaxing factor/nitric oxide modulates angiotensin II action in the isolated microperfused rabbit afferent but not efferent arteriole. J Clin Invest 1993; 91:2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19398/abstract/4\">",
"      Arima S, Endo Y, Yaoita H, et al. Possible role of P-450 metabolite of arachidonic acid in vasodilator mechanism of angiotensin II type 2 receptor in the isolated microperfused rabbit afferent arteriole. J Clin Invest 1997; 100:2816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19398/abstract/5\">",
"      Hall JE, Guyton AC, Jackson TE, et al. Control of glomerular filtration rate by renin-angiotensin system. Am J Physiol 1977; 233:F366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19398/abstract/6\">",
"      Hollenberg NK, Swartz SL, Passan DR, Williams GH. Increased glomerular filtration rate after converting-enzyme inhibition in essential hypertension. N Engl J Med 1979; 301:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19398/abstract/7\">",
"      Reams GP, Bauer JH. Effect of lisinopril monotherapy on renal hemodynamics. Am J Kidney Dis 1988; 11:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19398/abstract/8\">",
"      Toto RD, Mitchell HC, Lee HC, et al. Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis. Ann Intern Med 1991; 115:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19398/abstract/9\">",
"      Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001; 285:2719.",
"     </a>",
"    </li>",
"    <li>",
"     K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. Am J Kidney Dis 2004; 43:5(Suppl 1):S1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19398/abstract/11\">",
"      Himmelmann A, Hansson L, Hansson BG, et al. ACE inhibition preserves renal function better than beta-blockade in the treatment of essential hypertension. Blood Press 1995; 4:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19398/abstract/12\">",
"      Hricik DE. Captopril-induced renal insufficiency and the role of sodium balance. Ann Intern Med 1985; 103:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19398/abstract/13\">",
"      van de Ven PJ, Beutler JJ, Kaatee R, et al. Angiotensin converting enzyme inhibitor-induced renal dysfunction in atherosclerotic renovascular disease. Kidney Int 1998; 53:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19398/abstract/14\">",
"      Jaichenko J, Fudin R, Shostak A, Gotloib L. Use of angiotensin-converting enzyme inhibitors in patients with diabetic and nondiabetic chronic renal diseases: a need for reassessment. Nephron 1998; 80:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19398/abstract/15\">",
"      Mimran A, Ribstein J, DuCailar G. Converting enzyme inhibitors and renal function in essential and renovascular hypertension. Am J Hypertens 1991; 4:7S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19398/abstract/16\">",
"      Franklin SS, Smith RD. Comparison of effects of enalapril plus hydrochlorothiazide versus standard triple therapy on renal function in renovascular hypertension. Am J Med 1985; 79:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19398/abstract/17\">",
"      Izzo JL Jr, Weir MR. Angiotensin-converting enzyme inhibitors. J Clin Hypertens (Greenwich) 2011; 13:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19398/abstract/18\">",
"      Chrysochou C, Foley RN, Young JF, et al. Dispelling the myth: the use of renin-angiotensin blockade in atheromatous renovascular disease. Nephrol Dial Transplant 2012; 27:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19398/abstract/19\">",
"      Losito A, Errico R, Santirosi P, et al. Long-term follow-up of atherosclerotic renovascular disease. Beneficial effect of ACE inhibition. Nephrol Dial Transplant 2005; 20:1604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19398/abstract/20\">",
"      Losito A, Gaburri M, Errico R, et al. Survival of patients with renovascular disease and ACE inhibition. Clin Nephrol 1999; 52:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19398/abstract/21\">",
"      Miyamori I, Yasuhara S, Matsubara T, et al. Comparative effects of captopril and nifedipine on split renal function in renovascular hypertension. Am J Hypertens 1988; 1:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19398/abstract/22\">",
"      Textor SC, Novick AC, Tarazi RC, et al. Critical perfusion pressure for renal function in patients with bilateral atherosclerotic renal vascular disease. Ann Intern Med 1985; 102:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19398/abstract/23\">",
"      Devoy MA, Tomson CR, Edmunds ME, et al. Deterioration in renal function associated with angiotensin converting enzyme inhibitor therapy is not always reversible. J Intern Med 1992; 232:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19398/abstract/24\">",
"      Hannedouche T, Godin M, Fries D, Fillastre JP. Acute renal thrombosis induced by angiotensin-converting enzyme inhibitors in patients with renovascular hypertension. Nephron 1991; 57:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19398/abstract/25\">",
"      Wenting GJ, Tan-Tjiong HL, Derkx FH, et al. Splint renal function after captopril in unilateral renal artery stenosis. Br Med J (Clin Res Ed) 1984; 288:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19398/abstract/26\">",
"      Jackson B, McGrath BP, Matthews PG, et al. Differential renal function during angiotensin converting enzyme inhibition in renovascular hypertension. Hypertension 1986; 8:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19398/abstract/27\">",
"      Hricik DE, Dunn MJ. Angiotensin-converting enzyme inhibitor-induced renal failure: causes, consequences, and diagnostic uses. J Am Soc Nephrol 1990; 1:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19398/abstract/28\">",
"      Onuigbo MA, Onuigbo NT. Use of ultrahigh RAAS blockade: implications for exacerbation of renal failure. Kidney Int 2006; 69:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19398/abstract/29\">",
"      Ahmed AK, Kamath NS, El Kossi M, El Nahas AM. The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. Nephrol Dial Transplant 2010; 25:3977.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3873 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-77.94.48.4-84E1ECB1DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_60_19398=[""].join("\n");
var outline_f18_60_19398=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21519415\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANGIOTENSIN II AND AUTOREGULATION OF GFR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PRIMARY HYPERTENSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Long-term effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RENOVASCULAR HYPERTENSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Unilateral renal artery stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Risk of ischemic atrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21519415\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3873\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3873|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/29/33245\" title=\"figure 1\">",
"      A2 and autoregulation of GFR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/35/26173\" title=\"figure 2\">",
"      Nitroprusside in RA stenosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/42/6824?source=related_link\">",
"      Clinical features, diagnosis, and treatment of hypertensive nephrosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/17/31001?source=related_link\">",
"      Establishing the diagnosis of renovascular hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8040?source=related_link\">",
"      Treatment of bilateral atherosclerotic renal artery stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=related_link\">",
"      Treatment of hypertension in patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29369?source=related_link\">",
"      Treatment of unilateral atherosclerotic renal artery stenosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_60_19399="Conjugated equine estrogens (topical): Drug information";
var content_f18_60_19399=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Conjugated equine estrogens (topical): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?16/48/17158?source=see_link\">",
"    see \"Conjugated equine estrogens (topical): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/30/14821?source=see_link\">",
"    see \"Conjugated equine estrogens (topical): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F8090825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8090835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Premarin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8090836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Premarin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8090840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Estrogen Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8090932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Atrophic vaginitis, kraurosis vulvae:",
"     </b>",
"     Adult females: Intravaginal: 0.5 g/day (range 0.5-2 g/day) administered cyclically (21 days on, 7 days off). Adjust dose based on patient response.",
"     <b>",
"      Note:",
"     </b>",
"     Canadian labeling recommends oral estrogen therapy (~1.25 mg/day for 10 days) prior to initiating topical estrogen in severe atrophic vaginitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Moderate-to-severe dyspareunia due to menopause:",
"     </b>",
"     Adult females: Intravaginal: 0.5 g twice weekly (eg, Monday and Thursday)",
"     <b>",
"      or",
"     </b>",
"     once daily cyclically (21 days on, 7 days off)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8090933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. A higher incidence of stroke and breast cancer was observed in women &gt;75 years in a WHI substudy.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F13451780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied). Use with caution; may increase risk of fluid retention.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F13451781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is contraindicated with hepatic dysfunction or disease.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8090970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, vaginal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Premarin&reg;: 0.625 mg/g (30 g, 42.5 g [DSC])",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8090838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8090958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Administer at bedtime to minimize adverse effects. Applicator calibrated in 0.5 g increments up to 2 g. To clean applicator, remove plunger from barrel. Wash with mild soap and warm water; do not boil or use hot water.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8090859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of atrophic vaginitis and kraurosis vulvae; moderate-to-severe dyspareunia (pain during intercourse) due to vaginal/vulvar atrophy of menopause",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8090828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Premarin&reg; may be confused with Primaxin&reg;, Provera&reg;, Remeron&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate [topical]; Strength of recommendation - weak [topical]).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8090874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Due to systemic absorption, other adverse effects associated with systemic therapy may also occur. Frequency of adverse events reported with daily use:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Vasodilatation (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Pain (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast pain (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Vaginitis (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (5%), weakness (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylactic reactions, breast cancer, deep vein thrombosis (DVT), dementia, depression, endometrial cancer, gallbladder disease, gynecomastia (males), hypertension, leukorrhea, MI, pulmonary emboli  (PE), retinal vascular thrombosis, stroke, uterine leiomyomata (increase in size)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8090865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Undiagnosed abnormal vaginal bleeding; history of or current thrombophlebitis or venous thromboembolic disorders (including DVT, PE); active or history of arterial thromboembolic disease (eg, stroke, MI); carcinoma of the breast; estrogen-dependent tumor; hepatic dysfunction or disease; known protein C, protein S, antithrombin deficiency or other known thrombophilic disorders;  pregnancy",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Hypersensitivity to estrogens or any component of the formulation; endometrial hyperplasia; partial or complete vision loss due to ophthalmic vascular disease",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8090866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Breast cancer:",
"     <b>",
"      [U.S. Boxed Warning]: Based on data from the Women&rsquo;s Health Initiative (WHI) studies, an increased risk of invasive breast cancer was observed in postmenopausal women using conjugated estrogens (CE) in combination with medroxyprogesterone acetate (MPA).",
"     </b>",
"     This risk may be associated with duration of use and declines once combined therapy is discontinued (Chlebowski, 2009). The risk of invasive breast cancer was decreased in postmenopausal women with a hysterectomy using CE only, regardless of weight. However, the risk was not significantly decreased in women at high risk for breast cancer (family history of breast cancer, personal history of benign breast disease) (Anderson, 2012).An increase in abnormal mammogram findings has also been reported with estrogen alone or in combination with progestin therapy. Estrogen use may lead to severe hypercalcemia in patients with breast cancer and bone metastases; discontinue estrogen if hypercalcemia occurs. Use is contraindicated in patients with known or suspected breast cancer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dementia:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens with or without progestin should not be used to prevent dementia. In the Women&rsquo;s Health Initiative Memory Study (WHIMS), an increased incidence of dementia was observed in women &ge;65 years of age taking CE alone or in combination with MPA.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Endometrial carcinoma:",
"     <b>",
"      [U.S. Boxed Warning]: The use of unopposed estrogen in women with an intact uterus is associated with an increased risk of endometrial cancer. The addition of a progestin to estrogen therapy may decrease the risk of endometrial hyperplasia, a precursor to endometrial cancer. Adequate diagnostic measures, including endometrial sampling if indicated, should be performed to rule out malignancy in postmenopausal women with undiagnosed abnormal vaginal bleeding.",
"     </b>",
"     Estrogens may exacerbate endometriosis. Malignant transformation of residual endometrial implants has been reported posthysterectomy with unopposed estrogen therapy. Consider adding a progestin in women with residual endometriosis posthysterectomy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Inherited thrombophilia: Women with inherited thrombophilias (eg, protein C or S deficiency) may have increased risk of venous thromboembolism (DeSancho, 2010; van Vlijmen, 2011). Use is contraindicated in women with protein C, protein S, antithrombin deficiency, or other known thrombophilic disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lipid effects: Estrogen compounds are generally associated with lipid effects such as increased HDL-cholesterol and decreased LDL-cholesterol. Triglycerides may also be increased; discontinue if pancreatitis occurs. Use with caution in patients with familial defects of lipoprotein metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ovarian cancer: Postmenopausal estrogen therapy and combined estrogen/progesterone therapy may increase the risk of ovarian cancer; however, the absolute risk to an individual woman is small. Although results from various studies are not consistent, risk does not appear to be significantly associated with the duration, route, or dose of therapy. In one study, the risk decreased after 2 years following discontinuation of therapy (M&oslash;rch, 2009). Although the risk of ovarian cancer is rare, women who are at an increased risk (eg, family history) should be counseled about the association (NAMS, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Retinal vascular thrombosis: Estrogens may cause retinal vascular thrombosis; discontinue if migraine, loss of vision, proptosis, diplopia, or other visual disturbances occur; discontinue permanently if papilledema or retinal vascular lesions are observed on examination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Use caution in patients with asthma; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carbohydrate intolerance: May have adverse effects on glucose tolerance; use caution in women with diabetes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens with or without progestin should not be used to prevent cardiovascular disease.",
"     </b>",
"     Using data from the Women&rsquo;s Health Initiative (WHI) studies, an increased risk of deep vein thrombosis (DVT) and stroke has been reported with CE and an increased risk of DVT, stroke, pulmonary emboli (PE) and myocardial infarction (MI) has been reported with CE with MPA in postmenopausal women. Additional risk factors include diabetes mellitus, hypercholesterolemia, hypertension, SLE, obesity, tobacco use, and/or history of venous thromboembolism (VTE). Risk factors should be managed appropriately; discontinue use if adverse cardiovascular events occur or are suspected.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diseases exacerbated by fluid retention: Use with caution in patients with diseases which may be exacerbated by fluid retention, including cardiac or renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Epilepsy: Use caution with epilepsy; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gallbladder disease: Use of postmenopausal estrogen may be associated with an increased risk of gallbladder disease requiring surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic dysfunction: Estrogens are poorly metabolized in patients with hepatic dysfunction. Use caution with a history of cholestatic jaundice associated with prior estrogen use or pregnancy. Discontinue if jaundice develops or if acute or chronic hepatic disturbances occur. Use is contraindicated with hepatic disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic hemangiomas: Use with caution in patients with hepatic hemangiomas.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hereditary angioedema: Exogenous estrogens may exacerbate angioedema symptoms in women with hereditary angioedema.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoparathyroidism: Use caution in patients with hypoparathyroidism; estrogen induced hypocalcemia may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Migraine: Use caution with migraine; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Porphyria: Use with caution in patients with porphyria; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; SLE: Use with caution in patients with SLE; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid replacement therapy: Estrogens may increase thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels. Women on thyroid replacement therapy may require higher doses of thyroid hormone while receiving estrogens.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Low-dose intravaginal estrogen may be appropriate for use in the management of vaginal symptoms, lower urinary tract infections, and dyspareunia; in addition, evidence has shown that vaginal estrogens (particularly at estradiol doses of &lt;25 mcg twice weekly) in the treatment of vaginal dryness is safe and effective in women with breast cancer. (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical patients: Whenever possible, estrogens should be discontinued at least 4-6 weeks prior to elective surgery associated with an increased risk of thromboembolism or during periods of prolonged immobilization.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaginal cream: Use of the vaginal cream may weaken latex found in condoms, diaphragms or cervical caps. Systemic absorption occurs following vaginal use; warnings, precautions, and adverse events observed with oral therapy should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Laboratory changes: The use of estrogens and/or progestins may change the results of some laboratory tests (eg, coagulation factors, lipids, glucose tolerance, binding proteins). The dose, route, and the specific estrogen/progestin influences these changes. In addition, personal risk factors (eg, cardiovascular disease, smoking, diabetes, age) also contribute to adverse events; use of specific products may be contraindicated in women with certain risk factors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Risks vs benefits:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens with or without progestin should be used for the shortest duration possible at the lowest effective dose consistent with treatment goals.",
"     </b>",
"     Before prescribing estrogen therapy to postmenopausal women, the risks and benefits must be weighed for each patient. Women should be informed of these risks and benefits, as well as possible effects of progestin when added to estrogen therapy. Patients should be reevaluated as clinically appropriate to determine if treatment is still necessary. Available data related to treatment risks are from Women&rsquo;s Health Initiative (WHI) studies, which evaluated oral CE 0.625 mg with or without MPA 2.5 mg relative to placebo in postmenopausal women. Other combinations and dosage forms of estrogens and progestins were not studied.",
"     <b>",
"      Outcomes reported from clinical trials using CE with or without MPA should be assumed to be similar for other doses and other dosage forms of estrogens and progestins until comparable data becomes available.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vulvar and vaginal atrophy use: Moderate-to-severe symptoms of vulvar and vaginal atrophy include vaginal dryness, dyspareunia, and atrophic vaginitis.  When used solely for the treatment of vulvar and vaginal atrophy, topical vaginal products should be considered. Use caution applying topical products to severely atrophic vaginal mucosa. Use of a progestin is normally not required when low-dose estrogen is applied locally and only for this purpose (NAMS, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8090889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major), CYP2A6 (minor), CYP2B6 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak);",
"     <b>",
"      Induces",
"     </b>",
"     CYP3A4 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8090890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anastrozole: Estrogen Derivatives may diminish the therapeutic effect of Anastrozole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ascorbic Acid: May increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chenodiol: Estrogen Derivatives may diminish the therapeutic effect of Chenodiol.  Management: Monitor clinical response to chenodiol closely when used together with any estrogen derivative.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Estrogen Derivatives may increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Estrogenic Properties): May enhance the adverse/toxic effect of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving estrogens (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): May enhance the thrombogenic effect of Estrogen Derivatives. NSAID (COX-2 Inhibitor) may increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: Estrogen Derivatives may enhance the adverse/toxic effect of Ospemifene. Estrogen Derivatives may diminish the therapeutic effect of Ospemifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: Estrogen Derivatives may increase the serum concentration of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: Estrogen Derivatives may diminish the therapeutic effect of Somatropin. Shown to be a concern with oral hormone replacement therapy in postmenopausal women.  Management: Monitor for reduced growth hormone efficacy. A larger somatropin dose may be required to reach treatment goal.  This interaction does not appear to apply to non-orally administered estrogens (e.g., transdermal, vaginal ring).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Estrogen Derivatives may diminish the therapeutic effect of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: Estrogen Derivatives may enhance the dermatologic adverse effect of Tipranavir. The combination of tipranavir/ritonavir and ethinyl estradiol/norethindrone was associated with a high incidence of skin rash. Tipranavir may decrease the serum concentration of Estrogen Derivatives.  Management: Women using hormonal contraceptives should consider alternative, non-hormonal forms of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ursodiol: Estrogen Derivatives may diminish the therapeutic effect of Ursodiol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8090861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Estrogens are not indicated for use during pregnancy or immediately postpartum. In general, the use of estrogen and progestin as in combination hormonal contraceptives have not been associated with teratogenic effects when inadvertently taken early in pregnancy. These products are contraindicated for use during pregnancy. Use of the vaginal cream may weaken latex found in condoms, diaphragms, or cervical caps.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8090863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F8090864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Estrogen has been shown to decrease the quantity and quality of human milk. Use only if clearly needed. Monitor the growth of the infant closely.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8090972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Premarin Vaginal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.625 mg/g (30 g): $207.11",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F8090963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Routine physical examination that includes blood pressure and Papanicolaou smear, breast exam, mammogram. Monitor for signs of endometrial cancer in female patients with uterus. Adequate diagnostic measures, including endometrial sampling, if indicated, should be performed to rule out malignancy in all cases of undiagnosed abnormal vaginal bleeding. Monitor for loss of vision, sudden onset of proptosis, diplopia, migraine; signs and symptoms of thromboembolic disorders; glycemic control in patients with diabetes; lipid profiles in patients being treated for hyperlipidemias; thyroid function in patients on thyroid hormone replacement therapy.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8090912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Conjugated estrogens contain a mixture of estrone sulfate, equilin sulfate, 17 alpha-dihydroequilin, 17 alpha-estradiol and 17 beta-dihydroequilin. Estrogens are responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Estradiol is the principle intracellular human estrogen and is more potent than estrone and estriol at the receptor level; it is the primary estrogen secreted prior to menopause. Following menopause, estrone and estrone sulfate are more highly produced. Estrogens modulate the pituitary secretion of gonadotropins, luteinizing hormone, and follicle-stimulating hormone through a negative feedback system; estrogen replacement reduces elevated levels of these hormones in postmenopausal women.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8090915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Systemic absorption occurs",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Binds to sex-hormone-binding globulin and albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP3A4; estradiol is converted to estrone and estriol; also undergoes enterohepatic recirculation (avoided with vaginal administration); estrone sulfate is the main metabolite in postmenopausal women",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: Total estrone: 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (primarily estriol, also as estradiol, estrone, and conjugates",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/60/19399/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson GL, Chlebowski RT, Aragaki AK, et al, \"Conjugated Equine Oestrogen and Breast Cancer Incidence and Mortality in Postmenopausal Women With Hysterectomy: Extended Follow-Up of the Women's Health Initiative Randomised Placebo-Controlled Trial,\"",
"      <i>",
"       Lancet Oncol,",
"      </i>",
"      2012,13(5):476-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/60/19399/abstract-text/22401913/pubmed\" id=\"22401913\" target=\"_blank\">",
"        22401913",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson GL, Limacher M, Assaf AR, et al, \"Effects of Conjugated Equine Estrogen In Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial.\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2004, 291(14):1701-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/60/19399/abstract-text/15082697/pubmed\" id=\"15082697\" target=\"_blank\">",
"        15082697",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chlebowski RT, Kuller LH, Prentice RL, et al, \"Breast Cancer After Use of Estrogen Plus Progestin in Postmenopausal Women,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 360(6):573-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/60/19399/abstract-text/19196674/pubmed\" id=\"19196674\" target=\"_blank\">",
"        19196674",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeSancho MT, Dorff T, and Rand JH, \"Thrombophilia and the Risk of Thromboembolic Events In Women on Oral Contraceptives and Hormone Replacement Therapy,\"",
"      <i>",
"       Blood Coagul Fibrinolysis",
"      </i>",
"      , 2010, 21(6):534-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/60/19399/abstract-text/20581664/pubmed\" id=\"20581664\" target=\"_blank\">",
"        20581664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hsia J, Langer RD, Manson JE, et al, \"Conjugated Equine Estrogens and Coronary Heart Disease: The Women's Health Initiative,\"",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2006, 166(3):357-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/60/19399/abstract-text/16476878/pubmed\" id=\"16476878\" target=\"_blank\">",
"        16476878",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      M&oslash;rch LS, L&oslash;kkegaard E, Andreasen AH, et al, &ldquo;Hormone Therapy and Ovarian Cancer,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2009, 302(3):298-305.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/60/19399/abstract-text/19602689/pubmed\" id=\"19602689\" target=\"_blank\">",
"        19602689",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      North American Menopause Society [NAMS], \"The 2012 Hormone Therapy Position Statement of The North American Menopause Society,\"",
"      <i>",
"       Menopause",
"      </i>",
"      , 2012, 19(3):257-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/60/19399/abstract-text/22367731/pubmed\" id=\"22367731\" target=\"_blank\">",
"        22367731",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      North American Menopause Society (NAMS), ''The Role of Local Vaginal Estrogen for Treatment of Vaginal Atrophy in Postmenopausal Women: 2007 Position Statement of The North American Menopause Society,\"",
"      <i>",
"       Menopause",
"      </i>",
"      , 2007,14(3 Pt 1):355-69.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/60/19399/abstract-text/17438512/pubmed\" id=\"17438512\" target=\"_blank\">",
"        17438512",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rossouw JE, Anderson GL, Prentice RL, et al, &ldquo;Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principle Results From the Women's Health Initiative Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(3):321-33.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shumaker S, Legault C, Thal L, et al, &ldquo;Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women: The Women's Health Initiative Memory Study: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289:2651-62.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Vlijmen EF, Veeger NJ, Middeldorp S, et al, \"Thrombotic Risk During Oral Contraceptive Use and Pregnancy in Women With Factor V Leiden or Prothrombin Mutation: A Rational Approach to Contraception,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 118(8):2055-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/60/19399/abstract-text/21659542/pubmed\" id=\"21659542\" target=\"_blank\">",
"        21659542",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9124 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-2FACFC3B1A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_60_19399=[""].join("\n");
var outline_f18_60_19399=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090825\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090835\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090836\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090840\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090932\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090933\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13451780\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13451781\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090970\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090838\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090958\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090859\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090828\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090874\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090865\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090866\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090889\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090890\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090861\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090863\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090864\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090972\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090963\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090912\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090915\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9124\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9124|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/51/28472?source=related_link\">",
"      Conjugated equine estrogens (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/17/41238?source=related_link\">",
"      Conjugated equine estrogens (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/29/22998?source=related_link\">",
"      Conjugated equine estrogens (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/48/17158?source=related_link\">",
"      Conjugated equine estrogens (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/30/14821?source=related_link\">",
"      Conjugated equine estrogens (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_60_19400="Hyperbilirubinemia in the premature infant (less than 35 weeks gestation)";
var content_f18_60_19400=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hyperbilirubinemia in the premature infant (less than 35 weeks gestation)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/60/19400/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/60/19400/contributors\">",
"     Vinod K Bhutani, MD, FAAP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/60/19400/contributors\">",
"     Ronald J Wong, BA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/60/19400/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/60/19400/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/60/19400/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/60/19400/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/60/19400/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost all preterm infants less than 35 weeks gestational age (GA) have elevated total serum or plasma bilirubin (TB) levels, which results in neonatal jaundice, the yellowish discoloration of the skin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sclerae caused by bilirubin deposition. The major complication of an elevated TB (hyperbilirubinemia) is bilirubin-induced neurologic dysfunction (BIND), which occurs when circulating bilirubin crosses the blood-brain barrier and binds to brain tissue. Acute bilirubin encephalopathy (ABE) is the acute and reversible form of BIND, while kernicterus is the chronic and permanent neurologic sequelae of BIND.",
"   </p>",
"   <p>",
"    Therapeutic interventions (ie, phototherapy and exchange transfusion) reduce the TB levels in the blood, which is thought to prevent BIND and, hence, kernicterus. In infants at or greater than 35 weeks GA (ie, term and late preterm infants), universally-accepted guidelines based upon an age-specific, percentile-based TB nomogram are used to decide when to initiate phototherapy and exchange transfusions to prevent severe hyperbilirubinemia and BIND [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19400/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=see_link\">",
"     \"Treatment of unconjugated hyperbilirubinemia in term and late preterm infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, in infants less than 35 weeks GA, similar guidelines are not available, despite observational evidence that suggest preterm infants less than 35 weeks GA are more susceptible to BIND at lower TB levels than more mature infants. Lack of an evidence-based consensus on the management of hyperbilirubinemia in the preterm infant is due to the variability of clinical manifestations and spectrum of BIND, lack of reliable and predictive measures of bilirubin neurotoxicity, and the uncertainty of the relative risks and benefits of interventions to reduce TB levels (ie, phototherapy and exchange transfusions), particularly in the extremely low birth weight (ELBW) infant (birth weight [BW] &le;1000 g).",
"   </p>",
"   <p>",
"    Hyperbilirubinemia in the premature infant &lt;35 weeks GA will be reviewed here. The diagnosis, evaluation, and management of hyperbilirubinemia in the late preterm and term infant are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25593?source=see_link\">",
"     \"Clinical manifestations of unconjugated hyperbilirubinemia in term and late preterm infants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/39/11898?source=see_link\">",
"     \"Evaluation of unconjugated hyperbilirubinemia in term and late preterm infants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=see_link\">",
"     \"Treatment of unconjugated hyperbilirubinemia in term and late preterm infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of kernicterus in premature infants is uncertain. A retrospective study reported a 4 percent rate of kernicterus based upon characteristic postmortem neuropathological findings (ie, bilirubin staining and neuronal necrosis) in 81 preterm infants (GA &lt;34 weeks) who died after 48 hours of life [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19400/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although there have been small case series of survivors with neurologic sequelae associated with hyperbilirubinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19400/abstract/3,4\">",
"     3,4",
"    </a>",
"    ], there are no data on the prevalence of kernicterus in premature survivors. Determining the prevalence rate is limited by the variability and spectrum of BIND in preterm infants, presence of co-morbidities (eg, sepsis, periventricular leukomalacia, and intraventricular hemorrhage), and delayed manifestations of hypertonicity. Dystonic posture and abnormal muscle tone may not manifest until six months corrected age [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19400/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since the late 1970s, the incidence of kernicterus in preterm infants has declined to the point where kernicterus is rarely seen postmortem, and significant neurologic sequelae (eg, choreoathetoid cerebral palsy [CP], sensorineural hearing losses) due to hyperbilirubinemia have not emerged as clinically significant issues [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19400/abstract/3\">",
"     3",
"    </a>",
"    ]. However, a small number of cases of choreoathetoid CP or sensorineural hearing losses that are associated with hyperbilirubinemia continue to be reported in premature survivors [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19400/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The decreased incidence of kernicterus in preterm infants may, in part, be due to the initiation of proactive measures to reduce TB or to changes in neonatal care that have eliminated unappreciated risk factors for kernicterus. As an example, the incidence of kernicterus fell from 31 to 0 percent in one neonatal intensive care unit when the use of bacteriostatic saline containing benzyl alcohol to flush intravenous lines was discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19400/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hyperbilirubinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of hyperbilirubinemia in the preterm infant is similar to that of the term infant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39992?source=see_link\">",
"     \"Pathogenesis and etiology of unconjugated hyperbilirubinemia in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is primarily caused by the following alterations in bilirubin metabolism compared to adults:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased bilirubin production because of increased red blood cell (RBC) breakdown (turnover)",
"     </li>",
"     <li>",
"      Decreased bilirubin clearance and conjugation (immature liver)",
"     </li>",
"     <li>",
"      Increased enterohepatic circulation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hyperbilirubinemia in preterm infants is more prevalent, severe, and protracted than that in term infants because of the increased immaturity of the RBCs, liver, and gastrointestinal tract in preterm infants [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19400/abstract/3\">",
"     3",
"    </a>",
"    ]. There also is often a delay in enteral feeds, which may limit intestinal flow and bacterial colonization, resulting in further enhancement of the enterohepatic circulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Bilirubin-induced neurologic dysfunction (BIND)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preterm infants, compared to term infants, appear to be more vulnerable to BIND at lower TB levels. A review of several studies from the 1960s and 1970s reporting case series of kernicterus in premature infants, who had TB levels that ranged from 10 to 18",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (171 to 308",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    showed that these TB levels were much lower than comparable TB values associated with kernicterus in term infants (TB &gt;20",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [342",
"    <span class=\"nowrap\">",
"     micromol/L])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19400/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bilirubin is a potential neurotoxin. Unconjugated bilirubin, which is not bound to albumin (also referred to as \"free\" or unbound bilirubin), enters the brain and causes cell death by apoptosis (programmed cell death)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    necrosis resulting in BIND. Increases in free bilirubin levels can be due to decreases in albumin binding to bilirubin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a disruption of the blood-brain barrier. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25593?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical manifestations of unconjugated hyperbilirubinemia in term and late preterm infants\", section on 'Neurologic manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, it is unclear if other clinical factors contribute to the increased susceptibility of premature infants for kernicterus. Although hypothermia, asphyxia, acidosis, sepsis, meningitis, and multiple drug therapies have all been implicated as risk factors for kernicterus, published studies thus far have failed to demonstrate an association between kernicterus and any of these factors [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19400/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of hyperbilirubinemia are due to bilirubin deposition in the skin (jaundice) and to bilirubin toxicity to the vulnerable neurons of the developing brain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Jaundice",
"    </span>",
"    &nbsp;&mdash;&nbsp;Jaundice is the yellow color produced by the deposition of bilirubin in the skin and subcutaneous tissues. Although an important and time-honored clinical sign, the presence of visible jaundice is not a reliable method to assess TB levels (severity of hyperbilirubinemia) or identify infants at risk for rapidly rising TB levels, especially in neonates with dark skin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25593?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations of unconjugated hyperbilirubinemia in term and late preterm infants\", section on 'Jaundice'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Neurologic findings",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Acute",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike term infants, acute signs of bilirubin-induced neurologic dysfunction (BIND) (eg, hypertonia, irritability, posturing, arching, and seizures) are not easily identified in preterm infants [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19400/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Signs, such as apnea, periodic breathing, and hypotonia, may be masked because of the use of analgesics or sedatives, or may not manifest because of the immaturity of the neurologic system. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25593?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical manifestations of unconjugated hyperbilirubinemia in term and late preterm infants\", section on 'Acute bilirubin encephalopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Auditory brainstem-evoked response (ABR) can detect acute reversible bilirubin-induced auditory dysfunction as well as irreversible sensorineural hearing loss [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19400/abstract/4,5,8\">",
"     4,5,8",
"    </a>",
"    ]. In one study of 191 preterm infants, abnormal ABRs were associated with elevated free bilirubin levels and increases in the ratio of free to total bilirubin (TB) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19400/abstract/9\">",
"     9",
"    </a>",
"    ]. The use of an automated ABR has been proposed as a useful tool to detect acute BIND in preterm infants [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19400/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intractable apneic events, concurrent with an abnormal ABR, have been reported in preterm infants at risk of BIND [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19400/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Kernicterus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kernicterus is the chronic and permanent sequelae of BIND. The following major post-icteric features of kernicterus in preterm infants are usually similar to that observed in term infants, because the basal ganglia remain the primary target of brain injury.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Choreoathetoid cerebral palsy (CP, chorea, ballismus, tremor, and dystonia). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18058?source=see_link\">",
"       \"Hyperkinetic movement disorders in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sensorineural hearing loss commonly manifesting as auditory neuropathy (abnormal ABR with normal otoacoustic emissions). Observational studies suggest that isolated sensorineural hearing abnormalities may be the dominant or the sole manifestations of BIND. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19050?source=see_link&amp;anchor=H27#H27\">",
"       \"Etiology of hearing impairment in children\", section on 'Hyperbilirubinemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gaze abnormalities, especially limitation of upward gaze.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Total bilirubin (TB)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The measurement of TB is the most frequent clinical laboratory test used to assess hyperbilirubinemia. Although highly variable, it is the only currently available surrogate used to predict the risk of kernicterus in preterm infants. Algorithms for initiating intervention using threshold TB levels have been developed based upon birth weight, however, a threshold TB that is predictive of neurological sequelae in preterm infants has yet to be identified. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A retrospective study from the National Institute of Child Health and Human Development (NICHD) Neonatal Research Network (NRN) of ELBW infants (BW &lt;1000 g) born between 1994 and 1997 assessed the relationship between peak TB and neurodevelopmental outcome at 18 to 22 months postmenstrual age [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19400/abstract/11\">",
"     11",
"    </a>",
"    ]. Peak TB levels were associated with an increased risk of death or neurodevelopmental impairment (NDI) (odds ratio [OR] 1.07, 95% confidence interval [CI] 1.03-1.11), hearing impairment requiring hearing aids (OR 1.14, 95% CI 1-1.3), and significant psychomotor impairment (OR 1.06, 95% CI 1-1.12). There were no associations between peak TB with CP, significant mental impairment, and NDI alone. This study was not able to determine whether poor outcome was associated directly to hyperbilirubinemia or perhaps due to adverse effects of phototherapy. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other follow-up studies have also failed to show a predictable and consistent association between peak TB and long-term NDI in preterm survivors [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19400/abstract/12-15\">",
"     12-15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Free bilirubin",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been proposed that a more appropriate predictor of BIND may be measurement of unbound or free bilirubin [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19400/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. This was best illustrated by a study of 1101 ELBW infants from the NICHD NRN that demonstrated increasing levels of unbound bilirubin (measured at a mean age of five days of life) was associated with higher rates of death or NDI at 18 to 24 months corrected age (eg, CP, blindness, hearing loss, and Bayley Scales Mental or Psychomotor Developmental Index score below 70) regardless of clinical status [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19400/abstract/19\">",
"     19",
"    </a>",
"    ]. In contrast, TB was only directly associated with an increased risk of death or NDI in unstable, but not stable, infants.",
"   </p>",
"   <p>",
"    However, laboratory testing of free bilirubin is not generally available. The ratio of bilirubin to albumin",
"    <span class=\"nowrap\">",
"     (B/A)",
"    </span>",
"    may serve as an approximate surrogate for unbound bilirubin, and can be used as an additional factor in determining the need for exchange transfusion in neonates &ge;35 weeks GA. Preterm infants are likely to have lower serum albumin levels, and it has been suggested that the",
"    <span class=\"nowrap\">",
"     B/A",
"    </span>",
"    ratio would be a good measure of the risk of bilirubin toxicity based upon birth weight (",
"    <a class=\"graphic graphic_table graphicRef66898 \" href=\"UTD.htm?5/22/5483\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19400/abstract/9,20\">",
"     9,20",
"    </a>",
"    ]. However, its usefulness may be limited, as other factors (eg, acidosis, use of multiple drugs, elevated free fatty acids, photoisomers) may interfere with",
"    <span class=\"nowrap\">",
"     B/A",
"    </span>",
"    binding or binding of bilirubin to sites other than albumin [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19400/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=see_link&amp;anchor=H24#H24\">",
"     \"Treatment of unconjugated hyperbilirubinemia in term and late preterm infants\", section on 'Bilirubin/albumin ratio'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Unknown risk and benefit of phototherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;It remains unclear whether early aggressive phototherapy is beneficial or potentially harmful to a subset of more immature very low birth weight (VLBW) infants (BW &lt;1500 g). However, it is generally believed that infants born &lt;35 weeks GA are at greater risk to develop BIND than more mature infants [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19400/abstract/3\">",
"     3",
"    </a>",
"    ]. However, kernicterus is a rare complication in premature infants that may be due in part to the aggressive use of phototherapy. Follow-up studies, as noted above, also have failed to demonstrate an association between a specific threshold peak total bilirubin (TB) level and neurologic outcome. In addition, there is concern that phototherapy increases the risk of mortality in low birth weight infants (BW &le;2500 g) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19400/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an effort to answer whether aggressive phototherapy is beneficial or harmful in extremely low birth weight (ELBW) infants (BW &le;1000 g) with elevated TB levels, a randomized trial from the National Institute of Child Health and Human Development (NICHD) NRN evaluated the outcome of 1974 ELBW infants who were randomly assigned to aggressive or conservative phototherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19400/abstract/22\">",
"     22",
"    </a>",
"    ]. At 12 to 36 hours of life (mean age about 24 hours), infants were stratified into two groups by birth weight (BW) (low BW: 501 to 750 g, and high BW: 751 to 1000 g) and then randomly assigned to receive either aggressive or conservative therapy during the first 14 days of life. Aggressive phototherapy was initiated and continued for 24 hours when TB &ge;5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (86",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    for both BW groups, and the threshold was increased to TB &ge;7",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (120",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    for the high BW group during the second week. Conservative therapy was initiated and continued for 24 hours at higher levels of TB &ge;8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (137",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    in the low BW group and &ge;10",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (171",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    in the high BW group. Irradiance levels were increased if the TB exceeded 13",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (222",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    and 15",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (257",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    in the low and high BW groups, respectively. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mean peak TB levels were lower following aggressive compared to conservative phototherapy (7 versus 9.8",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [120 versus 168",
"      <span class=\"nowrap\">",
"       micromol/L]).",
"      </span>",
"     </li>",
"     <li>",
"      Exchange transfusions were performed in five patients who met the predetermined criteria for this intervention. Two were from the aggressive phototherapy group and three from the conservative group. An additional infant from each group who met the exchange transfusion criteria did not undergo the procedure based upon the attending neonatologist's clinical judgment.",
"     </li>",
"     <li>",
"      There was no difference in the rate of the primary composite outcome of death or (NDI) at 18 to 22 months corrected age between aggressive and conservative therapy (52 versus 55 percent).",
"     </li>",
"     <li>",
"      There was no difference in the rates of death between the aggressive and conservative treatment groups (24 versus 23 percent).",
"     </li>",
"     <li>",
"      Aggressive compared to conservative therapy was associated with a lower rate of NDI (26 versus 30 percent). There were fewer infants with profound NDI in the aggressive therapy group.",
"     </li>",
"     <li>",
"      There was a lower rate of bronchopulmonary dysplasia in the aggressive versus conservative phototherapy group (41 versus 48 percent). There were no differences between the groups in regards to other secondary outcome measures (ie, grade 3 or 4 intraventricular hemorrhage, patent ductus arteriosus, necrotizing enterocolitis, retinopathy of prematurity, or late-onset sepsis).",
"     </li>",
"     <li>",
"      A subset analysis based upon BW demonstrated a trend towards a higher rate of death with aggressive versus conservative therapy in the lower BW group (39 versus 34 percent) and a lower risk of NDI (27 versus 32 percent).",
"     </li>",
"     <li>",
"      In the higher BW group, there was a lower risk of NDI in infants who received aggressive compared to those who received conservative therapy (25 versus 29 percent). There was no difference in mortality rate or other secondary outcome measures between the two groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The possibility of increased mortality associated with aggressive phototherapy in the lower BW group is particularly worrisome. These concerns are supported by the findings of an earlier trial of an increased mortality rate in preterm infants who received phototherapy compared to controls who receive no phototherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19400/abstract/21\">",
"     21",
"    </a>",
"    ]. These results indicate potential adverse effects of phototherapy in the most premature infants, which may contribute to an increased risk of death. It is possible that phototherapy may result in photo-oxidative injury to cell membranes, to which the most immature infants would be the most susceptible because of the greater transmission of light through their thin and gelatinous skin. Another speculation relates to the possible antioxidant role of bilirubin. If bilirubin has an antioxidant role, its absence due to early use of phototherapy in the first 24 hours of life could have a deleterious effect in the most immature infants, who are the most vulnerable to oxidant risk because of reduced natural antioxidants.",
"   </p>",
"   <p>",
"    A subsequent report from the NICHD NRN trial assessed the effect of phototherapy exposure on death and NDI at 18 to 22 months corrected age for 1802 patients (91.4 percent of the original cohort), of whom 1607 received phototherapy treatment (PTx) and 195 did not (NoPTx) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19400/abstract/23\">",
"     23",
"    </a>",
"    ]. The NoPTx group had a higher mean BW and gestational age (GA), and rate of caesarean section, and was more likely to have mothers with a lower educational level. At 18 to 22 months corrected age, phototherapy during the birth hospitalization was not independently associated with the primary outcome of death or NDI, death alone, or NDI alone. In the subgroup of lower BW infants (501 to 750 g), mortality before discharge was lower in the PTx group; however, this result may have been biased due to early deaths in this group prior to meeting the criteria for phototherapy. Among the lower BW group, the NoPTx group had an increased risk of severe cognitive impairment (Bayley Scales Mental Development Index score of &lt;50) compared with the PTx group (29 versus 12 percent). In contrast, in the larger BW group, there was no difference in NDI or mortality between the PTx and NoPTx groups.",
"   </p>",
"   <p>",
"    In a second analysis that compared patients treated with aggressive phototherapy (n = 230) versus those treated with conservative phototherapy (n = 218) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19400/abstract/24\">",
"     24",
"    </a>",
"    ], aggressive phototherapy in lower BW infants (501 to 750 g) was associated with increased mortality, but a reduction in NDI including profound impairment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88254618\">",
"    <span class=\"h3\">",
"     Prophylactic phototherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of prophylactic phototherapy in preterm infants (defined as initiation of phototherapy soon after birth and within 36 hours of life) has been suggested to prevent hyperbilirubinemia. In a meta-analysis that included nine studies, prophylactic phototherapy appeared to lower peak TB, and reduced the number of patients with peak TB levels &gt;10",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (171",
"    <span class=\"nowrap\">",
"     micromol/L,",
"    </span>",
"    relative risk [RR] 0.27, 95% 0.22 -0.33) and &gt;15",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (257",
"    <span class=\"nowrap\">",
"     micromol/L,",
"    </span>",
"    RR 0.13, 95% CI 0.07-0.23) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19400/abstract/25\">",
"     25",
"    </a>",
"    ]. Although there was no difference in the rate of cerebral palsy in two of the studies, one large study reported a small decrease in the rate of NDI.",
"   </p>",
"   <p>",
"    However, we do not suggest that prophylactic phototherapy be used given the uncertainty of the benefit and safety of early and aggressive phototherapy as discussed previously. In addition, prophylactic use would expose more infants to phototherapy, needlessly exposing some who would never require phototherapy, and potentially lead to increased costs and potential side effects to ELBW infants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6787702\">",
"    <span class=\"h3\">",
"     Light source and devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following light sources and devices are used for neonatal phototherapy and are discussed in detail elsewhere (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=see_link&amp;anchor=H14988413#H14988413\">",
"     \"Treatment of unconjugated hyperbilirubinemia in term and late preterm infants\", section on 'Light sources and devices'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fluorescent blue lights",
"     </li>",
"     <li>",
"      Halogen white lights",
"     </li>",
"     <li>",
"      Fiberoptic blankets or pads",
"     </li>",
"     <li>",
"      Blue light-emitting diodes (LEDs)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A subsequent report from the NICHD NRN trial compared the efficacy of phototherapy devices [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19400/abstract/26\">",
"     26",
"    </a>",
"    ]. In this study, the absolute and relative decrease of TB during the first 24 hours was greatest for the LEDs (2.2",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    22 percent) followed by spotlights (1.7",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    19 percent), bank of lights (1.3",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    8 percent), and blankets (0.8",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    1 percent). At 18 to 22 months corrected age, there were no differences in the primary outcome of death and neurodevelopmental outcome based on the phototherapy devices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Exchange transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence-based data on the indications for exchange transfusion are even more scant than that for phototherapy in infants &lt;35 weeks GA. As a result, there is wide practice range, and the decision to perform an exchange transfusion in a preterm infant is based upon the clinical judgment of the attending neonatologist and a cautious extrapolation of guidelines for infants &lt;35 weeks GA. An operational guideline suggested in 1985 was based on the preterm infant's BW [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19400/abstract/27\">",
"     27",
"    </a>",
"    ] guided by the NICHD NRN Phototherapy trial initiated in 1974 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19400/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This operational guideline was used in the study design of the previously discussed NICHD NRN trial, in which the indication for exchange transfusion was defined as a TB that exceeded the threshold based upon BW despite increased irradiance. However, in this study, two patients were not exchanged despite meeting study criteria on the basis of the judgment of the attending neonatologist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;There remains no consensus on how best to manage hyperbilirubinemia in infants &lt;35 weeks GA. A variety of approaches, including aggressive and conservative treatment, have been proposed and generally are based upon using threshold TB stratified by BW [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19400/abstract/27-31\">",
"     27-31",
"    </a>",
"    ]. As noted above, the outcome of a specific approach may vary depending upon the BW and GA. However, caution is advised if only BW is used as a guide; for example, a preterm infant with significant edema due to hydrops fetalis or significant hypoalbuminemia may have a misleading higher BW.",
"   </p>",
"   <p>",
"    A more precise predictive measure of bilirubin neurotoxicity is required so that evidence-based consensus practice guidelines can be developed to optimally treat hyperbilirubinemia in preterm infants &lt;35 weeks GA.",
"   </p>",
"   <p>",
"    However, until such data are available, utilizing the currently available limited information, we initiate phototherapy in infants &lt;35 weeks GA and who are &lt; seven days of age using the following stratified approach based upon GA, which incorporates the protocol used by the NICHD study and published expert opinions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19400/abstract/22,32,33\">",
"     22,32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      GA &lt;28 weeks &ndash; TB &gt;5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (86",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      GA 28 to 29 weeks &ndash; TB 6 to 8",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (103 to 137",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      GA 30 to 31 weeks &ndash; TB 8 to 10",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (137 to 171",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      GA 32 to 33 weeks &ndash; TB 10 to 12",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (171 to 205",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      GA &gt;34 weeks &ndash; TB 12 to 14",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (205 to 239",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In infants less than 72 hours of age, the threshold ranges for TB is lowered if there is a decreased",
"    <span class=\"nowrap\">",
"     B/A",
"    </span>",
"    ratio.",
"   </p>",
"   <p>",
"    Similarly, there are no data on the optimal TB level required for exchange transfusion. Assessment of the",
"    <span class=\"nowrap\">",
"     risk/benefit",
"    </span>",
"    ratio of an exchange transfusion needs to include the safety, efficiency, and known complications of an exchange transfusion. We strongly consider performing an exchange transfusion in any infant with suspicious neurologic signs, or when the TB levels exceed the ability of the infant's serum albumin to bind bilirubin.",
"   </p>",
"   <p>",
"    The following stratified approach based upon GA is based on the protocol used by the NICHD study and published expert opinions, and is used in considering exchange transfusions in premature infants without neurologic findings [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19400/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      GA &lt;28 weeks &ndash; TB 11 to 14",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (188 to 239",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      GA 28 to 29 weeks &ndash; TB 12 to 14",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (205 to 239",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      GA 30 to 31 weeks &ndash; TB 13 to 16",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (222 to 274",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      GA 32 to 33 weeks &ndash; TB 15 to 18",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (257 to 308",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      GA &gt;34 weeks &ndash; TB 17 to 19",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (291 to 325",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69025065\">",
"    <span class=\"h2\">",
"     Other approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines for the management of hyperbilirubinemia have been developed in the United Kingdom (UK) and Norway.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The UK guideline to initiate phototherapy and exchange transfusion is based on consensus opinion and reported current care practice in neonatal units (",
"      <a class=\"external\" href=\"file://www.nice.org.uk/nicemedia/live/12986/48678/48678.pdf\">",
"       NICE guideline for Neonatal Jaundice",
"      </a>",
"      ). The threshold to initiate treatment for preterm infants greater than 72 hours of age is determined using the following formula that utilizes GA (weeks).",
"      <br/>",
"      <br/>",
"      Total bilirubin in",
"      <span class=\"nowrap\">",
"       micromol/L",
"      </span>",
"      = (gestational age &times; 10) &ndash; 100",
"     </li>",
"     <li>",
"      The guideline to initiate phototherapy from Norway is based on the BW and postnatal age of the preterm infant [",
"      <a class=\"abstract\" href=\"UTD.htm?18/60/19400/abstract/34\">",
"       34",
"      </a>",
"      ]. In general, for infants &gt; 4 days of age, the following thresholds of TB are used based on BW:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      BW &gt;2500 g, but GA between 34 and 37 weeks: 17.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (300",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      BW between 1500 and 2500 g: 14.6",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (250",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      BW between 1000 and 1499 g: 11.7 (200",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      BW between &lt;1000 g: 8.8",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (150",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperbilirubinemia in preterm infants is more prevalent, severe, and protracted than term infants because of the increased immaturity of the RBCs, liver, and gastrointestinal tract in preterm infants. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Hyperbilirubinemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical manifestations of hyperbilirubinemia are due to bilirubin deposition in the skin (jaundice) and the brain. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Jaundice is the yellowish discoloration of the skin, subcutaneous tissue,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      sclerae caused by bilirubin deposition.",
"     </li>",
"     <li>",
"      Acute neurologic findings of bilirubin-induced neurologic dysfunction (BIND) are often absent in preterm infants &lt;35 weeks gestational age (GA). Automated auditory brainstem-evoked response may detect acute reversible bilirubin-induced auditory dysfunction.",
"     </li>",
"     <li>",
"      Kernicterus is the chronic and permanent sequelae of BIND. The clinical manifestations of kernicterus in preterm infants are similar to that observed in term infants and included choreoathetoid cerebral palsy, sensorineural hearing loss, and gaze abnormalities.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Phototherapy and exchange transfusions are effective interventions that reduce total bilirubin (TB) but may have significant complications. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=see_link\">",
"       \"Treatment of unconjugated hyperbilirubinemia in term and late preterm infants\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although kernicterus has been reported in preterm infants with lower TB than that seen in term infants with kernicterus, a threshold TB that is predictive of neurological sequelae in preterm infants has yet to be identified. As a result, there is no consensus on how best to manage hyperbilirubinemia in infants &lt;35 weeks GA because of the inability to identify a predictive threshold of TB for adverse outcomes and potential concerns for adverse effects of therapy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Bilirubin-induced neurologic dysfunction (BIND)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Total bilirubin (TB)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Unknown risk and benefit of phototherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In preterm infants &lt;35 weeks GA, we suggest initiating phototherapy based upon TB that is stratified by GA (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Although there are a number of experience-based management approaches developed by experts in the field that are based upon TB stratified by birth weight, we utilize the following TB thresholds based on GA in our practice (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Management'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      GA &lt;28 weeks &ndash; TB &gt;5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (86",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      GA 28 to 29 weeks &ndash; TB 6 to 8",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (103 to 137",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      GA 30 to 31 weeks &ndash; TB 8 to 10",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (137 to 171",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      GA 32 to 33 weeks &ndash; TB 10 to 12",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (171 to 205",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      GA &gt;34 weeks &ndash; TB 12 to 14",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (205 to 239",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In preterm infants &lt;35 weeks GA, we suggest that the use of exchange transfusion be reserved for patients who do not respond to intensive phototherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We consider exchange transfusion in any infant with neurologic signs suspicious of BIND, TB that exceeds the ability of available phototherapy to effectively lower the TB level (eg, TB levels &gt;5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [86",
"      <span class=\"nowrap\">",
"       micromol/L]",
"      </span>",
"      greater than the values used to initiate phototherapy), failure of phototherapy, and the clinical benefit of exchange transfusion exceeds its potential risks.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19400/abstract/1\">",
"      American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004; 114:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19400/abstract/2\">",
"      Watchko JF, Claassen D. Kernicterus in premature infants: current prevalence and relationship to NICHD Phototherapy Study exchange criteria. Pediatrics 1994; 93:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19400/abstract/3\">",
"      Watchko JF, Maisels MJ. Jaundice in low birthweight infants: pathobiology and outcome. Arch Dis Child Fetal Neonatal Ed 2003; 88:F455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19400/abstract/4\">",
"      Okumura A, Kidokoro H, Shoji H, et al. Kernicterus in preterm infants. Pediatrics 2009; 123:e1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19400/abstract/5\">",
"      Bhutani VK, Johnson LH, Shapiro SM. Kernicterus in sick and preterm infants (1999-2002): a need for an effective preventive approach. Semin Perinatol 2004; 28:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19400/abstract/6\">",
"      Turkel SB, Guttenberg ME, Moynes DR, Hodgman JE. Lack of identifiable risk factors for kernicterus. Pediatrics 1980; 66:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19400/abstract/7\">",
"      Kim MH, Yoon JJ, Sher J, Brown AK. Lack of predictive indices in kernicterus: a comparison of clinical and pathologic factors in infants with or without kernicterus. Pediatrics 1980; 66:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19400/abstract/8\">",
"      Amin SB. Clinical assessment of bilirubin-induced neurotoxicity in premature infants. Semin Perinatol 2004; 28:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19400/abstract/9\">",
"      Ahlfors CE, Amin SB, Parker AE. Unbound bilirubin predicts abnormal automated auditory brainstem response in a diverse newborn population. J Perinatol 2009; 29:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19400/abstract/10\">",
"      Amin SB, Charafeddine L, Guillet R. Transient bilirubin encephalopathy and apnea of prematurity in 28 to 32 weeks gestational age infants. J Perinatol 2005; 25:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19400/abstract/11\">",
"      Oh W, Tyson JE, Fanaroff AA, et al. Association between peak serum bilirubin and neurodevelopmental outcomes in extremely low birth weight infants. Pediatrics 2003; 112:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19400/abstract/12\">",
"      Yeo KL, Perlman M, Hao Y, Mullaney P. Outcomes of extremely premature infants related to their peak serum bilirubin concentrations and exposure to phototherapy. Pediatrics 1998; 102:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19400/abstract/13\">",
"      Graziani LJ, Mitchell DG, Kornhauser M, et al. Neurodevelopment of preterm infants: neonatal neurosonographic and serum bilirubin studies. Pediatrics 1992; 89:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19400/abstract/14\">",
"      van de Bor M, Ens-Dokkum M, Schreuder AM, et al. Hyperbilirubinemia in low birth weight infants and outcome at 5 years of age. Pediatrics 1992; 89:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19400/abstract/15\">",
"      O'Shea TM, Dillard RG, Klinepeter KL, Goldstein DJ. Serum bilirubin levels, intracranial hemorrhage, and the risk of developmental problems in very low birth weight neonates. Pediatrics 1992; 90:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19400/abstract/16\">",
"      Wennberg RP, Ahlfors CE, Bhutani VK, et al. Toward understanding kernicterus: a challenge to improve the management of jaundiced newborns. Pediatrics 2006; 117:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19400/abstract/17\">",
"      Nakamura H, Yonetani M, Uetani Y, et al. Determination of serum unbound bilirubin for prediction of kernicterus in low birthweight infants. Acta Paediatr Jpn 1992; 34:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19400/abstract/18\">",
"      Hulzebos CV, van Imhoff DE, Bos AF, et al. Usefulness of the bilirubin/albumin ratio for predicting bilirubin-induced neurotoxicity in premature infants. Arch Dis Child Fetal Neonatal Ed 2008; 93:F384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19400/abstract/19\">",
"      Oh W, Stevenson DK, Tyson JE, et al. Influence of clinical status on the association between plasma total and unbound bilirubin and death or adverse neurodevelopmental outcomes in extremely low birth weight infants. Acta Paediatr 2010; 99:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19400/abstract/20\">",
"      Ahlfors CE. Criteria for exchange transfusion in jaundiced newborns. Pediatrics 1994; 93:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19400/abstract/21\">",
"      Lipsitz PJ, Gartner LM, Bryla DA. Neonatal and infant mortality in relation to phototherapy. Pediatrics 1985; 75:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19400/abstract/22\">",
"      Morris BH, Oh W, Tyson JE, et al. Aggressive vs. conservative phototherapy for infants with extremely low birth weight. N Engl J Med 2008; 359:1885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19400/abstract/23\">",
"      Hintz SR, Stevenson DK, Yao Q, et al. Is phototherapy exposure associated with better or worse outcomes in 501- to 1000-g-birth-weight infants? Acta Paediatr 2011; 100:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19400/abstract/24\">",
"      Tyson JE, Pedroza C, Langer J, et al. Does aggressive phototherapy increase mortality while decreasing profound impairment among the smallest and sickest newborns? J Perinatol 2012; 32:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19400/abstract/25\">",
"      Okwundu CI, Okoromah CA, Shah PS. Prophylactic phototherapy for preventing jaundice in preterm or low birth weight infants. Cochrane Database Syst Rev 2012; 1:CD007966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19400/abstract/26\">",
"      Morris BH, Tyson JE, Stevenson DK, et al. Efficacy of phototherapy devices and outcomes among extremely low birth weight infants: multi-center observational study. J Perinatol 2013; 33:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19400/abstract/27\">",
"      Lee KS, Gartner LM. Management of unconjugated hyperbilirubinemia in the newborn. Semin Liver Dis 1983; 3:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19400/abstract/28\">",
"      Brown AK, Kim MH, Wu PY, Bryla DA. Efficacy of phototherapy in prevention and management of neonatal hyperbilirubinemia. Pediatrics 1985; 75:393.",
"     </a>",
"    </li>",
"    <li>",
"     Maisels MJ. Neonatology: Pathophysiology and Management of the Newborn, 6th ed, Avery GB, Fletcher MA, Macdonald MG (Eds), Lippincott Williams &amp; Wilkins, 2005.",
"    </li>",
"    <li>",
"     Ives NK. Neonatal jaundice. In: Textbook of Neonatology, 3rd ed, Rennie JM (Ed), Churchill Livingston, Edinburgh 2005. p.675.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19400/abstract/31\">",
"      Maisels MJ, Watchko JF. Treatment of jaundice in low birthweight infants. Arch Dis Child Fetal Neonatal Ed 2003; 88:F459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19400/abstract/32\">",
"      Cashore WJ. Bilirubin and jaundice in the micropremie. Clin Perinatol 2000; 27:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19400/abstract/33\">",
"      Maisels MJ, Watchko JF, Bhutani VK, Stevenson DK. An approach to the management of hyperbilirubinemia in the preterm infant less than 35 weeks of gestation. J Perinatol 2012; 32:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19400/abstract/34\">",
"      Bratlid D, Nakstad B, Hansen TW. National guidelines for treatment of jaundice in the newborn. Acta Paediatr 2011; 100:499.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5037 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-194.187.108.93-5353394DC6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_60_19400=[""].join("\n");
var outline_f18_60_19400=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Bilirubin-induced neurologic dysfunction (BIND)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Jaundice",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Neurologic findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Acute",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Kernicterus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Total bilirubin (TB)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Free bilirubin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Unknown risk and benefit of phototherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H88254618\">",
"      - Prophylactic phototherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6787702\">",
"      - Light source and devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Exchange transfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Our approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H69025065\">",
"      Other approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5037\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5037|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/22/5483\" title=\"table 1\">",
"      Bilirubin albumin ratio BW",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25593?source=related_link\">",
"      Clinical manifestations of unconjugated hyperbilirubinemia in term and late preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19050?source=related_link\">",
"      Etiology of hearing impairment in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/39/11898?source=related_link\">",
"      Evaluation of unconjugated hyperbilirubinemia in term and late preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18058?source=related_link\">",
"      Hyperkinetic movement disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39992?source=related_link\">",
"      Pathogenesis and etiology of unconjugated hyperbilirubinemia in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=related_link\">",
"      Treatment of unconjugated hyperbilirubinemia in term and late preterm infants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_60_19401="Nonresponse and resistance to aspirin";
var content_f18_60_19401=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nonresponse and resistance to aspirin",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/60/19401/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/60/19401/contributors\">",
"     Charles H Hennekens, MD, DrPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/60/19401/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/60/19401/contributors\">",
"     James L Zehnder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/60/19401/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/60/19401/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/60/19401/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/60/19401/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/60/19401/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H21311303\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    resistance\" has been used to describe the occurrence of occlusive cardiovascular disease (CVD) events despite regular intake of this agent at recommended doses [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. Such circumstances are best termed treatment failures, which resemble those with other drugs of life-saving benefit in the treatment of occlusive CVD events, including statins, beta blockers, as well as angiotensin converting enzyme inhibitors and angiotensin receptor blockers.",
"   </p>",
"   <p>",
"    When used for secondary prevention, antiplatelet therapies reduce nonfatal CVD by approximately one-fourth, and fatal events by approximately one-sixth. Accordingly, three-fourths of nonfatal and five-sixths of fatal events are not prevented by these drugs. Thus, for any drug of lifesaving benefit that has less than 100 percent efficacy, treatment failure does not necessarily imply \"resistance.\" For CVD events, treatment failures may be due to numerous reasons, only one of which is inability of the antiplatelet agent to specifically block its platelet target [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues related to nonresponse, treatment failure, and \"resistance\" after the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    will be reviewed here [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/10\">",
"     10",
"    </a>",
"    ]. The various uses of aspirin in the treatment of patients with CVD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27786?source=see_link&amp;anchor=H2#H2\">",
"     \"Antithrombotic therapy for percutaneous coronary intervention: General use\", section on 'Aspirin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/35/2618?source=see_link\">",
"     \"Antiplatelet therapy for secondary prevention of stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues related to nonresponse, treatment failure, and &ldquo;resistance&rdquo; to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37418?source=see_link\">",
"     \"Nonresponse and resistance to clopidogrel\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21311310\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is useful to describe how the terms resistance, nonresponse, and failure, as applied to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , have been utilized in the literature:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment failure following the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      is a clinical observation, which can be operationally defined as the failure of aspirin to prevent occlusive CVD events. Treatment failure, however, does not necessarily imply \"resistance,\" since no effective cardiovascular drug prevents all events. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37418?source=see_link&amp;anchor=H1#H1\">",
"       \"Nonresponse and resistance to clopidogrel\", section on 'Introduction'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      resistance is a laboratory phenomenon, in which there is the inability of aspirin to inhibit one or more in vitro tests of platelet function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on considerations discussed below, the terms \"",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    resistance\" and \"aspirin treatment failure\" are insufficiently precise to offer a credible basis for clinical decision making. Considering the current totality of evidence, the more appropriate term for this purpose is \"aspirin nonresponse\" [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21311359\">",
"    <span class=\"h1\">",
"     ASPIRIN RESISTANCE TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;While thrombosis is the proximate cause of virtually all occlusive CVD events, other factors such as vascular function and perhaps interactions with endothelial cells",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    monocytes are also likely to be important. However, mechanistic approaches to investigating \"",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    resistance\" have relied heavily upon ex vivo evaluation of platelet function, using such tests as light transmission platelet aggregometry following addition of arachidonic acid or ADP, the Platelet Function Analyzer (PFA-100), the VerifyNow Aspirin rapid platelet function assay, or measurement of thromboxane generation in vitro or via serum levels of thromboxane B2 or urinary levels of 11-dehydrothromboxane B2 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/6,12,13\">",
"     6,12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6234625\">",
"    <span class=\"h2\">",
"     Arachidonic acid-induced platelet activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    resistance has also been defined as the inability of aspirin to inhibit platelet thromboxane A2 production or to inhibit tests of platelet function that are dependent upon platelet thromboxane production. This is most often demonstrated via the ability of aspirin to markedly inhibit arachidonic acid-induced platelet activation and aggregation, via aspirin's inhibitory effect on platelet cyclooxygenase-1 (COX-1) activity.",
"   </p>",
"   <p>",
"    This effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    has shown little laboratory or genetic variability and can be demonstrated in virtually all patients taking 81",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of aspirin [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. Using this method, aspirin resistance has been generally defined as &ge;20 percent platelet aggregation when using 0.5 to 1.0",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    arachidonic acid as the agonist [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6234632\">",
"    <span class=\"h2\">",
"     Other in vitro tests of platelet function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether the inhibition of in vitro platelet function by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    as measured by platelet aggregation responses to agonists other than arachidonic acid (eg, ADP, collagen, epinephrine) has clinical relevance is unclear. Resistance to these effects of aspirin, which may be only partially dependent upon or independent of COX-1, has shown laboratory and genetic variability, as well as a dose dependency, which may partially explain treatment failure with antiplatelet therapies (eg, aspirin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ) in patients with CVD [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/14-17,20-24\">",
"     14-17,20-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      resistance, as defined by an Aspirin Reaction Unit score of &ge;550 units using the VerifyNow Aspirin assay, was present in 27 percent of 468 patients with stable coronary disease [",
"      <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/20\">",
"       20",
"      </a>",
"      ]. Multivariate predictors of aspirin resistance in these patients included anemia and aspirin dose. For patients taking 300, 150, or &le;100",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of aspirin for &ge;4 weeks, resistance was found in zero, 17, and 30 percent of patients, respectively.",
"     </li>",
"     <li>",
"      Using the Ultegra Rapid Platelet Function Assay ASA, which employs propyl gallate to activate platelets,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      resistance was noted in 21 percent of 200 hypertensive subjects [",
"      <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/25\">",
"       25",
"      </a>",
"      ]. In this study, testing was done only once and there was no control for compliance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6234963\">",
"    <span class=\"h2\">",
"     Test correlations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of \"",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    resistance\", as defined by the various available tests, varies widely, being highest for the PFA-100 test (60 percent, see below) and lowest using light transmission platelet aggregometry following addition of arachidonic acid or measurement of serum levels of thromboxane B2 (1 to 4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/26-28\">",
"     26-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These different laboratory methods for detecting \"",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    resistance\" correlate poorly with one another, if at all, suggesting that they are sensitive to different parameters of ex vivo platelet function, including pre-existing platelet hyperreactivity [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/13,29\">",
"     13,29",
"    </a>",
"    ]. This variability has been shown in normal volunteers as well as in patients with coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/30-35\">",
"     30-35",
"    </a>",
"    ]. In one study performed in 951 consecutive patients receiving dual antiplatelet therapy and undergoing percutaneous coronary intervention, none of the four tests employed was able to identify patients at risk for bleeding, further limiting their usefulness [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of six different platelet function assays in 48 young, healthy volunteers taking 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of enteric-coated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for one to eight weeks, aspirin was shown to variably suppress the following measures of platelet function [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum thromboxane B2 levels &mdash; 99+ percent reduction at one week (range: 96.3 to 99.9 percent), with little or no inter- or intra-individual variation",
"     </li>",
"     <li>",
"      Arachidonic acid-induced platelet aggregation &mdash; 80 percent inhibition (range: 50 to 97 percent)",
"     </li>",
"     <li>",
"      Urinary 11-dehydro-thromboxane B2 levels &mdash; 66 percent reduction at one week (range: 46 to 93 percent)",
"     </li>",
"     <li>",
"      Collagen-induced platelet aggregation &mdash; 50 percent inhibition by three weeks, with wide interindividual variability",
"     </li>",
"     <li>",
"      ADP-induced platelet aggregation &mdash; 40 percent maximal inhibition by three weeks, with substantial interindividual variability",
"     </li>",
"     <li>",
"      VerifyNow",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      assay &mdash; 30 to 35 percent inhibition over the entire eight week period",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recovery of platelet function, as assessed by these functional assays, reached approximately 70 percent of baseline levels at day 3 post-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    . Of importance, using any of the above functional assays except serum thromboxane B2 levels, subjects found to be \"resistant\" at a specific time point were found to be responsive on previous or subsequent measurements, indicating that such resistance was not a stable phenomenon over time [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of six different platelet function tests in 201 patients with stable coronary artery disease who were receiving &gt;80",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , the prevalence of \"aspirin resistance\" varied according to the assay used, as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Aggregometry after 1.6 mM arachidonic acid &mdash; 4 percent",
"     </li>",
"     <li>",
"      VerifyNow",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      assay &mdash; 7 percent",
"     </li>",
"     <li>",
"      Aggregometry after 5 to 20 microM ADP &mdash; 10 to 52 percent",
"     </li>",
"     <li>",
"      Whole blood aggregometry &mdash; 18 percent",
"     </li>",
"     <li>",
"      Urinary 11-dehydrothromboxane B2 &mdash; 23 percent",
"     </li>",
"     <li>",
"      PFA-100 &mdash; 60 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is not known how precisely the impact of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    on the ex vivo response to selected concentrations of a single aggregating agonist might model its efficacy in decreasing occlusive CVD events in vivo. Multiple technical as well as clinical factors may confound platelet aggregometry, including posture, time of day, smoking, exercise, blood cholesterol, as well as the choice of agent used for anticoagulation of the blood sample [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/36\">",
"     36",
"    </a>",
"    ]. In addition, platelet aggregability may recover despite sustained inhibition of thromboxane synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/37\">",
"     37",
"    </a>",
"    ]. Finally, the capacity of platelets to generate thromboxane has to be suppressed by &gt;95 percent before inhibition of aggregation occurs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6234971\">",
"    <span class=\"h1\">",
"     CAUSES OF ASPIRIN NONRESPONSE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21311374\">",
"    <span class=\"h2\">",
"     Genetic variability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on laboratory testing of platelet function in patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , or high baseline in vitro platelet function, a number of single nucleotide polymorphisms (SNPs) have been reported as &ldquo;aspirin resistant&rdquo; in both diabetic and non-diabetic subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Whether these SNPs affected clinical outcomes in patients with angiographically significant coronary heart disease was explored in data from a case series of 648 subjects who had banked DNA data, reported regular aspirin use, and were followed over a median of 3.5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/38\">",
"     38",
"    </a>",
"    ]. In both univariate and multivariate analyses, no candidate SNPs were significantly associated with death, myocardial infarction, or stroke.",
"   </p>",
"   <p>",
"    The authors concluded that their descriptive data, while useful to formulate but not test hypotheses, did not support the use of these SNPs to guide more aggressive antiplatelet therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6235097\">",
"    <span class=\"h2\">",
"     Compliance issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro arachidonic acid-induced platelet aggregation was studied in a case series of 203 patients undergoing PCI who reported compliance with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Aspirin \"resistance\" was noted in seven patients (3.4 percent), all of whom later admitted to being aspirin non-compliant when told of the test results. All seven were found to be aspirin sensitive after in-hospital supervised administration of 325 mg of aspirin. Overall, only one patient in the total group of 233 patients with coronary artery disease (0.4 percent) was truly aspirin \"resistant.\"",
"   </p>",
"   <p>",
"    Similar results were noted in a second case series of consecutive patients undergoing coronary stenting and receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    at a dose of 75",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/42\">",
"     42",
"    </a>",
"    ]. One month after hospital discharge, 19 of the 136 patients (14 percent) were identified as nonresponders to arachidonic acid-induced platelet aggregation. After controlled administration of aspirin, all except one became responders and were identified as patients with noncompliance rather than biological resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H437013703\">",
"    <span class=\"h2\">",
"     Use of enteric coated aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enteric coated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    is sometimes administered instead of non-enteric coated aspirin (ie, dispersible or immediate release aspirin) to prevent or reduce gastrointestinal toxicity, but absorption is delayed. This may result in an insufficient antithrombotic effect, especially in the acute setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link&amp;anchor=H4#H4\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\", section on 'Enteric-coated and buffered aspirin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A series of 400 volunteers were screened for their response to a single oral dose of 325 mg immediate release or enteric coated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    as determined by several in vitro tests of platelet function [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/43\">",
"     43",
"    </a>",
"    ]. Individuals who appeared \"aspirin resistant\" underwent repeat testing, and those who continued to appear \"resistant\" received one week of low dose enteric coated aspirin (81 mg). While there was a high frequency of apparent resistance to a single dose of 325 mg enteric coated aspirin (up to 49 percent), this was not the case with immediate release aspirin (0 percent). All except one individual who initially did not respond to enteric coated aspirin subsequently did respond to one of the following: re-exposure, serial dosing with enteric-coated aspirin, change to non-enteric coated aspirin, or addition of aspirin to their platelets ex vivo. The individual who did not respond to aspirin re-exposure and extension of the post dosing interval also showed resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , which inhibits platelets by a separate mechanism, suggesting a more general platelet abnormality in this subject. The authors concluded that pharmacological resistance to aspirin is rare; this study failed to identify a single case of true drug resistance. Pseudoresistance, reflecting delayed and reduced drug absorption, complicates enteric coated but not immediate release aspirin administration.",
"   </p>",
"   <p>",
"    Thus, for acute events, non-enteric coated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    is necessary to achieve a rapid clinical antithrombotic effect. In addition, evidence in patients with stable coronary artery disease and apparently healthy volunteers suggests that the 81 mg dose of enteric coated aspirin may have reduced clinical efficacy. At present, the totality of evidence suggests that low dose enteric coated aspirin may be insufficient to attain a clinical antithrombotic effect. In the acute setting, if enteric coated aspirin is the only available preparation, the tablet(s) should be crushed or chewed to provide an appropriate dose (ideally 325 mg). With respect to chronic administration, the totality of evidence is incomplete but suggestive that doses higher than 81 mg may be necessary if the aspirin is enteric coated [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/43-47\">",
"     43-47",
"    </a>",
"    ]. Issues regarding the choice aspirin formulation in patients with cardiovascular disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link&amp;anchor=H21#H21\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\", section on 'Aspirin formulation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6235111\">",
"    <span class=\"h2\">",
"     Use of proton pump inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two studies have suggested that the use of proton pump inhibitors (PPIs) interferes with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    function:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a case-control study including 418 patients with coronary disease, in vitro platelet aggregation following arachidonic acid was significantly greater in patients treated with PPIs than in those not taking these medications [",
"      <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective nationwide study followed all",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      treated patients surviving 30 days after a first myocardial infarction. Treatment with a PPI, compared with non-users of a PPI, was associated with a significantly greater risk of the combined endpoint of cardiovascular death, myocardial infarction, or stroke (HR 1.46; 95% CI 1.33-1.61) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since the most plausible effect size is small to moderate, large scale randomized trials represent the most reliable design strategy to test the hypothesis formulated from these observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6235466\">",
"    <span class=\"h2\">",
"     Other possible mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The biologic mechanisms by which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    nonresponse might occur are not well understood [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/1,3,4,51-55\">",
"     1,3,4,51-55",
"    </a>",
"    ]. The following are among the hypotheses that have been proposed in addition to noncompliance with aspirin [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/2,3,8,56\">",
"     2,3,8,56",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      nonresponse may differ from responders. As an example, they may have more advanced atherosclerosis as well as more macrophages in the atherosclerotic plaques, which may produce thromboxane by synthesizing new COX-2 after inhibition by aspirin [",
"      <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/52,57\">",
"       52,57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There may be an intrinsic platelet mechanism that allows thromboxane production despite the presence of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      . Such an effect could be related to polymorphisms in the COX-1 gene that confer relative nonresponse to low dose aspirin [",
"      <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/52,57\">",
"       52,57",
"      </a>",
"      ], to residual thromboxane production by the platelet or other sources (eg, vascular endothelium) that may or may not be independent of COX-1",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      COX-2 [",
"      <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/55,58,59\">",
"       55,58,59",
"      </a>",
"      ],",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      to active extrusion of aspirin from the platelet by means of multidrug resistance protein-4-mediated transport [",
"      <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Drugs such as nonaspirin NSAIDs (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      ) may interfere with the beneficial effect of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/61\">",
"       61",
"      </a>",
"      ], and other agents may reduce the absorption of aspirin from the gastrointestinal tract. In a nested case-control study from the Physicians' Health Study, noncompliance and concomitant use of NSAIDs (for more than 60 days per year) offered a plausible explanation for the lack of clinical benefit on first MI in subjects randomly assigned to treatment with aspirin [",
"      <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/62\">",
"       62",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=see_link\">",
"       \"Nonselective NSAIDs: Adverse cardiovascular effects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Platelet function inhibition by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      may be a matter of degree, rather than being \"all or none.\" Accordingly, underdosing (eg, increased body weight), poor absorption of aspirin, or increased platelet turnover or activation may also be a factor in aspirin nonresponse [",
"      <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/1,4,20,26,40,58,63\">",
"       1,4,20,26,40,58,63",
"      </a>",
"      ]. As an example, twice-daily dosing of low-dose aspirin may be more effective than once-daily dosing in essential thrombocythemia because of enhanced platelet turnover and therefore faster renewal of platelet COX-1 [",
"      <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/64\">",
"       64",
"      </a>",
"      ]. In vitro studies in patients with essential thrombocythemia or diabetes [",
"      <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/65,66\">",
"       65,66",
"      </a>",
"      ] show that 100 mg aspirin twice daily is superior to once daily dosing. The possible clinical relevance of these in vitro findings has not been studied. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/28/32202?source=see_link&amp;anchor=H19#H19\">",
"       \"Prognosis and treatment of essential thrombocythemia\", section on 'Low dose aspirin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      may have antithrombotic effects unrelated to its COX-1-dependent inhibition of platelet function (eg, reduction in thrombin generation, acetylation of fibrinogen resulting in increased fibrin clot permeability and enhanced clot lysis, genetic variability in pathways regulating the response to platelet agonists other than arachidonate) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/14,56\">",
"       14,56",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While currently a research question, in vitro assessment of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    resistance may assume future clinical relevance if the failure of aspirin in these patients can be traced to pathways that are only partially dependent upon, or independent of, aspirin's inhibitory effect on COX-1. This was shown in a study of platelet responsiveness to aspirin in 1880 asymptomatic subjects recruited from 309 white and 208 black families with premature coronary heart disease. The following observations were made [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For the pathway directly attributable to COX-1 inhibition by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (ie, platelet aggregation following arachidonate), there was little or no clinical or genetic variability. In these patients, aspirin inhibited arachidonate-induced platelet aggregation and thromboxane B2 production by &ge;99 percent.",
"     </li>",
"     <li>",
"      The ability of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      to inhibit pathways only partially dependent upon, or independent of, COX-1 varied widely. As examples, platelet aggregation to collagen, epinephrine, or ADP was inhibited by 88, 58, and 20 percent, respectively. In addition, genetic variability could be shown for these pathways.",
"     </li>",
"     <li>",
"      The heritable factors affecting platelet responsiveness were independent of traditional cardiac risk factors (eg, hypertension, diabetes mellitus, cigarette smoking, hypercholesterolemia, obesity).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21311381\">",
"    <span class=\"h1\">",
"     CLINICAL AND EPIDEMIOLOGIC OBSERVATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of case series have been published that are useful to formulate, but not test, hypotheses concerning",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    nonresponse [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/11,20,67-71\">",
"     11,20,67-71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A case series of 326 patients with stable cardiovascular disease who were taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (325",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      for at least seven days and no other antiplatelet agent were tested for aspirin sensitivity by in vitro optical platelet aggregation testing [",
"      <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/67\">",
"       67",
"      </a>",
"      ]. Using a definition based upon the degree of platelet aggregation after addition of the platelet agonists adenosine diphosphate and arachidonic acid, \"aspirin resistance\" was present in 17 patients (5.2 percent). After a mean follow-up of 1.9 years, the patients with \"aspirin resistance\" had a significantly higher rate of the composite end point of death, myocardial infarction (MI), or stroke (24 versus 10 percent in the remaining 309 patients), even after multivariate adjustment for other risk factors (hazard ratio 4.14).",
"     </li>",
"     <li>",
"      A second case series described the possible role of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      resistance in 151 patients who were taking aspirin (80 to 325",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      for a least one week prior to undergoing elective percutaneous coronary intervention (PCI) (90 percent with stenting) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/68\">",
"       68",
"      </a>",
"      ]. Aspirin-induced platelet inhibition was measured in vitro using a modified platelet aggregometry device (VerifyNow Aspirin). All patients received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      300 mg 12 to 24 hours prior to the procedure followed by a maintenance dose of 75",
"      <span class=\"nowrap\">",
"       mg/day;",
"      </span>",
"      no patient received a GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor. The 19 percent of patients with aspirin resistance had a significantly higher incidence of post-PCI elevations in serum CK-MB (52 versus 25 percent) and cardiac troponin I (66 versus 39 percent).",
"     </li>",
"     <li>",
"      In a third case series, 468 patients with stable coronary disease were tested for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      resistance at the start of the study using the VerifyNow Aspirin assay, and were followed prospectively for a mean of 379 &plusmn; 200 days for the composite endpoint of cardiovascular death, myocardial infarction, stroke, transient ischemic attack, or unstable angina requiring hospitalization [",
"      <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/20,69\">",
"       20,69",
"      </a>",
"      ]. Aspirin resistance, diabetes mellitus, prior myocardial infarction, and low hemoglobin level were independent predictors of unfavorable clinical outcomes, with a hazard ratio of 2.5 (95% CI 1.3-4.8) for aspirin resistance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The major limitation of these three reports is the lack of a comparison group of patients taking other antiplatelet agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , to which about 25 to 30 percent of patients do not respond [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. Other limitations include the small number of events, measurement of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    nonresponse only at baseline, and lack of information on compliance, such as measurement of pill counts or plasma salicylate concentrations.",
"   </p>",
"   <p>",
"    In a systematic review and meta-analysis of 15 articles and one meeting abstract, the incidence of \"laboratory",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    resistance\" (LAR) ranged from 5 to 65 percent. Despite the marked heterogeneity among studies, the data were pooled to calculate a single odds ratio of 3.8 (95% CI 2.3-6.1) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/70\">",
"     70",
"    </a>",
"    ]. Other limitations of this analysis include measurement of aspirin resistance only once in most studies, marked differences in the laboratory tests and agonists used to determine aspirin resistance, compliance assessment in only three of the articles, and lack of blinding and randomization in most of the studies.",
"   </p>",
"   <p>",
"    A nested case-control study of 970 patients enrolled in the HOPE trial who reported",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    use had baseline measurements taken of urinary 11-dehydrothromboxane B2 levels, a marker of overall thromboxane generation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/57\">",
"     57",
"    </a>",
"    ]. After a five-year follow-up, those with levels in the highest quartile (a presumed reflection of a lesser response to aspirin) had a significantly greater risk for a composite end point of nonfatal MI, nonfatal stroke, or cardiovascular death compared with those in the lowest quartile (adjusted odds ratio [OR] 1.8; 95% CI 1.2-2.7) with significant increases in MI and cardiovascular death.",
"   </p>",
"   <p>",
"    Similar results were seen in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    -treated patients enrolled in the CHARISMA and RIGOR studies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the CHARISMA study, baseline urinary 11-dehydrothromboxane B2 (UTXB",
"      <sub>",
"       2",
"      </sub>",
"      ) concentrations in the highest quartile were associated with an increased risk of stroke, myocardial infarction, or cardiovascular death compared with results in the lowest quartile (adjusted hazard ratio 1.7; 95% CI 1.1-2.6) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The RIGOR study evaluated 229 subjects treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      following coronary artery bypass graft surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/59\">",
"       59",
"      </a>",
"      ]. Although arachidonic acid-induced platelet aggregation was inhibited by &gt;99 percent at six months, 31 percent of subjects still had elevated urinary UTXB",
"      <sub>",
"       2",
"      </sub>",
"      excretion. In multivariate analysis, there was a statistically significant association between UTXB",
"      <sub>",
"       2",
"      </sub>",
"      excretion &ge;450",
"      <span class=\"nowrap\">",
"       pg/mg",
"      </span>",
"      creatinine and graft occlusion (odds ratio 2.59).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6236001\">",
"    <span class=\"h1\">",
"     THERAPEUTIC OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro assessment of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    resistance may be useful in selected patients with aspirin treatment failure. If the arachidonic acid response is robust (ie, demonstrating lack of aspirin effect), this information may be useful in addressing compliance issues or adjusting the aspirin dosage, as noted above [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/44\">",
"     44",
"    </a>",
"    ]. Whether or not treatment with omega-3 fatty acids is helpful in aspirin compliant patients is not clear [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/75-77\">",
"     75-77",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6235097\">",
"     'Compliance issues'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H437013703\">",
"     'Use of enteric coated aspirin'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If the patient is demonstrated to have inhibition of arachidonic acid-induced aggregation, then changing to or adding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    could be considered. At present, adequate tests of this hypothesis have not been conducted. Accordingly, this approach is not recommended.",
"   </p>",
"   <p>",
"    Given limitations in the available data,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    nonresponse is a clinical reality, but \"aspirin resistance\" remains a theoretical possibility, the clinical relevance of which has not yet been adequately demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/11,19,78,79\">",
"     11,19,78,79",
"    </a>",
"    ]. Furthermore, diagnostic testing using unvalidated methods of measurement are premature and unwarranted [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/1,3,12,54\">",
"     1,3,12,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Until further data are forthcoming, we suggest against laboratory testing of patients for \"",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    resistance\" and we suggest against use of alternative antiplatelet strategies (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ) in patients with aspirin nonresponse based upon the results of in vitro assays. Similar conclusions have been reached by others, including the 2005 Working Group on Aspirin Resistance, a 2005 review of the available evidence, and the 2008 American College of Chest Physicians Clinical Practice Guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19401/abstract/1,27,78,80-82\">",
"     1,27,78,80-82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21313333\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonresponse to the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    exists when this agent fails to prevent occlusive CVD events. This could result from numerous factors, including noncompliance, events independent of their specific actions on platelet function, inadequate response to the agent, or drug resistance. (See",
"    <a class=\"local\" href=\"#H21311310\">",
"     'Definitions'",
"    </a>",
"    above.).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multiple tests are available for the documentation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      response in vitro, although these tests correlate poorly with one another. (See",
"      <a class=\"local\" href=\"#H21311359\">",
"       'Aspirin resistance testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the in vitro response to arachidonic acid is robust, demonstrating lack of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      effect, this information may be useful in addressing compliance issues or adjusting the aspirin dosage. (See",
"      <a class=\"local\" href=\"#H6235097\">",
"       'Compliance issues'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H437013703\">",
"       'Use of enteric coated aspirin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      True pharmacological resistance to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      is rare.",
"     </li>",
"     <li>",
"      The various causes of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      nonresponse are presented above. (See",
"      <a class=\"local\" href=\"#H6234971\">",
"       'Causes of aspirin nonresponse'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Enteric coating can delay or reduce",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      absorption. Thus, for acute events (eg, acute myocardial infarction or acute occlusive stroke), non-enteric coated aspirin is necessary to achieve a rapid clinical antithrombotic effect. If the only available preparation is enteric coated, then the pill or pills should be crushed or chewed. With respect to chronic administration, the totality of the evidence is incomplete but suggestive that higher doses may be necessary if the aspirin is enteric coated. (See",
"      <a class=\"local\" href=\"#H437013703\">",
"       'Use of enteric coated aspirin'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link&amp;anchor=H21#H21\">",
"       \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\", section on 'Aspirin formulation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Until further data are available, the current totality of clinical evidence does not support routine testing of patients for \"",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      resistance\", whether by in vitro testing of platelet function or by genetic testing (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21311381\">",
"       'Clinical and epidemiologic observations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We further suggest against the use of alternative antiplatelet strategies in patients with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      nonresponse based upon the results of in vitro testing of platelet function alone (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6236001\">",
"       'Therapeutic options'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/1\">",
"      Michelson AD, Cattaneo M, Eikelboom JW, et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 2005; 3:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/2\">",
"      Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006; 367:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/3\">",
"      Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 2006; 27:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/4\">",
"      Michos ED, Ardehali R, Blumenthal RS, et al. Aspirin and clopidogrel resistance. Mayo Clin Proc 2006; 81:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/5\">",
"      Angiolillo DJ. Variability in responsiveness to oral antiplatelet therapy. Am J Cardiol 2009; 103:27A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/6\">",
"      Sweeny JM, Gorog DA, Fuster V. Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements. Nat Rev Cardiol 2009; 6:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/7\">",
"      Hjemdahl P. Should we monitor platelet function during antiplatelet therapy? Heart 2008; 94:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/8\">",
"      Jennings LK. Variability in platelet response to the antiplatelet agents aspirin and clopidogrel: mechanisms, measurement, and clinical relevance. Crit Pathw Cardiol 2009; 8:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/9\">",
"      Beigel R, Hod H, Fefer P, et al. Relation of aspirin failure to clinical outcome and to platelet response to aspirin in patients with acute myocardial infarction. Am J Cardiol 2011; 107:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/10\">",
"      Ben-Dor I, Kleiman NS, Lev E. Assessment, mechanisms, and clinical implication of variability in platelet response to aspirin and clopidogrel therapy. Am J Cardiol 2009; 104:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/11\">",
"      Hennekens CH, Schror K, Weisman S, FitzGerald GA. Terms and conditions: semantic complexity and aspirin resistance. Circulation 2004; 110:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/12\">",
"      Gachet C, Aleil B. Testing antiplatelet therapy. Eur Heart J 2008; 10(Suppl A):A28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/13\">",
"      Renda G, Zurro M, Malatesta G, et al. Inconsistency of different methods for assessing ex vivo platelet function: relevance for the detection of aspirin resistance. Haematologica 2010; 95:2095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/14\">",
"      Faraday N, Yanek LR, Mathias R, et al. Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation 2007; 115:2490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/15\">",
"      Gurbel PA, Bliden KP, DiChiara J, et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 2007; 115:3156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/16\">",
"      Assadian A, Lax J, Meixner-Loicht U, et al. Aspirin resistance among long-term aspirin users after carotid endarterectomy and controls: flow cytometric measurement of aspirin-induced platelet inhibition. J Vasc Surg 2007; 45:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/17\">",
"      Fitzgerald DJ, Maree A. Aspirin and clopidogrel resistance. Hematology Am Soc Hematol Educ Program 2007; :114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/18\">",
"      Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/19\">",
"      Gasparyan AY, Watson T, Lip GY. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol 2008; 51:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/20\">",
"      Lee PY, Chen WH, Ng W, et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med 2005; 118:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/21\">",
"      Gurbel PA, Becker RC, Mann KG, et al. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007; 50:1822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/22\">",
"      Geisler T, Kapp M, G&ouml;hring-Frischholz K, et al. Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease. Heart 2008; 94:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/23\">",
"      Michelson AD. Methods for the measurement of platelet function. Am J Cardiol 2009; 103:20A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/24\">",
"      Gurbel PA, Mahla E, Antonino MJ, Tantry US. Response variability and the role of platelet function testing. J Invasive Cardiol 2009; 21:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/25\">",
"      Ozben B, Tanrikulu AM, Ozben T, Caymaz O. Aspirin resistance in hypertensive patients. J Clin Hypertens (Greenwich) 2010; 12:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/26\">",
"      Dalen JE. Aspirin resistance: is it real? Is it clinically significant? Am J Med 2007; 120:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/27\">",
"      Cattaneo M. Laboratory detection of 'aspirin resistance': what test should we use (if any)? Eur Heart J 2007; 28:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/28\">",
"      Muir AR, McMullin MF, Patterson C, McKeown PP. Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease. Heart 2009; 95:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/29\">",
"      Frelinger AL, Li Y, Linden MD, et al. Aspirin 'resistance': role of pre-existent platelet reactivity and correlation between tests. J Thromb Haemost 2008; 6:2035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/30\">",
"      Santilli F, Rocca B, De Cristofaro R, et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin \"resistance\". J Am Coll Cardiol 2009; 53:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/31\">",
"      Lev EI. Aspirin resistance transient laboratory finding or important clinical entity? J Am Coll Cardiol 2009; 53:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/32\">",
"      Lordkipanidz&eacute; M, Pharand C, Schampaert E, et al. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007; 28:1702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/33\">",
"      Shen H, Herzog W, Drolet M, et al. Aspirin Resistance in healthy drug-naive men versus women (from the Heredity and Phenotype Intervention Heart Study). Am J Cardiol 2009; 104:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/34\">",
"      Grove EL, Hvas AM, Johnsen HL, et al. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thromb Haemost 2010; 103:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/35\">",
"      Breet NJ, van Werkum JW, Bouman HJ, et al. High on-aspirin platelet reactivity as measured with aggregation-based, cyclooxygenase-1 inhibition sensitive platelet function tests is associated with the occurrence of atherothrombotic events. J Thromb Haemost 2010; 8:2140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/36\">",
"      Bouman HJ, van Werkum JW, Hackeng CM, et al. The importance of anticoagulant agents in measuring platelet aggregation in patients treated with clopidogrel and aspirin. J Thromb Haemost 2008; 6:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/37\">",
"      Ohmori T, Yatomi Y, Nonaka T, et al. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J Thromb Haemost 2006; 4:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/38\">",
"      Voora D, Horton J, Shah SH, et al. Polymorphisms associated with in vitro aspirin resistance are not associated with clinical outcomes in patients with coronary artery disease who report regular aspirin use. Am Heart J 2011; 162:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/39\">",
"      Postula M, Kaplon-Cieslicka A, Rosiak M, et al. Genetic determinants of platelet reactivity during acetylsalicylic acid therapy in diabetic patients: evaluation of 27 polymorphisms within candidate genes. J Thromb Haemost 2011; 9:2291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/40\">",
"      Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 2005; 46:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/41\">",
"      Kolandaivelu K, Bhatt DL. Overcoming 'resistance' to antiplatelet therapy: targeting the issue of nonadherence. Nat Rev Cardiol 2010; 7:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/42\">",
"      Cuisset T, Frere C, Quilici J, et al. Aspirin noncompliance is the major cause of \"aspirin resistance\" in patients undergoing coronary stenting. Am Heart J 2009; 157:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/43\">",
"      Grosser T, Fries S, Lawson JA, et al. Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation 2013; 127:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/44\">",
"      Peace A, McCall M, Tedesco T, et al. The role of weight and enteric coating on aspirin response in cardiovascular patients. J Thromb Haemost 2010; 8:2323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/45\">",
"      Ridker PM, Hennekens CH, Tofler GH, et al. Anti-platelet effects of 100 mg alternate day oral aspirin: a randomized, double-blind, placebo-controlled trial of regular and enteric coated formulations in men and women. J Cardiovasc Risk 1996; 3:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/46\">",
"      Cox D, Maree AO, Dooley M, et al. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke 2006; 37:2153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/47\">",
"      Charles H Hennekens, Scott Hetzel, Michael Pfeffer, et al. Low-dose enteric-coated aspirin does not inhibit thromboxane B2 adn prostaglandin E2: data-derived hypothesis formulation. Clinical Investigation 2012; 2:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/48\">",
"      W&uuml;rtz M, Grove EL, Kristensen SD, Hvas AM. The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease. Heart 2010; 96:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/49\">",
"      Charlot M, Grove EL, Hansen PR, et al. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ 2011; 342:d2690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/50\">",
"      Hennekens CH, DeMets D. Statistical association and causation: contributions of different types of evidence. JAMA 2011; 305:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/51\">",
"      McKee SA, Sane DC, Deliargyris EN. Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance. Thromb Haemost 2002; 88:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/52\">",
"      Halushka MK, Halushka PV. Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2? Circulation 2002; 105:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/53\">",
"      Sanderson S, Emery J, Baglin T, Kinmonth AL. Narrative review: aspirin resistance and its clinical implications. Ann Intern Med 2005; 142:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/54\">",
"      Mason PJ, Jacobs AK, Freedman JE. Aspirin resistance and atherothrombotic disease. J Am Coll Cardiol 2005; 46:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/55\">",
"      Frelinger AL 3rd, Furman MI, Linden MD, et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation 2006; 113:2888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/56\">",
"      Undas A, Brummel-Ziedins KE, Mann KG. Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. Blood 2007; 109:2285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/57\">",
"      Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/58\">",
"      Dragani A, Pascale S, Recchiuti A, et al. The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. Blood 2010; 115:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/59\">",
"      Gluckman TJ, McLean RC, Schulman SP, et al. Effects of aspirin responsiveness and platelet reactivity on early vein graft thrombosis after coronary artery bypass graft surgery. J Am Coll Cardiol 2011; 57:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/60\">",
"      Mattiello T, Guerriero R, Lotti LV, et al. Aspirin extrusion from human platelets through multidrug resistance protein-4-mediated transport: evidence of a reduced drug action in patients after coronary artery bypass grafting. J Am Coll Cardiol 2011; 58:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/61\">",
"      Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345:1809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/62\">",
"      Kurth T, Hennekens CH, Gaziano JM. Aspirin non-response a clinical reality and aspirin resistance a theoretical possibility: confounding by non-compliance and NSAIDs in subgroup analyses from the Physician's Health Study (abstract). Circulation 2005; 112:II791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/63\">",
"      Grove EL, Hvas AM, Mortensen SB, et al. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. J Thromb Haemost 2011; 9:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/64\">",
"      Pascale S, Petrucci G, Dragani A, et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood 2012; 119:3595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/65\">",
"      Rocca B, Santilli F, Pitocco D, et al. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. J Thromb Haemost 2012; 10:1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/66\">",
"      Lordkipanidz&eacute; M, Harrison P. Aspirin twice a day keeps new COX-1 at bay. J Thromb Haemost 2012; 10:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/67\">",
"      Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/68\">",
"      Chen WH, Lee PY, Ng W, et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004; 43:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/69\">",
"      Chen WH, Cheng X, Lee PY, et al. Aspirin resistance and adverse clinical events in patients with coronary artery disease. Am J Med 2007; 120:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/70\">",
"      Snoep JD, Hovens MM, Eikenboom JC, et al. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007; 167:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/71\">",
"      Frelinger AL 3rd, Li Y, Linden MD, et al. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation 2009; 120:2586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/72\">",
"      Lev EI, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 2006; 47:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/73\">",
"      Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107:2908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/74\">",
"      Eikelboom JW, Hankey GJ, Thom J, et al. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation 2008; 118:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/75\">",
"      Larson MK, Ashmore JH, Harris KA, et al. Effects of omega-3 acid ethyl esters and aspirin, alone and in combination, on platelet function in healthy subjects. Thromb Haemost 2008; 100:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/76\">",
"      Lev EI, Solodky A, Harel N, et al. Treatment of aspirin-resistant patients with omega-3 fatty acids versus aspirin dose escalation. J Am Coll Cardiol 2010; 55:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/77\">",
"      Gajos G, Rostoff P, Undas A, Piwowarska W. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) study. J Am Coll Cardiol 2010; 55:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/78\">",
"      Patrono C, Garc&iacute;a Rodr&iacute;guez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353:2373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/79\">",
"      Gladding P, Webster M, Ormiston J, et al. Antiplatelet drug nonresponsiveness. Am Heart J 2008; 155:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/80\">",
"      Buch AN, Singh S, Roy P, et al. Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention. Am J Cardiol 2007; 99:1518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/81\">",
"      Storey RF. Variability of response to antiplatelet therapy. Eur Heart J 2008; 10(Suppl A):A21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19401/abstract/82\">",
"      Douketis JD, Berger PB, Dunn AS, et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:299S.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16946 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-A58E39C754-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_60_19401=[""].join("\n");
var outline_f18_60_19401=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21313333\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21311303\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21311310\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21311359\">",
"      ASPIRIN RESISTANCE TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6234625\">",
"      Arachidonic acid-induced platelet activation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6234632\">",
"      Other in vitro tests of platelet function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6234963\">",
"      Test correlations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6234971\">",
"      CAUSES OF ASPIRIN NONRESPONSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21311374\">",
"      Genetic variability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6235097\">",
"      Compliance issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H437013703\">",
"      Use of enteric coated aspirin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6235111\">",
"      Use of proton pump inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6235466\">",
"      Other possible mechanisms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21311381\">",
"      CLINICAL AND EPIDEMIOLOGIC OBSERVATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6236001\">",
"      THERAPEUTIC OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21313333\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/35/2618?source=related_link\">",
"      Antiplatelet therapy for secondary prevention of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27786?source=related_link\">",
"      Antithrombotic therapy for percutaneous coronary intervention: General use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=related_link\">",
"      NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37418?source=related_link\">",
"      Nonresponse and resistance to clopidogrel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=related_link\">",
"      Nonselective NSAIDs: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/28/32202?source=related_link\">",
"      Prognosis and treatment of essential thrombocythemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_60_19402="Cryptogenic organizing pneumonia";
var content_f18_60_19402=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cryptogenic organizing pneumonia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/60/19402/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/60/19402/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/60/19402/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/60/19402/contributors\">",
"     Kevin R Flaherty, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/60/19402/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/60/19402/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/60/19402/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryptogenic organizing pneumonia (COP), the idiopathic form of organizing pneumonia (formerly called bronchiolitis obliterans organizing pneumonia or BOOP), is a type of diffuse interstitial lung disease that affects the distal bronchioles, respiratory bronchioles, alveolar ducts, and alveolar walls [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/1-7\">",
"     1-7",
"    </a>",
"    ]. The primary area of injury is within the alveolar wall.",
"   </p>",
"   <p>",
"    In addition to the cryptogenic form, secondary organizing pneumonia can be seen in association with connective tissue diseases, a variety of drugs, malignancy, and other interstitial pneumonias [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/2,8\">",
"     2,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cryptogenic organizing pneumonia will be reviewed here. The other idiopathic interstitial pneumonias and an approach to the evaluation and diagnosis of interstitial lung disease in adults are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=see_link\">",
"     \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Clinical evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Diagnostic testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The American Thoracic Society (ATS) and European Respiratory Society (ERS) statement on the classification of idiopathic interstitial pneumonias, as well as other ATS guidelines, can be accessed through the ATS web site at",
"    <a class=\"external\" href=\"file://www.thoracic.org/statements\">",
"     www.thoracic.org/statements",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11161611\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact incidence and prevalence of COP are unknown. A cumulative incidence of six to seven cases per 100,000 hospital admissions was found at a major teaching hospital in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/9\">",
"     9",
"    </a>",
"    ], while in a 20 year review of national statistics for Iceland, the mean annual incidence was 1.1 per 100,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/10\">",
"     10",
"    </a>",
"    ]. In separate reports, approximately 56 to 68 percent of OP cases have been deemed cryptogenic rather than secondary [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histopathologic lesions characteristic of COP include excessive proliferation of granulation tissue, which consists of loose collagen-embedded fibroblasts and myofibroblasts, involving alveolar ducts and alveoli, with or without bronchiolar intraluminal polyps. Intraluminal plugs of granulation tissue may extend from one alveolus to the adjacent one through the pores of Kohn, giving rise to the characteristic \"butterfly\" pattern (",
"    <a class=\"graphic graphic_picture graphicRef60476 \" href=\"UTD.htm?14/53/15194\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef72270 \" href=\"UTD.htm?2/22/2410\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/12\">",
"     12",
"    </a>",
"    ]. It is thought that bronchiolar lesions reflect extension of intraluminal plugs of granulation tissue from alveolar sacs and ducts to the bronchioles. Other features include a uniform appearance within involved areas and a patchy distribution without severe disruption of the lung architecture. While the pathologic lesion is predominantly within the airspace, mild chronic inflammation (eg, lymphocytes and plasma cells) is present in the alveolar walls (",
"    <a class=\"graphic graphic_picture graphicRef81647 \" href=\"UTD.htm?17/44/18122\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There are, in addition, other key histopathologic features that are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef60654 \" href=\"UTD.htm?33/19/34107\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Histologic features of OP can also be seen in combination with other idiopathic interstitial pneumonias (",
"    <a class=\"graphic graphic_table graphicRef68251 \" href=\"UTD.htm?23/25/23963\">",
"     table 2",
"    </a>",
"    ). However, the portion of changes suggestive of OP is small (&lt;10 percent) relative to the characteristic changes of these other interstitial pneumonias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/63/21497?source=see_link&amp;anchor=H11388821#H11388821\">",
"     \"Interpretation of lung biopsy results in interstitial lung disease\", section on 'Interstitial pneumonias'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=see_link&amp;anchor=H20#H20\">",
"     \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\", section on 'Pathology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19821905\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact pathogenesis of COP remains unknown. It is thought that organizing pneumonia is a consequence of alveolar epithelial injury [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/1,13\">",
"     1,13",
"    </a>",
"    ]. The initial injury is followed by leakage of plasma proteins, recruitment of fibroblasts, and fibrin formation within the alveolar lumen.",
"   </p>",
"   <p>",
"    Abnormal regulation of vascular endothelial growth factor and matrix metalloproteinase has been reported in association with COP [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. However, dysregulation of these proteins has been observed in a large number of other pulmonary diseases, and their precise role in the pathogenesis of COP remains speculative [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/16\">",
"     16",
"    </a>",
"    ]. Regulation of angiogenesis and apoptosis may influence the reversibility of the fibrotic lesions in COP, compared to the irreversible lesions in usual interstitial pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/14,15,17\">",
"     14,15,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The disease onset is typically in the fifth or sixth decades of life, with men and women affected equally [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/10,11,18\">",
"     10,11,18",
"    </a>",
"    ]. COP is only rarely reported in children. The reported frequency of current or past cigarette smoking ranges from 25 to 50 percent, making smoking unlikely to be a precipitating factor [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/6,9,19,20\">",
"     6,9,19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;COP typically presents with cough, dyspnea, fever, and malaise that are of relatively short duration (eg, weeks to months) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/1\">",
"     1",
"    </a>",
"    ]. In almost three-fourths of the patients, symptoms are present for less than two months (",
"    <a class=\"graphic graphic_figure graphicRef53619 \" href=\"UTD.htm?21/57/22429\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/12\">",
"     12",
"    </a>",
"    ]. In one-half, the onset is heralded by the acute onset of a flu-like illness with fever, malaise, fatigue, and cough, but in other patients the onset of symptoms is less acute. In some patients, a lack of response to empiric antibiotics for community acquired pneumonia may be the initial clue to the presence of a noninfectious, inflammatory pneumonia.",
"   </p>",
"   <p>",
"    The most common features of the history at presentation are [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Persistent nonproductive cough (72 percent)",
"     </li>",
"     <li>",
"      Dyspnea (66 percent)",
"     </li>",
"     <li>",
"      Fever (51 percent)",
"     </li>",
"     <li>",
"      Malaise (48 percent)",
"     </li>",
"     <li>",
"      Weight loss of greater than 10 pounds (57 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hemoptysis is rarely reported as a presenting manifestation of COP [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with all patients who present with interstitial lung disease, the history should include questions about any symptoms or history suggestive of connective tissue disease (eg, arthralgias, dry eyes, dry mouth, muscle weakness, numbness, tingling), current and recent medications, and history of exposure to therapeutic irradiation, fumes, or dusts. A list of diseases and medications that have been associated with secondary organizing pneumonia is provided in the table (",
"    <a class=\"graphic graphic_table graphicRef77030 \" href=\"UTD.htm?21/21/21851\">",
"     table 3",
"    </a>",
"    ). A more complete list of drugs associated with secondary organizing pneumonia is available at",
"    <a class=\"external\" href=\"file://www.pneumotox.com/\">",
"     www.pneumotox.com",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=see_link&amp;anchor=H4#H4\">",
"     \"Approach to the adult with interstitial lung disease: Clinical evaluation\", section on 'History'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11161794\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with COP, the physical examination often reveals inspiratory crackles (74 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/12\">",
"     12",
"    </a>",
"    ]. Wheezing is rare and, when present, is heard in combination with crackles; clubbing is seen in less than 5 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/22\">",
"     22",
"    </a>",
"    ]. A normal pulmonary examination is found in one-fourth of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the association of organizing pneumonia with many connective tissue diseases (",
"    <a class=\"graphic graphic_table graphicRef77030 \" href=\"UTD.htm?21/21/21851\">",
"     table 3",
"    </a>",
"    ), the patient should be examined for extrapulmonary manifestations of these diseases such as alopecia, Gottron sign, heliotrope rash, muscle weakness or tenderness, sclerodactyly, and abnormal nailfold capillaroscopy. Identification of these features is described separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=see_link&amp;anchor=H13#H13\">",
"       \"Approach to the adult with interstitial lung disease: Clinical evaluation\", section on 'Physical examination'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"       \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=see_link&amp;anchor=H12#H12\">",
"       \"Clinical features of rheumatoid arthritis\", section on 'Physical findings'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"       \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29224?source=see_link&amp;anchor=H3#H3\">",
"       \"Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults\", section on 'Skin involvement'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11161913\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of patients with suspected COP usually begins with a chest radiograph obtained because of symptoms of dyspnea",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cough. The chest radiographic appearance or a lack of clinical response to antibiotic therapy generally lead to additional studies to exclude atypical infections, malignancy, and systemic illnesses that might be associated with diffuse parenchymal lung disease. These studies typically include laboratory testing, high resolution computed tomography, pulmonary function testing, bronchoalveolar lavage, and transbronchoscopic or surgical lung biopsy. The evaluation of interstitial lung disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Clinical evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Diagnostic testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;No laboratory studies are specific for COP [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/5,23,24\">",
"     5,23,24",
"    </a>",
"    ]. However, in the evaluation of patients with dyspnea, cough, fever, and pulmonary radiographic opacities, the usual laboratory tests include a complete blood count and differential, blood urea nitrogen, creatinine, hepatic function tests, and urinalysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=see_link&amp;anchor=H3#H3\">",
"     \"Approach to the adult with interstitial lung disease: Diagnostic testing\", section on 'Laboratory tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Leukocytosis is present in about 50 percent of patients with COP [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/12,22\">",
"     12,22",
"    </a>",
"    ]. An elevated initial erythrocyte sedimentation rate (ESR) (frequently reaching or exceeding 100 mm) and a positive C-reactive protein are each observed in 70 to 80 percent, although we do not routinely obtain these tests.",
"   </p>",
"   <p>",
"    For hospitalized patients whose clinical presentation suggests community acquired pneumonia, additional tests are usually obtained, such as blood cultures, sputum gram stain, sputum enzyme immunoassay (EIA), immunofluorescence, or polymerase chain reaction (PCR) for respiratory viruses, urinary studies for pneumococcal and Legionella antigens, and HIV testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=see_link&amp;anchor=H7#H7\">",
"     \"Diagnostic approach to community-acquired pneumonia in adults\", section on 'Hospitalized patients'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As organizing pneumonia may also occur in association with various connective tissue diseases, testing for these diseases (eg, antinuclear antibody, rheumatoid factor, creatine kinase, anti-topoisomerase (anti-Scl70), anti-centromere antibody, anti-double-stranded DNA, anti-JO1) is appropriate when a connective tissue disease is suspected on the basis of symptoms or signs (",
"    <a class=\"graphic graphic_table graphicRef77030 \" href=\"UTD.htm?21/21/21851\">",
"     table 3",
"    </a>",
"    ). In patients with COP (ie, without concomitant connective tissue disease), autoantibodies are usually negative or present in very low titer [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/12\">",
"     12",
"    </a>",
"    ]. &nbsp;Laboratory testing to identify underlying connective tissues disease in the setting of interstitial lung disease is discussed separately (",
"    <a class=\"graphic graphic_algorithm graphicRef69044 \" href=\"UTD.htm?17/14/17632\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=see_link&amp;anchor=H3#H3\">",
"     \"Approach to the adult with interstitial lung disease: Diagnostic testing\", section on 'Laboratory tests'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Chest imaging studies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19098198\">",
"    <span class=\"h3\">",
"     Chest radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;A chest radiograph is obtained in virtually all adults with persistent symptoms of dyspnea and cough, particularly in the presence of fever. The chest radiograph manifestations of COP are typically quite distinctive with bilateral, patchy or diffuse, consolidative or ground glass opacities in the presence of normal lung volumes (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51281 \" href=\"UTD.htm?28/62/29679\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58934 \" href=\"UTD.htm?7/54/8032\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/25\">",
"     25",
"    </a>",
"    ]. Other findings may include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A peripheral distribution of the opacities, similar to that seen in chronic eosinophilic pneumonia (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef51281 \" href=\"UTD.htm?28/62/29679\">",
"       image 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/5,26\">",
"       5,26",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27688?source=see_link&amp;anchor=H10#H10\">",
"       \"Causes of pulmonary eosinophilia\", section on 'Chronic eosinophilic pneumonia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Recurrent or migratory pulmonary opacities are common (up to 50 percent of subjects in some series).",
"     </li>",
"     <li>",
"      Rarely, unilateral consolidative and ground-glass opacities [",
"      <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rarely, irregular linear or nodular opacities as the only radiographic manifestation (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef70500 \" href=\"UTD.htm?5/61/6096\">",
"       image 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Other rare radiographic abnormalities include pleural effusion, pleural thickening, hyperinflation, and cavities.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Computed tomographic scanning",
"    </span>",
"    &nbsp;&mdash;&nbsp;High resolution computed tomography (HRCT) lung scans are typically obtained to evaluate abnormalities seen on conventional chest radiographs. Rarely, a patient may have dyspnea and hypoxemia or a reduced diffusing capacity (DLCO) without a definite abnormality on chest radiograph, and an HRCT is obtained to evaluate the gas transfer abnormality. HRCT results are also used to guide site selection for patients undergoing bronchoalveolar lavage or lung biopsy.",
"   </p>",
"   <p>",
"    HRCTs from patients with COP often reveal more extensive disease than expected from review of the plain chest radiograph. Radiographic patterns include patchy air-space consolidation, ground-glass opacities, small nodular opacities, and bronchial wall thickening with dilation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81785 \" href=\"UTD.htm?2/48/2818\">",
"     image 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/27-31\">",
"     27-31",
"    </a>",
"    ]. Patchy opacities occur more frequently in the periphery of the lung and are often in the lower lung zone.",
"   </p>",
"   <p>",
"    Less common radiographic appearances include multiple nodules or masses that may cavitate, micronodules, irregular reticular opacities in a subpleural location, and crescentic or ring-shaped opacities [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/1,12,30,32-34\">",
"     1,12,30,32-34",
"    </a>",
"    ]. Rarely, a single nodule is the only manifestation of organizing pneumonia; this is termed focal organizing pneumonia (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef87705 \" href=\"UTD.htm?4/24/4484\">",
"     image 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. In a case series, mediastinal lymphadenopathy (diameter &ge;10 mm in short axis) was reported in 6 of 16 patients with COP [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/35\">",
"     35",
"    </a>",
"    ]. Pleural effusion is uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Confident radiographic differentiation of COP from chronic eosinophilic pneumonia is frequently NOT possible, as both diseases have a predilection for the peripheral lung fields (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61940 \" href=\"UTD.htm?38/22/39279\">",
"     image 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73715 \" href=\"UTD.htm?3/40/3715\">",
"     image 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11162171\">",
"     'Differential diagnosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27688?source=see_link&amp;anchor=H10#H10\">",
"     \"Causes of pulmonary eosinophilia\", section on 'Chronic eosinophilic pneumonia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pulmonary function tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary function tests are obtained in most ambulatory adults with dyspnea and cough to determine whether the symptoms are associated with an obstructive or restrictive impairment and whether a gas transfer defect is present. The severity of the impairment is one of the factors used to determine the need for invasive diagnostic testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=see_link&amp;anchor=H10#H10\">",
"     \"Approach to the adult with interstitial lung disease: Diagnostic testing\", section on 'Pulmonary function testing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=see_link\">",
"     \"Overview of pulmonary function testing in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A mild to moderate restrictive ventilatory defect is the most common finding in COP (",
"    <a class=\"graphic graphic_figure graphicRef59123 \" href=\"UTD.htm?31/12/31949\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/7,9,37,38\">",
"     7,9,37,38",
"    </a>",
"    ]. However, an obstructive defect",
"    <span class=\"nowrap\">",
"     (FEV",
"     <sub>",
"      1",
"     </sub>",
"     /FVC",
"    </span>",
"    ratio less than 70 percent) was found in 20 percent of patients in one report, all of whom were current or former smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/37\">",
"     37",
"    </a>",
"    ]. Lung volumes and flow measurements are occasionally normal.",
"   </p>",
"   <p>",
"    Gas exchange abnormalities are extremely common. The diffusing capacity (DLCO) is reduced in the majority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/6,9,22,37\">",
"     6,9,22,37",
"    </a>",
"    ]. Resting",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    exercise arterial hypoxemia (each defined by an alveolar-arterial oxygen gradient greater than 20 mmHg) are present in more than 80 percent of subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/37\">",
"     37",
"    </a>",
"    ]. Pulse oxygen saturation (SpO",
"    <sub>",
"     2",
"    </sub>",
"    ) may be normal or reduced at rest, but commonly is decreased with exertion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2124653\">",
"    <span class=\"h2\">",
"     Flexible bronchoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flexible bronchoscopy is usually performed to obtain bronchoalveolar lavage (BAL) samples to evaluate for infection, hemorrhage, and malignancy. A transbronchial biopsy is sometimes performed during the procedure to obtain tissue for histopathologic and microbiologic studies, although the size of the samples is generally not large enough to make a definitive diagnosis of COP. Alternatively, the evaluation may proceed directly to surgical lung biopsy when infection seems unlikely or the diagnostic process needs to be expedited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Bronchoalveolar lavage",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with COP, BAL findings are nonspecific, so the main role for BAL is to identify processes that are in the differential diagnosis of subacute onset of cough, dyspnea, and radiographic opacities, such as alveolar hemorrhage, malignancy, or opportunistic infection. The technique of BAL and the preparation of lavage samples are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=see_link\">",
"     \"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/41/25239?source=see_link\">",
"     \"Basic principles and technique of bronchoalveolar lavage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The location for BAL may be chosen based on examination of the chest HRCT to select an area with radiographic evidence of involvement. Alternatively, in diffuse disease, the right middle lobe or lingula is lavaged most commonly to optimize fluid recovery.(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/41/25239?source=see_link&amp;anchor=H4#H4\">",
"     \"Basic principles and technique of bronchoalveolar lavage\", section on 'Optimal site'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    BAL findings have been reported in a limited number of patients with COP [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/11,18,39\">",
"     11,18,39",
"    </a>",
"    ]. The percentage of the volume of bronchoalveolar lavage (BAL) fluid recovered from patients with COP is less than that recovered from healthy volunteers, but the total number of cells recovered is greater [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/37\">",
"     37",
"    </a>",
"    ]. Typical BAL findings include increases in lymphocytes (20 to 40 percent), neutrophils (5 to 10 percent), and eosinophils (5 to 25 percent) with the level of lymphocytes being higher than that of eosinophils [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/1,18\">",
"     1,18",
"    </a>",
"    ]. This \"mixed pattern\" of increased cellularity is thought to be characteristic, although not diagnostic of COP [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients with COP tend to have higher lymphocyte counts than do those with idiopathic pulmonary fibrosis, but similar in proportion to hypersensitivity pneumonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/12,40\">",
"     12,40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=see_link&amp;anchor=H6#H6\">",
"     \"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease\", section on 'Mixed cellularity BAL'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other (nondiagnostic) BAL abnormalities that may be found in COP patients include foamy macrophages, mast cells, plasma cells, a decreased",
"    <span class=\"nowrap\">",
"     CD4/CD8",
"    </span>",
"    T cell ratio, an increase in activated T lymphocytes based on HLA-DR or interleukin-2 receptor expression [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/11,39,41\">",
"     11,39,41",
"    </a>",
"    ]. In research studies, increased levels of Th1 related cytokines, including interferon (IFN)-y, interleukin (IL)-12 and IL-18, have been reported, although these tests are not used clinically [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/40,42\">",
"     40,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2124691\">",
"    <span class=\"h3\">",
"     Transbronchial lung biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main role for transbronchial biopsy in patients with suspected COP is to identify other disease processes in the differential diagnosis, because the small size of transbronchial lung biopsies is often inadequate for definitive confirmation of COP and exclusion of other concomitant processes. The histologic features of organizing pneumonia can be seen as a minor finding in other interstitial lung diseases, so reliance on small transbronchial biopsies increases the likelihood of missing the central diagnosis. On the other hand, some guidelines suggest that a diagnosis can be made on the basis of a transbronchial biopsy in a patient with typical clinical and radiologic features [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/24,39,43-45\">",
"     24,39,43-45",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Pathology'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H11162171\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The location for performing transbronchial biopsies is chosen based on examination of the chest HRCT, which allows selection of an area with radiographic evidence of involvement. Transbronchial biopsy samples are sent for histopathologic analysis and microbiologic stains and cultures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43816?source=see_link&amp;anchor=H5040289#H5040289\">",
"     \"Flexible bronchoscopy: Equipment, procedure, and complications\", section on 'Transbronchial biopsy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=see_link&amp;anchor=H4#H4\">",
"     \"Role of lung biopsy in the diagnosis of interstitial lung disease\", section on 'Transbronchial lung biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2124602\">",
"    <span class=\"h2\">",
"     Surgical lung biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An open or thoracoscopic lung biopsy is generally needed to obtain an adequate sample of lung tissue (eg, &gt;4 cm diameter in the greatest dimension when inflated) for definitive diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/12,43\">",
"     12,43",
"    </a>",
"    ]. The location of the lung biopsy is typically chosen based on areas of abnormality identified on the HRCT scan and on the accessibility of these areas to the surgical approach. Samples are sent for histopathologic and microbiologic analysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=see_link&amp;anchor=H5#H5\">",
"     \"Role of lung biopsy in the diagnosis of interstitial lung disease\", section on 'Surgical lung biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to an adequate sample of tissue, it is important that the pathologist be given adequate clinical information to guide the search for the specific lesions and patterns that support the diagnosis. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Pathology'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/63/21497?source=see_link&amp;anchor=H11388807#H11388807\">",
"     \"Interpretation of lung biopsy results in interstitial lung disease\", section on 'Clinician - pathologist interaction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19822032\">",
"    <span class=\"h2\">",
"     Cryptogenic organizing pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of COP depends upon demonstration of the typical histopathologic features in a patient with a compatible clinical and radiographic pattern in the absence of a contributing factor or disease process (",
"    <a class=\"graphic graphic_table graphicRef77030 \" href=\"UTD.htm?21/21/21851\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/1,12,43\">",
"     1,12,43",
"    </a>",
"    ]. When making a histopathologic diagnosis of COP, it is necessary to satisfy two key criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of the characteristic histopathologic features of organizing pneumonia (OP), including intraluminal plugs of inflammatory debris predominantly within small airways, alveolar ducts, and adjacent alveoli and also mild interstitial inflammation in the surrounding lung (",
"      <a class=\"graphic graphic_table graphicRef60654 \" href=\"UTD.htm?33/19/34107\">",
"       table 1",
"      </a>",
"      ). The &ldquo;plugs&rdquo; of inflammatory debris consist of granulation tissue with fibroblasts and myofibroblasts embedded in a connective matrix. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The absence of histopathologic features suggestive of another process (eg, poorly formed granulomas suggestive of hypersensitivity pneumonitis, prominent eosinophilia suggestive of chronic eosinophilic pneumonia, temporal heterogeneity of the lesions and fibroblast foci suggestive of usual interstitial pneumonitis) (",
"      <a class=\"graphic graphic_table graphicRef87711 \" href=\"UTD.htm?0/55/891\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11162171\">",
"       'Differential diagnosis'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In order to have enough tissue for the pathologist to exclude other processes, such as nonspecific interstitial pneumonia or usual interstitial pneumonia, we prefer to obtain a lung biopsy via video-assisted thoracoscopic surgery (VATS) or open thoracotomy rather than transbronchial biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2124691\">",
"     'Transbronchial lung biopsy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H2124602\">",
"     'Surgical lung biopsy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11162193\">",
"    <span class=\"h2\">",
"     Excluding other etiologies of organizing pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the diagnosis of OP is made by lung biopsy, the next step is to determine whether the disease is cryptogenic or secondary to another process. It is impossible to differentiate COP from secondary OP based on radiologic or pathologic findings. Thus, a careful review of the patient&rsquo;s history, physical examination, medication usage, potential exposures, and underlying diseases is needed to determine whether COP is indeed cryptogenic. Potential disease and drug associations with organizing pneumonia are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef77030 \" href=\"UTD.htm?21/21/21851\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11162171\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of COP includes a broad spectrum of diseases that have similar clinical features, a similar radiographic appearance, similar histopathologic findings, or overlapping histopathologic features.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Community acquired pneumonia  The onset of symptoms and radiographic appearance of COP often mimic community acquired pneumonia, but the persistence of symptoms and lack of response to antibiotics suggests COP rather than bacterial or viral pneumonia. As organizing pneumonia can be a consequence of certain infections, positive culture results do not necessarily exclude the diagnosis (",
"      <a class=\"graphic graphic_table graphicRef77030 \" href=\"UTD.htm?21/21/21851\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=see_link\">",
"       \"Diagnostic approach to community-acquired pneumonia in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Idiopathic interstitial pneumonias  COP is one type of idiopathic interstitial pneumonia (IIP), and the other types of IIP are in the differential of COP (",
"      <a class=\"graphic graphic_table graphicRef68251 \" href=\"UTD.htm?23/25/23963\">",
"       table 2",
"      </a>",
"      ). Sometimes small areas (&lt;10 percent) of organizing pneumonia are seen within a broader appearance of another IIP, such as nonspecific interstitial pneumonia or idiopathic pulmonary fibrosis (",
"      <a class=\"graphic graphic_table graphicRef87711 \" href=\"UTD.htm?0/55/891\">",
"       table 4",
"      </a>",
"      ). Clinicopathologic collaboration is needed to determine the correct diagnosis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathology'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/63/21497?source=see_link&amp;anchor=H11388807#H11388807\">",
"       \"Interpretation of lung biopsy results in interstitial lung disease\", section on 'Clinician - pathologist interaction'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/63/21497?source=see_link&amp;anchor=H11388821#H11388821\">",
"       \"Interpretation of lung biopsy results in interstitial lung disease\", section on 'Interstitial pneumonias'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=see_link\">",
"       \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypersensitivity pneumonitis  The clinical presentation of COP is similar to that of subacute hypersensitivity pneumonitis (cough, dyspnea, fatigue, anorexia, and weight loss). The radiographic findings typical of subacute hypersensitivity pneumonitis (eg, diffuse micronodules, ground glass attenuation) are also seen in some patients with COP. A known exposure to an etiologic agent, a higher percentage of lymphocytes on bronchoalveolar lavage, and the presence of poorly formed granulomas on lung biopsy all favor hypersensitivity pneumonitis. However, small areas of organizing pneumonia can be seen in hypersensitivity pneumonitis, so differentiation of these diseases requires clinicopathologic collaboration (",
"      <a class=\"graphic graphic_table graphicRef87711 \" href=\"UTD.htm?0/55/891\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/49/19222?source=see_link&amp;anchor=H7#H7\">",
"       \"Classification and clinical manifestations of hypersensitivity pneumonitis (extrinsic allergic alveolitis)\", section on 'Subacute or intermittent HP'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/63/21497?source=see_link&amp;anchor=H11388807#H11388807\">",
"       \"Interpretation of lung biopsy results in interstitial lung disease\", section on 'Clinician - pathologist interaction'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chronic eosinophilic pneumonia  Chronic eosinophilic pneumonia (CEP) can have a similar clinical presentation to COP, and the radiographic pattern of subpleural patchy areas of consolidation can be seen in both of these diseases. Furthermore, a mixed picture that includes features of organizing pneumonia and eosinophilic pneumonia may be seen, suggesting that CEP can transition to COP in some patients. The differentiation of these processes usually depends on the relative proportions of the histopathologic patterns and the response to systemic glucocorticoids. COP generally has a slower response over several days to a week, while chronic eosinophilic pneumonia typically has a more rapid response (hours to a couple of days). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27688?source=see_link&amp;anchor=H10#H10\">",
"       \"Causes of pulmonary eosinophilia\", section on 'Chronic eosinophilic pneumonia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/63/21497?source=see_link&amp;anchor=H5487133#H5487133\">",
"       \"Interpretation of lung biopsy results in interstitial lung disease\", section on 'Eosinophilic pneumonia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20581?source=see_link&amp;anchor=H6#H6\">",
"       \"Treatment of chronic eosinophilic pneumonia\", section on 'Assessing the response to therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary lymphoma  The radiographic appearance of pulmonary lymphoma can be similar to COP with patchy, nodular areas of consolidation and an air bronchogram. A single area of consolidation is more common in lymphoma than in COP, although focal COP can be seen. The diseases are differentiated by the histopathologic and immunohistochemical appearance. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19610?source=see_link&amp;anchor=H2#H2\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas\", section on 'Extranodal (MALT) MZL'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Pulmonary lymphomatoid granulomatosis (PLG) is a form of lymphoproliferative disease that is in the differential of COP and pulmonary lymphoma. In PLG, multiple poorly defined nodules are typically present on chest computed tomography and lung biopsy shows the triad of polymorphic lymphoid infiltrates, transmural infiltration of arteries and veins by lymphoid cells (\"angiitis\"), and focal areas of necrosis within the lymphoid infiltrates. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/20/41287?source=see_link&amp;anchor=H10#H10\">",
"       \"Pulmonary lymphomatoid granulomatosis\", section on 'Pathology'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diffuse alveolar damage  Diffuse alveolar damage (DAD) is a nonspecific histopathologic reaction to lung injury, most commonly seen in patients with the acute respiratory distress syndrome (ARDS). Occasional cases of COP have a fulminant onset and progress rapidly to respiratory failure [",
"      <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/43\">",
"       43",
"      </a>",
"      ]. In these patients, COP is the dominant pattern with areas of DAD. Conversely, a component of OP may be seen on lung biopsy specimens obtained during the proliferative phase of ARDS due to other causes (eg, acute interstitial pneumonia). Careful review of the histopathologic findings is needed to differentiate these processes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22792?source=see_link&amp;anchor=H3#H3\">",
"       \"Acute interstitial pneumonia (Hamman-Rich syndrome)\", section on 'Pathology'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29945?source=see_link&amp;anchor=H8#H8\">",
"       \"Acute respiratory distress syndrome: Epidemiology; pathophysiology; pathology; and etiology\", section on 'Pathologic stages'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute fibrinous and organizing pneumonia &nbsp;Acute fibrinous and organizing pneumonia (AFOP) is associated with a clinical picture of acute lung injury and can be idiopathic or associated with other processes such as hypersensitivity pneumonitis, infection, drug toxicity, eosinophilic pneumonia, and rheumatic disease [",
"      <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/46-49\">",
"       46-49",
"      </a>",
"      ]. The histopathology is characterized by intra-alveolar fibrin deposition (fibrin &ldquo;balls&rdquo;) and associated organizing pneumonia, but without hyaline membranes. While DAD is characterized by diffuse pathology affecting all aspects of lung parenchyma, AFOP is patchy, typically involving the alveoli and terminal bronchioles. It is unclear whether AFOP is a distinct entity or a part of the spectrum of DAD and OP.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of COP has not been studied in randomized trials, so treatment decisions are based on practice guidelines, observations from case series, and our clinical experience [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/6,12,18,23,43\">",
"     6,12,18,23,43",
"    </a>",
"    ]. The decision to initiate therapy and the choice of initial therapy depend on the severity of symptoms and pulmonary function impairment at presentation, the radiographic extent of disease, and the rapidity of progression. [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/12,43\">",
"     12,43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19822257\">",
"    <span class=\"h2\">",
"     Mild stable disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with minimal symptoms, near normal or normal pulmonary function tests, and mild radiographic involvement, it is reasonable to monitor without therapy pending any worsening of symptoms or pulmonary function. Among such patients with mild disease, spontaneous remission may occasionally occur [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/43\">",
"     43",
"    </a>",
"    ]. Patients are reassessed at 8 to 12 week intervals regarding any increase in symptoms or worsening of pulmonary function.",
"   </p>",
"   <p>",
"    For patients with mild to moderate disease, macrolides may be an option, particularly for patients who prefer to avoid glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/50\">",
"     50",
"    </a>",
"    ]. A few case reports have described responses to a macrolide antibiotic (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    250 to 500 mg twice a day) in patients with mild symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/6,51-54\">",
"     6,51-54",
"    </a>",
"    ]. In these cases, a prolonged course of three to six months was needed; tapering of the macrolide to a once daily dose was successful in some patients, but early discontinuation often led to recurrent disease. It is thought that the benefit of the macrolide is related to anti-inflammatory rather than antimicrobial effects [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/51\">",
"     51",
"    </a>",
"    ]. However, the diagnosis of COP is often made after a patient has failed one or more courses of a macrolide antibiotic for a presumed community acquired pneumonia, in which case it is unlikely that macrolide therapy will be sufficient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19822264\">",
"    <span class=\"h2\">",
"     Persistent or gradually worsening disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with COP have persistent, bothersome, and progressive symptoms associated with moderate pulmonary function test impairment and diffuse radiographic changes. For these patients, we suggest initial therapy with oral glucocorticoids, which are usually associated with rapid improvement. In 12 studies with a total of 160 patients, a complete response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    was seen in 60 percent, partial response in 27 percent, nonresponse in 14 percent, and a fatal outcome in 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/43\">",
"     43",
"    </a>",
"    ]. The optimal initial dose of systemic glucocorticoid therapy is not known. We typically use an initial dose of prednisone of 0.75 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, using ideal body weight (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?2/41/2706?source=see_link\">",
"     calculator 1",
"    </a>",
"    ), to a maximum of 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    given as a single oral dose in the morning, as suggested by the British Thoracic Society guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/6,19,43\">",
"     6,19,43",
"    </a>",
"    ]. In our practice, the initial dose for most patients is 60 mg per day. &nbsp;",
"   </p>",
"   <p>",
"    We suggest maintaining the initial oral dose for four to eight weeks. If the patient is stable or improved, the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    dose is gradually tapered to 0.5 to 0.75",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (using ideal body weight) for the ensuing four to six weeks. After three to six months of oral prednisone, the dose is gradually tapered to zero if the patient remains stable or improved.",
"   </p>",
"   <p>",
"    In addition to clinical assessment, the patient should be routinely followed with a conventional chest radiograph and pulmonary function testing every two to three months as long as systemic glucocorticoid therapy is required. At the first sign of worsening or recurrent disease, the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    dose should be increased to the prior dose or reinstituted promptly. Importantly, the chest radiograph may change before the patient develops significant symptoms. After cessation of glucocorticoids, we follow the patient clinically for the next year and repeat the chest radiograph approximately every three months. &nbsp;",
"   </p>",
"   <p>",
"    Glucocorticoid treatment is associated with a variety of side effects. Thus, there needs to be a careful and ongoing assessment of risks and benefits. Steps to minimize the adverse effects (eg, infection, osteoporosis, myopathy, adrenal suppression) of systemic glucocorticoids are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23208?source=see_link&amp;anchor=H23#H23\">",
"     \"Pharmacologic use of glucocorticoids\", section on 'Minimizing glucocorticoid side effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22103?source=see_link&amp;anchor=H16#H16\">",
"     \"Glucocorticoid withdrawal\", section on 'Recommended tapering regimen'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19822219\">",
"    <span class=\"h2\">",
"     Failure to respond to systemic glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who have stable disease but fail to improve with systemic glucocorticoids, we review the initial diagnostic testing results to be sure that the patient does not have an alternate diagnosis. (See",
"    <a class=\"local\" href=\"#H11162171\">",
"     'Differential diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Superimposed infection is also excluded, particularly if deterioration has followed an initial improvement. In this setting, a repeat bronchoscopy with bronchoalveolar lavage is often indicated.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Cytotoxic therapy",
"      </strong>",
"      &minus; After reconfirming the diagnosis of COP, a cytotoxic agent is usually started while maintaining oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      . We typically use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , although data in support of this choice are limited to case reports [",
"      <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/5,55,56\">",
"       5,55,56",
"      </a>",
"      ]. For patients with normal renal function, the initial dose is 1 to 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day (given as a single daily dose) up to a maximum of 150",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      although the optimal dose in COP is unknown. We usually start at 50 mg daily and slowly increase the dose over two to four weeks. For patients with abnormal renal function, the dose of cyclophosphamide is modified (",
"      <a class=\"graphic graphic_table graphicRef60883 \" href=\"UTD.htm?6/31/6652\">",
"       table 5",
"      </a>",
"      ), or an alternate agent is used. A trial of at least three months is needed to ensure an adequate opportunity for clinical response. Due to the toxicity of cyclophosphamide, we discontinue this agent after six months. Potential adverse effects of cyclophosphamide and guidance for its safe administration are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=see_link\">",
"       \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=see_link\">",
"       \"General principles of the use of cyclophosphamide in rheumatic and renal disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Other therapies",
"      </strong>",
"      &minus; The addition of a macrolide antibiotic to systemic glucocorticoid therapy has been beneficial in case reports [",
"      <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/53,57\">",
"       53,57",
"      </a>",
"      ]. In a case report, a patient with COP refractory to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , responded to the combination of prednisolone 0.75",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      500 mg every other day [",
"      <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/53\">",
"       53",
"      </a>",
"      ]. After one year, prednisolone was tapered off and azithromycin continued three times a week.",
"      <br/>",
"      <br/>",
"      In a few case reports,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      has been used in combination with glucocorticoids to treat rapidly progressive disease [",
"      <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/57,58\">",
"       57,58",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19821878\">",
"    <span class=\"h2\">",
"     Inability to taper glucocorticoids or intolerance of adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relapses are common and usually occur when the glucocorticoids are tapered after one to three months of treatment. In some series, over one-half of patients experience at least one clinical relapse during the course of their disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/8,19,31\">",
"     8,19,31",
"    </a>",
"    ]. Most of these patients will improve when retreated with glucocorticoids, and the occurrence of relapses generally does not appear to affect the overall long-term prognosis.",
"   </p>",
"   <p>",
"    Patients with persistent or frequently recurrent (&gt;3) episodes may require long-term treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and a glucocorticoid-sparing agent. We typically use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    as a glucocorticoid-sparing agent in patients who have responded to glucocorticoid therapy, but require a high dose to control their disease, and those who are intolerant of glucocorticoid adverse effects. However, data in support of glucocorticoid-sparing agents for COP are limited. A few case reports have described a favorable outcome with a combination of azathioprine and low dose prednisone [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/59-61\">",
"     59-61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Toxicity of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    is partly related to deficiency in the enzyme thiopurine methyltransferase (TPMT), and analysis of the TPMT gene",
"    <strong>",
"     prior",
"    </strong>",
"    &nbsp;to the administration of azathioprine may help predict those individuals at risk for severe toxicity. The pharmacology and adverse effects of azathioprine are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=see_link\">",
"     \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33236333\">",
"    <span class=\"h2\">",
"     Fulminant disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the minority of patients who present with rapidly progressive and extensive disease (eg, requiring high flow supplemental oxygen), after exclusion of infection, we suggest initial therapy with intravenous glucocorticoids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    125 to 250 mg every 6 hours or a pulse of 750 to 1000 mg given once daily for 3 to 5 days) based on clinical experience and case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/43,62,63\">",
"     43,62,63",
"    </a>",
"    ]. Once the patient shows signs of improvement (usually within five days), glucocorticoid therapy is transitioned to oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    at a dose of 0.75 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (using ideal body weight) to a maximum of 100",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    Subsequent tapering and prevention of long-term adverse effects of glucocorticoid therapy are described above. (See",
"    <a class=\"local\" href=\"#H19822264\">",
"     'Persistent or gradually worsening disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    It is unknown whether a second immunosuppressive agent should be added in patients who require mechanical ventilation for respiratory failure or do not respond rapidly to intravenous glucocorticoids, but we generally add a second agent. We typically choose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , given the greater experience with it. Cyclophosphamide is discontinued after six months or sooner if the patient has adverse effects. (See",
"    <a class=\"local\" href=\"#H19822219\">",
"     'Failure to respond to systemic glucocorticoids'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=see_link\">",
"     \"General principles of the use of cyclophosphamide in rheumatic and renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Use of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil in combination with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    has been described in a case report, although it is unclear whether mycophenolate contributed to the resolution of the patient&rsquo;s fulminant organizing pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Focal organizing pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resection of a solitary lung nodule containing focal organizing pneumonia is adequate initial therapy for most patients. In two retrospective studies, focal organizing pneumonia was found in resected solitary pulmonary nodules in a combined total of 43 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. No further therapy was given and there was no recurrence in 41 patients; the two patients with local recurrences were treated successfully with glucocorticoids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recovery, usually with complete clinical and physiologic improvement and normalization of the chest film, occurs in two-thirds of patients treated with glucocorticoids (",
"    <a class=\"graphic graphic_figure graphicRef65385 \" href=\"UTD.htm?28/45/29405\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/1\">",
"     1",
"    </a>",
"    ]. Symptomatic improvement is occasionally quite dramatic, occurring in one to two weeks, although most patients improve more gradually over several weeks to a few months. Serial HRCT scans may reveal persistent abnormalities despite clinical improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/31\">",
"     31",
"    </a>",
"    ]. Patients with airspace opacities on chest radiograph have a much better outcome than those with reticular opacities [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/24,65\">",
"     24,65",
"    </a>",
"    ]. Approximately one-third of patients experience persistent symptoms, abnormalities on pulmonary function testing, and radiographic disease.",
"   </p>",
"   <p>",
"    The overall prognosis of COP is much better than that of other interstitial lung diseases, such as idiopathic pulmonary fibrosis, fibrosis nonspecific interstitial pneumonia, and acute interstitial pneumonia. Rapidly fatal COP is uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?18/60/19402/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33234011\">",
"    <span class=\"h2\">",
"     Clinical manifestations and diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cryptogenic organizing pneumonia (COP) is one of the idiopathic interstitial pneumonias (",
"      <a class=\"graphic graphic_algorithm graphicRef77345 \" href=\"UTD.htm?42/30/43502\">",
"       algorithm 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When organizing pneumonia is seen in association with other processes, such as connective tissue diseases, a variety of drugs, malignancy, or other interstitial pneumonias, it is called secondary organizing pneumonia. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Disease onset is typically in the fifth or sixth decades of life with men and women affected equally. Most patients are symptomatic for less than two months and have a clinical presentation that mimics community-acquired pneumonia (eg, cough, dyspnea with exertion, weight loss). Approximately half of cases are heralded by a flu-like illness. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common chest imaging features of COP are multiple ground-glass or consolidative opacities. Pulmonary function tests usually show a restrictive pattern with an associated gas transfer defect. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Chest imaging studies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Pulmonary function tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Frequently, flexible bronchoscopy is performed to obtain bronchoalveolar lavage (BAL) samples to evaluate for infection, hemorrhage, and malignancy. A transbronchial biopsy is sometimes performed during the procedure to obtain tissue for histopathologic and microbiologic studies. However, a surgical lung biopsy (thoracoscopic or open) is generally preferred over transbronchial biopsy to make a definitive diagnosis of COP. (See",
"      <a class=\"local\" href=\"#H2124602\">",
"       'Surgical lung biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Histopathologic lesions characteristic of COP include excessive proliferation or &ldquo;plugs&rdquo; of granulation tissue within alveolar ducts and alveoli, associated with chronic inflammation in the surrounding alveoli (",
"      <a class=\"graphic graphic_table graphicRef60654 \" href=\"UTD.htm?33/19/34107\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of COP requires histopathologic identification of a predominant pattern of organizing pneumonia and the exclusion of any possible cause, which may be relatively evident or may require a laborious search (",
"      <a class=\"graphic graphic_table graphicRef77030 \" href=\"UTD.htm?21/21/21851\">",
"       table 3",
"      </a>",
"      ). In addition, several diseases are in the differential diagnosis of COP and need to be excluded. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11162171\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33234004\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The decision to initiate therapy for COP and the choice of initial therapy depend on the severity of symptoms and pulmonary function impairment at presentation, the radiographic extent of disease, and the rapidity of progression. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with COP who are minimally symptomatic and have absent or only mild abnormalities on pulmonary function tests, it is reasonable to monitor without therapy pending any worsening of symptoms or pulmonary function. Patients are reassessed at 8 to 12 week intervals regarding any increase in symptoms, worsening of pulmonary function, or progression of the radiographic opacities. (See",
"      <a class=\"local\" href=\"#H19822257\">",
"       'Mild stable disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For symptomatic patients with moderate or more severe respiratory impairment due to COP, we recommend initiation of systemic glucocorticoid therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The usual dose is the equivalent of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      0.75 to 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day (using ideal body weight) to a maximum of 100",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      given as a single oral dose in the morning; most patients respond to a dose of 60 mg per day. (See",
"      <a class=\"local\" href=\"#H19822264\">",
"       'Persistent or gradually worsening disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with rapidly progressive disease or",
"      <span class=\"nowrap\">",
"       actual/impending",
"      </span>",
"      respiratory failure, we suggest initial high-dose glucocorticoid therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      500 to 1000 mg intravenously each day for three to five days rather than a lower oral dose (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients who fail to respond to initial therapy with systemic glucocorticoids or present with fulminant disease, we suggest addition of a second immunosuppressive agent, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19822219\">",
"       'Failure to respond to systemic glucocorticoids'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H33236333\">",
"       'Fulminant disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Glucocorticoid therapy usually induces clinical improvement and clearing of the opacities on chest imaging of several days to a few weeks. Oral glucocorticoid therapy is gradually tapered as tolerated over 6 to 12 months. Relapses are common upon stopping or reduction of glucocorticoids, often leading to prolonged treatment. (See",
"      <a class=\"local\" href=\"#H19822264\">",
"       'Persistent or gradually worsening disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who are unable to taper glucocorticoids to a level that does not cause intolerable adverse effects, we suggest adding a second immunosuppressive agent, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19821878\">",
"       'Inability to taper glucocorticoids or intolerance of adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Glucocorticoid treatment is associated with a variety of side effects. Steps to minimize the adverse effects (eg, infection, osteoporosis, myopathy, adrenal suppression) of systemic glucocorticoids are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"       \"Major side effects of systemic glucocorticoids\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/1\">",
"      Cordier JF. Cryptogenic organising pneumonia. Eur Respir J 2006; 28:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/2\">",
"      Epler GR. Bronchiolitis obliterans organizing pneumonia. Arch Intern Med 2001; 161:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/3\">",
"      Ryu JH, Myers JL, Swensen SJ. Bronchiolar disorders. Am J Respir Crit Care Med 2003; 168:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/4\">",
"      Grinblat J, Mechlis S, Lewitus Z. Organizing pneumonia-like process: an unusual observation in steroid responsive cases with features of chronic interstitial pneumonia. Chest 1981; 80:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/5\">",
"      Davison AG, Heard BE, McAllister WA, Turner-Warwick ME. Cryptogenic organizing pneumonitis. Q J Med 1983; 52:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/6\">",
"      Epler GR, Colby TV, McLoud TC, et al. Bronchiolitis obliterans organizing pneumonia. N Engl J Med 1985; 312:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/7\">",
"      Cordier JF. Organising pneumonia. Thorax 2000; 55:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/8\">",
"      Barroso E, Hernandez L, Gil J, et al. Idiopathic organizing pneumonia: a relapsing disease. 19 years of experience in a hospital setting. Respiration 2007; 74:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/9\">",
"      Alasaly K, Muller N, Ostrow DN, et al. Cryptogenic organizing pneumonia. A report of 25 cases and a review of the literature. Medicine (Baltimore) 1995; 74:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/10\">",
"      Gudmundsson G, Sveinsson O, Isaksson HJ, et al. Epidemiology of organising pneumonia in Iceland. Thorax 2006; 61:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/11\">",
"      Cazzato S, Zompatori M, Baruzzi G, et al. Bronchiolitis obliterans-organizing pneumonia: an Italian experience. Respir Med 2000; 94:702.",
"     </a>",
"    </li>",
"    <li>",
"     King TE Jr. Organizing pneumonia. In: Interstitial lung disease, 5, Schwarz MI, King TE Jr.  (Eds), People's Medical Publishing House, Shelton, CT 2011. p.981.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/13\">",
"      Myers JL, Katzenstein AL. Ultrastructural evidence of alveolar epithelial injury in idiopathic bronchiolitis obliterans-organizing pneumonia. Am J Pathol 1988; 132:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/14\">",
"      Choi KH, Lee HB, Jeong MY, et al. The role of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in cryptogenic organizing pneumonia. Chest 2002; 121:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/15\">",
"      Lappi-Blanco E, Soini Y, Kinnula V, P&auml;&auml;kk&ouml; P. VEGF and bFGF are highly expressed in intraluminal fibromyxoid lesions in bronchiolitis obliterans organizing pneumonia. J Pathol 2002; 196:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/16\">",
"      Suga M, Iyonaga K, Okamoto T, et al. Characteristic elevation of matrix metalloproteinase activity in idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2000; 162:1949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/17\">",
"      Lappi-Blanco E, Soini Y, P&auml;&auml;kk&ouml; P. Apoptotic activity is increased in the newly formed fibromyxoid connective tissue in bronchiolitis obliterans organizing pneumonia. Lung 1999; 177:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/18\">",
"      Oymak FS, Demirba HM, Mavili E, et al. Bronchiolitis obliterans organizing pneumonia. Clinical and roentgenological features in 26 cases. Respiration 2005; 72:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/19\">",
"      Lazor R, Vandevenne A, Pelletier A, et al. Cryptogenic organizing pneumonia. Characteristics of relapses in a series of 48 patients. The Groupe d'Etudes et de Recherche sur les Maladles \"Orphelines\" Pulmonaires (GERM\"O\"P). Am J Respir Crit Care Med 2000; 162:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/20\">",
"      Yoo JW, Song JW, Jang SJ, et al. Comparison between cryptogenic organizing pneumonia and connective tissue disease-related organizing pneumonia. Rheumatology (Oxford) 2011; 50:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/21\">",
"      Mroz BJ, Sexauer WP, Meade A, Balsara G. Hemoptysis as the presenting symptom in bronchiolitis obliterans organizing pneumonia. Chest 1997; 111:1775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/22\">",
"      Cordier JF. Cryptogenic organizing pneumonitis. Bronchiolitis obliterans organizing pneumonia. Clin Chest Med 1993; 14:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/23\">",
"      M&uuml;ller NL, Guerry-Force ML, Staples CA, et al. Differential diagnosis of bronchiolitis obliterans with organizing pneumonia and usual interstitial pneumonia: clinical, functional, and radiologic findings. Radiology 1987; 162:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/24\">",
"      Bartter T, Irwin RS, Nash G, et al. Idiopathic bronchiolitis obliterans organizing pneumonia with peripheral infiltrates on chest roentgenogram. Arch Intern Med 1989; 149:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/25\">",
"      Cordier JF, Loire R, Brune J. Idiopathic bronchiolitis obliterans organizing pneumonia. Definition of characteristic clinical profiles in a series of 16 patients. Chest 1989; 96:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/26\">",
"      Izumi T, Kitaichi M, Nishimura K, Nagai S. Bronchiolitis obliterans organizing pneumonia. Clinical features and differential diagnosis. Chest 1992; 102:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/27\">",
"      M&uuml;ller NL, Staples CA, Miller RR. Bronchiolitis obliterans organizing pneumonia: CT features in 14 patients. AJR Am J Roentgenol 1990; 154:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/28\">",
"      Ujita M, Renzoni EA, Veeraraghavan S, et al. Organizing pneumonia: perilobular pattern at thin-section CT. Radiology 2004; 232:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/29\">",
"      Costabel U, Teschler H, Guzman J. Bronchiolitis obliterans organizing pneumonia (BOOP): the cytological and immunocytological profile of bronchoalveolar lavage. Eur Respir J 1992; 5:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/30\">",
"      Kim SJ, Lee KS, Ryu YH, et al. Reversed halo sign on high-resolution CT of cryptogenic organizing pneumonia: diagnostic implications. AJR Am J Roentgenol 2003; 180:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/31\">",
"      Lee JW, Lee KS, Lee HY, et al. Cryptogenic organizing pneumonia: serial high-resolution CT findings in 22 patients. AJR Am J Roentgenol 2010; 195:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/32\">",
"      Maldonado F, Daniels CE, Hoffman EA, et al. Focal organizing pneumonia on surgical lung biopsy: causes, clinicoradiologic features, and outcomes. Chest 2007; 132:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/33\">",
"      Melloni G, Cremona G, Bandiera A, et al. Localized organizing pneumonia: report of 21 cases. Ann Thorac Surg 2007; 83:1946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/34\">",
"      Marchiori E, Marom EM, Zanetti G, et al. Reversed halo sign in invasive fungal infections: criteria for differentiation from organizing pneumonia. Chest 2012; 142:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/35\">",
"      Souza CA, M&uuml;ller NL, Lee KS, et al. Idiopathic interstitial pneumonias: prevalence of mediastinal lymph node enlargement in 206 patients. AJR Am J Roentgenol 2006; 186:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/36\">",
"      Arakawa H, Kurihara Y, Niimi H, et al. Bronchiolitis obliterans with organizing pneumonia versus chronic eosinophilic pneumonia: high-resolution CT findings in 81 patients. AJR Am J Roentgenol 2001; 176:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/37\">",
"      King TE Jr, Mortenson RL. Cryptogenic organizing pneumonitis. The North American experience. Chest 1992; 102:8S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/38\">",
"      Cordier JF. Cryptogenic organizing pneumonia. Clin Chest Med 2004; 25:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/39\">",
"      Poletti V, Cazzato S, Minicuci N, et al. The diagnostic value of bronchoalveolar lavage and transbronchial lung biopsy in cryptogenic organizing pneumonia. Eur Respir J 1996; 9:2513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/40\">",
"      Katzenstein AL, Myers JL, Prophet WD, et al. Bronchiolitis obliterans and usual interstitial pneumonia. A comparative clinicopathologic study. Am J Surg Pathol 1986; 10:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/41\">",
"      Colby, TV, Myers, JL. The clinical and histologic spectrum of bronchiolitis obliterans including bronchiolitis obliterans organizing pneumonia (BOOP). Semin Respir Med 1992; 13:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/42\">",
"      Forlani S, Ratta L, Bulgheroni A, et al. Cytokine profile of broncho-alveolar lavage in BOOP and UIP. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/43\">",
"      Bradley B, Branley HM, Egan JJ, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008; 63 Suppl 5:v1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/44\">",
"      Azzam ZS, Bentur L, Rubin AH, et al. Bronchiolitis obliterans organizing pneumonia. Diagnosis by transbronchial biopsy. Chest 1993; 104:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/45\">",
"      Dina R, Sheppard MN. The histological diagnosis of clinically documented cases of cryptogenic organizing pneumonia: diagnostic features in transbronchial biopsies. Histopathology 1993; 23:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/46\">",
"      Beasley MB, Franks TJ, Galvin JR, et al. Acute fibrinous and organizing pneumonia: a histological pattern of lung injury and possible variant of diffuse alveolar damage. Arch Pathol Lab Med 2002; 126:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/47\">",
"      Hariri LP, Unizony S, Stone J, et al. Acute fibrinous and organizing pneumonia in systemic lupus erythematosus: a case report and review of the literature. Pathol Int 2010; 60:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/48\">",
"      Balduin R, Giacometti C, Saccarola L, et al. Acute fibrinous and organizing pneumonia in a patient with collagen vascular disease \"stigma\". Sarcoidosis Vasc Diffuse Lung Dis 2007; 24:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/49\">",
"      Yokogawa N, Alcid DV. Acute fibrinous and organizing pneumonia as a rare presentation of abacavir hypersensitivity reaction. AIDS 2007; 21:2116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/50\">",
"      Friedlander AL, Albert RK. Chronic macrolide therapy in inflammatory airways diseases. Chest 2010; 138:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/51\">",
"      Stover DE, Mangino D. Macrolides: a treatment alternative for bronchiolitis obliterans organizing pneumonia? Chest 2005; 128:3611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/52\">",
"      Ichikawa Y, Ninomiya H, Katsuki M, et al. Low-dose/long-term erythromycin for treatment of bronchiolitis obliterans organizing pneumonia (BOOP). Kurume Med J 1993; 40:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/53\">",
"      Vaz AP, Morais A, Melo N, et al. [Azithromycin as an adjuvant therapy in cryptogenic organizing pneumonia]. Rev Port Pneumol 2011; 17:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/54\">",
"      Radzikowska E, Wiatr E, Gawryluk D, et al. [Organizing pneumonia--clarithromycin treatment]. Pneumonol Alergol Pol 2008; 76:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/55\">",
"      Purcell IF, Bourke SJ, Marshall SM. Cyclophosphamide in severe steroid-resistant bronchiolitis obliterans organizing pneumonia. Respir Med 1997; 91:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/56\">",
"      Ning-Sheng L, Chun-Liang L, Ray-Sheng L. Bronchiolitis obliterans organizing pneumonia in a patient with Beh&ccedil;et's disease. Scand J Rheumatol 2004; 33:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/57\">",
"      Lee J, Cha SI, Park TI, et al. Adjunctive effects of cyclosporine and macrolide in rapidly progressive cryptogenic organizing pneumonia with no prompt response to steroid. Intern Med 2011; 50:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/58\">",
"      Koinuma D, Miki M, Ebina M, et al. Successful treatment of a case with rapidly progressive Bronchiolitis obliterans organizing pneumonia (BOOP) using cyclosporin A and corticosteroid. Intern Med 2002; 41:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/59\">",
"      Lee YH, Choi SJ, Ji JD, et al. Dermatomyositis without elevation of creatine kinase presented as bronchiolitis obliterans organizing pneumonia. Korean J Intern Med 2000; 15:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/60\">",
"      Laszlo A, Espolio Y, Auckenthaler A, et al. Azathioprine and low-dose corticosteroids for the treatment of cryptogenic organizing pneumonia in an older patient. J Am Geriatr Soc 2003; 51:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/61\">",
"      Strobel ES, Bonnet RB, Werner P, et al. Bronchiolitis obliterans organising pneumonia and primary biliary cirrhosis-like lung involvement in a patient with primary biliary cirrhosis. Clin Rheumatol 1998; 17:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/62\">",
"      Nizami IY, Kissner DG, Visscher DW, Dubaybo BA. Idiopathic bronchiolitis obliterans with organizing pneumonia. An acute and life-threatening syndrome. Chest 1995; 108:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/63\">",
"      P&eacute;rez de Llano LA, Soil&aacute;n JL, Garc&iacute;a Pais MJ, et al. Idiopathic bronchiolitis obliterans with organizing pneumonia presenting with adult respiratory distress syndrome. Respir Med 1998; 92:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/64\">",
"      Bhatti S, Hakeem A, Torrealba J, et al. Severe acute fibrinous and organizing pneumonia (AFOP) causing ventilatory failure: successful treatment with mycophenolate mofetil and corticosteroids. Respir Med 2009; 103:1764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/65\">",
"      Chandler PW, Shin MS, Friedman SE, et al. Radiographic manifestations of bronchiolitis obliterans with organizing pneumonia vs usual interstitial pneumonia. AJR Am J Roentgenol 1986; 147:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/60/19402/abstract/66\">",
"      Cohen AJ, King TE Jr, Downey GP. Rapidly progressive bronchiolitis obliterans with organizing pneumonia. Am J Respir Crit Care Med 1994; 149:1670.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4332 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-7E15F350EB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_60_19402=[""].join("\n");
var outline_f18_60_19402=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11161611\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19821905\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11161794\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11161913\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Chest imaging studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19098198\">",
"      - Chest radiograph",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Computed tomographic scanning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pulmonary function tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2124653\">",
"      Flexible bronchoscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Bronchoalveolar lavage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2124691\">",
"      - Transbronchial lung biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2124602\">",
"      Surgical lung biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19822032\">",
"      Cryptogenic organizing pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11162193\">",
"      Excluding other etiologies of organizing pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11162171\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19822257\">",
"      Mild stable disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19822264\">",
"      Persistent or gradually worsening disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19822219\">",
"      Failure to respond to systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19821878\">",
"      Inability to taper glucocorticoids or intolerance of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33236333\">",
"      Fulminant disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Focal organizing pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33234011\">",
"      Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33234004\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4332\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4332|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?17/14/17632\" title=\"algorithm 1\">",
"      Approach to patient with ILD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?42/30/43502\" title=\"algorithm 2\">",
"      Classification diffuse lung dz",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4332|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/62/29679\" title=\"diagnostic image 1\">",
"      Cryptogenic organizing pneumonia CXR I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/54/8032\" title=\"diagnostic image 2\">",
"      Cryptogenic organizing pneumonia CXR II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?5/61/6096\" title=\"diagnostic image 3\">",
"      Cryptogenic organizing pneumonia CXR III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/48/2818\" title=\"diagnostic image 4\">",
"      Cryptogenic organizing pneumonia CT I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?4/24/4484\" title=\"diagnostic image 5\">",
"      Focal organizing pneumonia CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/22/39279\" title=\"diagnostic image 6\">",
"      Cryptogenic organizing pneumonia CT II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/40/3715\" title=\"diagnostic image 7\">",
"      Cryptogenic organizing pneumonia CT III",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4332|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/57/22429\" title=\"figure 1\">",
"      COP vs IPF duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/12/31949\" title=\"figure 2\">",
"      Severity restrictive dz",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/45/29405\" title=\"figure 3\">",
"      COP vs IPF outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4332|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/53/15194\" title=\"picture 1\">",
"      COP lung biopsy high power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/22/2410\" title=\"picture 2\">",
"      Organizing pneumonia low power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/44/18122\" title=\"picture 3\">",
"      COP lung biopsy low power",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4332|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/19/34107\" title=\"table 1\">",
"      Histologic features of OP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/25/23963\" title=\"table 2\">",
"      Histologic clinical class idiopathic interstitial pneumonias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/21/21851\" title=\"table 3\">",
"      Causes of organizing pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/55/891\" title=\"table 4\">",
"      Interstitial lung diseases that may include a component of OP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/31/6652\" title=\"table 5\">",
"      Adjusting cyclophosphamide dose",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?2/41/2706?source=related_link\" title=\"calculator 1\">",
"      Calculator: Ideal body weight (method of Devine) and dosing weight for adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22792?source=related_link\">",
"      Acute interstitial pneumonia (Hamman-Rich syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29945?source=related_link\">",
"      Acute respiratory distress syndrome: Epidemiology; pathophysiology; pathology; and etiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Clinical evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/41/25239?source=related_link\">",
"      Basic principles and technique of bronchoalveolar lavage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27688?source=related_link\">",
"      Causes of pulmonary eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/49/19222?source=related_link\">",
"      Classification and clinical manifestations of hypersensitivity pneumonitis (extrinsic allergic alveolitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=related_link\">",
"      Clinical features of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=related_link\">",
"      Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19610?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=related_link\">",
"      Diagnostic approach to community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43816?source=related_link\">",
"      Flexible bronchoscopy: Equipment, procedure, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=related_link\">",
"      General principles of the use of cyclophosphamide in rheumatic and renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=related_link\">",
"      General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22103?source=related_link\">",
"      Glucocorticoid withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=related_link\">",
"      Idiopathic interstitial pneumonias: Clinical manifestations and pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/63/21497?source=related_link\">",
"      Interpretation of lung biopsy results in interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=related_link\">",
"      Overview of pulmonary function testing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29224?source=related_link\">",
"      Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23208?source=related_link\">",
"      Pharmacologic use of glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=related_link\">",
"      Pharmacology and side effects of azathioprine when used in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/20/41287?source=related_link\">",
"      Pulmonary lymphomatoid granulomatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=related_link\">",
"      Role of bronchoalveolar lavage in diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=related_link\">",
"      Role of lung biopsy in the diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20581?source=related_link\">",
"      Treatment of chronic eosinophilic pneumonia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_60_19403="Criteria paranoid personality";
var content_f18_60_19403=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F52389&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F52389&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic criteria for paranoid personality disorder",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Four or more of following plus general criteria for personality disorder:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1. Suspects, without sufficient basis, that others are exploiting or deceiving him or her",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2. Is preoccupied with unjustified doubts about the loyalty or trustworthiness of friends or associates",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3. Is reluctant to confide in others because of unwarranted fear that the information will be used maliciously against him or her",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4. Reads hidden demeaning or threatening meanings into benign remarks or events",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5. Persistently bears grudges, ie, unforgiving of insults, injuries, or slights",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       6. Perceives attacks on his or her character or reputation that are not apparent to others and is quick to react angrily or counterattack",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       7. Has recurrent suspicions, without justification, regarding fidelity of spouse or sexual partner",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, Text revision (DSM-IV-TR). American Psychiatric Association, Washington, DC, 2000.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_60_19403=[""].join("\n");
var outline_f18_60_19403=null;
var title_f18_60_19404="Gest troph neopl survival";
var content_f18_60_19404=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F70087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F70087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Gestational trophoblastic neoplasia survival",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Patients (n)",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"3\">",
"       Overall survival (percent) at",
"      </td>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Hazards ratio (95% CI)*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       1 year",
"      </td>",
"      <td class=\"subtitle2\">",
"       2 years",
"      </td>",
"      <td class=\"subtitle2\">",
"       5 years",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"6\">",
"       Survival by FIGO stage for patients with gestational trophoblastic neoplasia: 1999-2001 FIGO statistics",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_left\" colspan=\"6\">",
"       Stage",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       I",
"      </td>",
"      <td>",
"       200",
"      </td>",
"      <td>",
"       99.5",
"      </td>",
"      <td>",
"       98.4",
"      </td>",
"      <td>",
"       97.3",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       II",
"      </td>",
"      <td>",
"       7",
"      </td>",
"      <td>",
"       85.7",
"      </td>",
"      <td>",
"       85.7",
"      </td>",
"      <td>",
"       85.7",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       III",
"      </td>",
"      <td>",
"       30",
"      </td>",
"      <td>",
"       86.4",
"      </td>",
"      <td>",
"       82.8",
"      </td>",
"      <td>",
"       82.8",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       IV",
"      </td>",
"      <td>",
"       17",
"      </td>",
"      <td>",
"       81.8",
"      </td>",
"      <td>",
"       69.2",
"      </td>",
"      <td>",
"       61.9",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"6\">",
"       Survival by modified WHO prognostic risk score",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_left\" colspan=\"6\">",
"       Risk score",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Low (0-6)",
"      </td>",
"      <td>",
"       195",
"      </td>",
"      <td>",
"       98.4",
"      </td>",
"      <td>",
"       97.9",
"      </td>",
"      <td>",
"       97.3",
"      </td>",
"      <td>",
"       Reference",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       High (&gt;6)",
"      </td>",
"      <td>",
"       62",
"      </td>",
"      <td>",
"       90.2",
"      </td>",
"      <td>",
"       85.2",
"      </td>",
"      <td>",
"       79.5",
"      </td>",
"      <td>",
"       8.8 (2.2-35.1)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Hazards ratio and 95% Confidence Intervals obtained from a Cox model adjusted for age, stage, and country.",
"    </div>",
"    <div class=\"reference\">",
"     Original table modified for this publication. From: Ngan HY, Odicino F, Maisonneuve P, et al. Gestational trophoblastic neoplasia. Int J Gynaecol Obstet 2006; 95:S193. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_60_19404=[""].join("\n");
var outline_f18_60_19404=null;
var title_f18_60_19405="Pediatric calorie needs";
var content_f18_60_19405=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52158&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52158&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pediatric daily calorie needs based on age, gender, and physical activity level*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Gender",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age (years)",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         Calorie requirements (kcals) for sedentary level of activity",
"         <span class=\"bullet\">",
"          <sup>",
"           &bull;",
"          </sup>",
"         </span>",
"        </p>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Calorie requirements (kcals) for moderate activity",
"        <span class=\"bullet\">",
"         <sup>",
"          &bull;",
"         </sup>",
"        </span>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Calorie requirements (kcals) for active activity",
"        <span class=\"bullet\">",
"         <sup>",
"          &bull;",
"         </sup>",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Child",
"       </td>",
"       <td>",
"        2-3",
"       </td>",
"       <td>",
"        1000-1200",
"       </td>",
"       <td>",
"        1000-1400",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        1000-1400",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Female",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        4-8",
"       </td>",
"       <td>",
"        1200-1400",
"       </td>",
"       <td>",
"        1400-1600",
"       </td>",
"       <td>",
"        1400-1800",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Female",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        9-13",
"       </td>",
"       <td>",
"        1400-1600",
"       </td>",
"       <td>",
"        1600-2000",
"       </td>",
"       <td>",
"        1800-2200",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Female",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        14-18",
"       </td>",
"       <td>",
"        1800",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"       <td>",
"        2400",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Female",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        19-30",
"       </td>",
"       <td>",
"        1800-2000",
"       </td>",
"       <td>",
"        2000-2200",
"       </td>",
"       <td>",
"        2400",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Male",
"       </td>",
"       <td>",
"        4-8",
"       </td>",
"       <td>",
"        1200-1400",
"       </td>",
"       <td>",
"        1400-1600",
"       </td>",
"       <td>",
"        1600-2000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Male",
"       </td>",
"       <td>",
"        9-13",
"       </td>",
"       <td>",
"        1600-2000",
"       </td>",
"       <td>",
"        1800-2200",
"       </td>",
"       <td>",
"        2000-2600",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Male",
"       </td>",
"       <td>",
"        14-18",
"       </td>",
"       <td>",
"        2000-2400",
"       </td>",
"       <td>",
"        2400-2800",
"       </td>",
"       <td>",
"        2800-3200",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Male",
"       </td>",
"       <td>",
"        19-30",
"       </td>",
"       <td>",
"        2400-2600",
"       </td>",
"       <td>",
"        2600-2800",
"       </td>",
"       <td>",
"        3000",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Estimated amounts of calories needed to maintain caloric balance for various gender and age groups at three different levels of physical activity. The estimates are rounded to the nearest 200 calories. An individual's calorie needs may be higher or lower than these average estimates.",
"    <div class=\"footnotes\">",
"     * Based on Estimated Energy Requirements (EER) equations, using reference heights (average) and reference weights (health) for each age/gender group. For children and adolescents, reference height and weight vary. For adults, the reference man is 5 feet 10 inches tall and weighs 154 pounds. The reference woman is 5 feet 4 inches tall and weighs 126 pounds. EER equations are from the Institute of Medicine. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington (DC): The National Academies Press; 2002.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Sedentary means a lifestyle that includes only the light physical activity associated with typical day-to-day life. Moderately active means a lifestyle that includes physical activity equivalent to walking about 1.5 to 3 miles per day at 3 to 4 miles per hour, in addition to the light physical activity associated with typical day-to-day life. Active means a lifestyle that includes physical activity equivalent to walking more than 3 miles per day at 3 to 4 miles per hour, in addition to the light physical activity associated with typical day-to-day life.",
"      <br>",
"       &Delta; The calorie ranges shown are to accommodate needs of different ages within the group. For children and adolescents, more calories are needed at older ages. For adults, fewer calories are needed at older ages.",
"       <br>",
"        <span class=\"lozenge\">",
"         &loz;",
"        </span>",
"        Estimates for females do not include women who are pregnant or breastfeeding.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report.",
"     <a href=\"file://www.nhlbi.nih.gov/guidelines/cvd_ped/summary.htm#chap5\" target=\"_blank\">",
"      file://www.nhlbi.nih.gov/guidelines/cvd_ped/summary.htm#chap5",
"     </a>",
"     (Accessed January 3, 2012).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_60_19405=[""].join("\n");
var outline_f18_60_19405=null;
var title_f18_60_19406="Crohns disease capsule endoscopy";
var content_f18_60_19406=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F76042&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F76042&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Crohn's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Small bowel ulceration as seen during capsule endoscopy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Given Imaging, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_60_19406=[""].join("\n");
var outline_f18_60_19406=null;
var title_f18_60_19407="Complete CBD transection II";
var content_f18_60_19407=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F68567&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F68567&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Complete transection of common bile duct after cholecystectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 352px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    ERCP shows complete transection of the comon bile duct.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Bourke, MBBS, FRACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_60_19407=[""].join("\n");
var outline_f18_60_19407=null;
